

(19)



(11)

EP 2 741 085 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:

11.06.2014 Bulletin 2014/24

(51) Int Cl.:

G01N 33/574 ^(2006.01) **C12Q 1/68** ^(2006.01)
G01N 33/53 ^(2006.01) **C07K 14/47** ^(2006.01)
C07K 16/18 ^(2006.01) **C12N 15/02** ^(2006.01)
C12P 21/08 ^(2006.01)

(21) Application number: **12819473.5**

(22) Date of filing: **03.08.2012**

(86) International application number:

PCT/JP2012/069824

(87) International publication number:

WO 2013/018885 (07.02.2013 Gazette 2013/06)

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **OKANO, Fumiyoshi**
Kamakura-shi
Kanagawa 248-8555 (JP)

(30) Priority: **04.08.2011 JP 2011171364**

(74) Representative: **Denison, Christopher Marcus et al**

(71) Applicant: **Toray Industries, Inc.**
Tokyo, 103-8666 (JP)

Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS (GB)

(72) Inventors:

- **IDO, Takayoshi**
Kamakura-shi
Kanagawa 248-8555 (JP)

(54) **METHOD FOR DETECTING PANCREATIC CANCER**

(57) This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against

CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same.

EP 2 741 085 A1

Description

Technical Field

5 **[0001]** The present invention relates to a method for detecting pancreatic cancer using CAPRIN-1 as a tumor marker.

Background Art

10 **[0002]** It is reported that there are over 10,000 patients with refractory pancreatic cancer in Japan, the occurrence thereof is increasing year after year, and it is assumed that the number of patients will continue to increase. Even if pancreatic cancer were surgically removed, small cancer cells have often infiltrated and metastasized to other organs. Accordingly, pancreatic cancer often relapses, and the 5-year survival rate is as low as 9%; that is, the prognosis of pancreatic cancer is very poor. For the purpose of preventing postoperative recurrence, Gemcitabine, an anticancer agent, has been employed. However, the primary purpose of Gemcitabine administration is pain relief, and tumor size reduction or survival advantage can hardly be expected. At some hospitals, another anti-cancer agent, TS-1, which is currently used for gastric cancer, is used, although it is difficult to expect any therapeutic effects.

15 **[0003]** In order to improve the prognosis for pancreatic cancer, early detection is important, as it is with other cancers; however, early detection is difficult because pancreatic cancer shows substantially no initial symptoms. To date, methods of detecting pancreatic cancer using carcinoembryonic antigen (CEA) and glycoproteins (CA19-9 and Dupan-2) in biological samples as tumor markers of pancreatic cancer have been actively employed. However, the levels of such tumor markers do not become elevated unless pancreatic cancer advances, and such markers occasionally show normal values in the progressive stage. Accordingly, such tumor markers are not considered to be sufficient for accurate detection of pancreatic cancer. In addition, most tumor markers that are currently known are present in very small amounts in the body fluids (at the pg/ml level). In order to detect such small amounts of markers, accordingly, detection techniques with high sensitivity or special techniques are necessary. Under such circumstances, a novel technique for detecting pancreatic cancer in a simple manner with high sensitivity is expected to be applicable to diagnosis of pancreatic cancer. It is necessary to undergo periodic thorough examinations in order to detect early-stage pancreatic cancer. Accordingly, a method of detecting cancer that can be carried out in a simple manner with the use of blood serum or urine samples without the imposition of physical or financial burdens on either healthy individuals without pancreatic cancer or patients with cancer has been awaited.

20 **[0004]** Also, pancreatic cancer is refractory in dogs. Although a lump can be observed in the abdominal region of a dog afflicted with pancreatic cancer, the major symptoms are rapid energy loss, unsteady gait, and gait abnormalities resulting from hypoglycemia. In most cases, the development of cancer would not be detected until such symptoms are observed. In addition, pancreatic cancer is often likely already to be in the advanced stage when such symptoms are observed. In addition to surgical removal of pancreatic cancer, accordingly, therapeutic techniques are limited to supportive therapy and administration of anticancer agents. As with the case of human patients, early detection is important for dogs afflicted with pancreatic cancer in order to effectively treat such pancreatic cancer. As with the case for humans, there were no diagnostic agents for dogs in the past that allowed detection of pancreatic cancer at the early stage in a simple manner. In the field of veterinary medicine, detection techniques such as radiographic techniques by means of X-rays, CT, or MRI have not yet become common. At present, detection is carried out by palpation, simple blood testing, and X-ray photography, and diagnosis is heavily dependent on the experience of veterinary doctors. If a simple means for cancer detection with high sensitivity that can be applied to diagnosis of pancreatic cancer in dogs is provided, adequate treatment can be performed, which has great advantages for dog owners and veterinary doctors.

25 **[0005]** Cytoplasmic- and proliferation-associated protein 1 (CAPRIN-1) is an intracellular protein that is expressed when normal cells in the resting phase are activated or undergo cell division. CAPRIN-1 is also known to be involved in the control of the transport and translation of mRNAs through formation of cytoplasmic stress granules and RNA in a cell. Also, genes encoding CAPRIN-1 proteins are demonstrated to be expressed specifically in canine and human testis and malignant tumor cells, FCM analysis of breast cancer cells with the use of antibodies against CAPRIN-1 demonstrates CAPRIN-1 expression on the surfaces of breast cancer cells, and immunohistochemical staining using breast cancer tissues demonstrates CAPRIN-1 expression at high level in breast cancer cells. In addition, it has been reported that the antibodies mentioned above would damage breast cancer cells through the functions of lymphocytes, and that antibodies against CAPRIN-1 exert potent antitumor effects in cancer-carrying mouse models into which breast cancer cells had been transplanted (Patent Literature 1). Also, it has been reported that cancers such as breast cancer could be diagnosed by measuring either antibodies induced in the body of a subject against CAPRIN-1 present in the blood serum or polypeptides that undergo antigen-antibody reactions with CAPRIN-1 (Patent Literature 2). Up to the present, however, there have been no reports of the fact that pancreatic cancer can be diagnosed by measuring either antibodies against CAPRIN-1 induced in the blood serum of a patient with pancreatic cancer or polypeptides that undergo antigen-antibody reactions with the CAPRIN-1.

Prior Art Literatures

Patent Literature

5 **[0006]**

Patent Literature 1: International Publication No. WO 2010/016526

Patent Literature 2: International Publication No. WO 2010/016527

10 Summary of the Invention

Problem to Be Attained by the Invention

15 **[0007]** It is an object of the present invention to provide a means for detecting pancreatic cancer that is useful for diagnosis of pancreatic cancer.

Means for Solving the Problem

20 **[0008]** The present inventors have conducted concentrated studies. As a result, the present inventors have now found that pancreatic cancer can be diagnosed, examined, or detected on the basis of CAPRIN-1 expression in pancreatic cancer, measurement (or assay) of antibodies against CAPRIN-1 induced in the blood serum of a patient with pancreatic cancer with the use of a CAPRIN-1 protein, and binding of the antibodies produced with the use of such proteins to CAPRIN-1 in the pancreatic cancer tissue. This has led to the completion of the present invention.

25 **[0009]** Specifically, the present invention provides a method for detecting pancreatic cancer comprising measuring a CAPRIN-1 expression in a sample separated from a subject. The term "detecting" as used herein can be used interchangeably with the term "examining" or "evaluating." Also, the present invention provides a reagent or kit for detecting pancreatic cancer comprising a polypeptide that undergoes an antigen-antibody reaction with an antibody against CAPRIN-1 induced or elicited in the body of a subject. Further, the present invention provides a reagent or kit for detecting pancreatic cancer comprising an antibody that undergoes an antigen-antibody reaction with CAPRIN-1 or an antigen-binding fragment of the antibody. Furthermore, the present invention provides a reagent or kit for detecting pancreatic cancer comprising a polynucleotide hybridizing specifically to a partial sequence comprising at least 15 to 19 nucleotides or at least 20 to 30 nucleotides of the nucleotide sequence represented by any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, ...,29. The "reagent or kit for detecting pancreatic cancer" used herein can also be referred to as a "reagent or kit for pancreatic cancer detection."

35 **[0010]** Specifically, the present invention has the features described below.

(1) A method for detecting pancreatic cancer comprising measuring the presence or amount of a polypeptide having a reactivity of specifically binding to an antibody against a CAPRIN-1 protein via an antigen-antibody reaction, or the presence or amount of a nucleic acid encoding the polypeptide in a sample separated from a subject.

40 (2) The method according to (1), wherein the polypeptide to be measured is a CAPRIN-1 protein consisting of an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30 or a polypeptide consisting of an amino acid sequence having 85-90% or higher sequence identity with the CAPRIN-1 protein.

(3) The method according to (1) or (2), wherein the subject is a human or a dog.

45 (4) The method according to (3), wherein the subject is a dog and the polypeptide to be measured comprises an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30.

(5) The method according to (4), wherein the subject is a dog and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 6, 8, 10, 12, or 14.

(6) The method according to (3), wherein the subject is a human and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 2 or 4.

50 (7) The method according to any of (1) to (6), wherein the presence or amount of the polypeptide is determined by immunologically measuring an antibody induced against the polypeptide to be measured in the body of a subject, which can be contained in the sample.

(8) The method according to any of (1) to (6), wherein the presence or amount of a nucleic acid encoding the polypeptide is determined by measuring a nucleic acid encoding such polypeptide contained in the sample.

55 (9) The method according to (8), wherein the presence or amount of the nucleic acid in the sample is measured using a polynucleotide specifically hybridizing to a partial sequence comprising at least 15 to 19 nucleotides, preferably at least 20 to 25 nucleotides, and more preferably at least 30 nucleotides of the nucleotide sequence in the nucleic acid or a sequence complementary thereto.

(10) The method according to (9), wherein the subject is a dog and the polynucleotide specifically hybridizes to a partial sequence comprising at least 15 to 19 nucleotides, preferably at least 20 to 25 nucleotides, and more preferably at least 30 nucleotides in the nucleotide sequence represented by SEQ ID NO: 5, 7, 9, 11, or 13 or a sequence complementary thereto.

(11) The method according to (9), wherein the subject is a human and the polynucleotide specifically hybridizes to a partial sequence comprising at least 15 to 19 nucleotides, preferably at least 20 to 25 nucleotides, and more preferably at least 30 nucleotides in the nucleotide sequence represented by SEQ ID NO: 1 or 3 or a sequence complementary thereto.

(12) The method according to any of (1) to (6), wherein the presence or amount of the polypeptide is determined by measuring the polypeptide contained in the sample.

(13) The method according to (12), wherein the assay is an immunological assay.

(14) The method according to any of (1) to (13), wherein the sample is blood, serum, blood plasma, ascites fluid, pleural effusion, tissues, or cells.

(15) A reagent or kit for detecting pancreatic cancer comprising one or more polypeptides having a reactivity of binding via an antigen-antibody reaction to an antibody induced against a CAPRIN-1 protein in the body of a subject.

(16) A reagent or kit for detecting pancreatic cancer comprising one or more antibodies that undergo an antigen-antibody reaction with a polypeptide having a reactivity of binding via an antigen-antibody reaction to an antibody against a CAPRIN-1 protein and produced in the body of a subject or to an antigen-binding fragment of the antibody.

(17) The reagent or kit according to (15) or (16), wherein the CAPRIN-1 protein has an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30.

(18) The reagent or kit according to (16) or (17), wherein the antibody or an antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the polypeptide is an antibody or an antigen-binding fragment thereof that binds to the surface of a pancreatic cancer cell.

(19) The reagent or kit according to any of (16) to (18), wherein the antibody or an antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the polypeptide comprises an antibody or a fragment thereof having an immunological reactivity with a polypeptide consisting of an amino acid sequence comprising at least 7 to 12 continuous amino acid residues within the region of amino acid residue Nos. 50 to 98 or amino acid residue Nos. 233 to 344 of the amino acid sequence represented by any of the even-numbered SEQ IDS NO: 2 to 30 except for SEQ ID NOs: 6 and 18 or with a polypeptide comprising the polypeptide as a partial sequence.

(20) The reagent or kit according to any of (16) to (19), wherein the antibody or an antigen-binding fragment that undergoes an antigen-antibody reaction with the polypeptide is one or more antibodies selected from the group consisting of: an antibody binding to a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 43 or antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 45 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 46 or an antigen-binding fragment of each thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 47 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 48 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 49 and 50 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 51 and 52 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 53 and 54 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 55 and 56 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 57 and 58 or an antigen-binding fragment thereof; and a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 59 and 60 or an antigen-binding fragment thereof.

(21) A reagent or kit for detecting pancreatic cancer comprising one or more polynucleotides that specifically hybridize to a partial sequence comprising at least 15 to 19 nucleotides, preferably at least 20 to 25 nucleotides, and more preferably at least 30 nucleotides in the nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29 and encoding a CAPRIN-1 protein or in a sequence complementary to the nucleotide sequence.

(22) A method for detecting pancreatic cancer comprising measuring the presence or amount of a CAPRIN-1 protein, an antibody against a CAPRIN-1 protein, or a nucleic acid encoding the CAPRIN-1 protein in a sample from a subject using at least one reagent or kit according to any of (15) to (21).

(23) The method for detecting pancreatic cancer according to any of (1) to (14), comprising measuring the presence or an amount of a CAPRIN-1 protein, an antibody against a CAPRIN-1 protein, or a nucleic acid encoding the CAPRIN-1 protein in a sample from a subject using at least one reagent or kit according to any one of (15) to (21).

[0011] According to the present invention, a novel method for detecting pancreatic cancer is provided. As specifically described in the examples below, a recombinant polypeptide prepared based on the amino acid sequence of CAPRIN-

1 (or Caprin-1) is capable of specifically reacting with an antibody that exists in the serum of a patient with pancreatic cancer. As such, the pancreatic cancer existing in a subject can be detected by measuring the antibody in a sample by the method of the present invention. Also, pancreatic cancer existing in a subject can be detected by measuring (or assaying) CAPRIN-1 itself. As described in the examples below, in addition, high levels of CAPRIN-1 gene expression are observed specifically in testis and pancreatic cancer cells of subjects (hereinafter, such expression product is occasionally referred to as a "nucleic acid encoding a CAPRIN-1 (protein)"). Therefore, pancreatic cancer can also be detected by measuring a nucleic acid. Further, the presence or amount of CAPRIN-1 (expression) in the pancreatic cancer tissue can be measured with the use of an antibody against CAPRIN-1. Patients with pancreatic cancer may be subjected to such measurement in advance, so that the patients to whom a CAPRIN-1-targeted therapeutic agent (e.g., antibody medicine) is applicable can be selected.

Embodiments for Carrying out the Invention

[0012] According to the method of the present invention, the presence or an amount of CAPRIN-1 (expression) is measured using a sample separated from a subject. Examples of methods for measuring the presence or an amount of CAPRIN-1 (expression) include: a method for immunologically measuring an antibody against CAPRIN-1 contained in a sample (the first method); a method for immunologically measuring CAPRIN-1 itself contained in a sample (the second method); and a method for measuring a nucleic acid encoding CAPRIN-1 contained in a sample, such as mRNA or cDNA synthesized from mRNA (the third method). In the present invention, the presence or an amount of CAPRIN-1 (expression) may be measured by any of the above methods. In the present invention, the term "measuring" is intended to include any of the following meaning: detecting, qualitatively measuring, quantitatively measuring, and semi-quantitatively measuring.

[0013] The amino acid sequence represented by SEQ ID NOs: 6, 8, 10, 12, or 14 is an amino acid sequence of canine CAPRIN-1. Canine CAPRIN-1 having such an amino acid sequence has been identified as a polypeptide binding to an antibody specifically existing in the serum derived from a cancer-bearing dog (see Example 1). An antibody against CAPRIN-1 having the amino acid sequence represented by SEQ ID NO: 6, 8, 10, 12, or 14 is specifically induced or elicited in the body of a cancer-bearing dog. Specifically, canine pancreatic cancer can be detected by measuring the above antibody against CAPRIN-1 having the amino acid sequence represented by SEQ ID NO: 6, 8, 10, 12, or 14 by the first method. Also, canine pancreatic cancer can be detected by measuring CAPRIN-1 itself as an antigen having the amino acid sequence represented by SEQ ID NO: 6, 8, 10, 12, or 14 by the second method. Since the CAPRIN-1 gene is expressed at significantly high levels in pancreatic cancer cells, canine pancreatic cancer can be detected by measuring the nucleic acid in accordance with the third method.

[0014] The term "having an amino acid sequence" used herein refers to amino acid residues aligned in a given order. Therefore, for example, the expression "polypeptide having the amino acid sequence represented by SEQ ID NO: 2" refers to a polypeptide having 709 amino acid residues, which consists of the amino acid sequence of Met Pro Ser Ala ... (partially omitted) ... Gln Gln Val Asn represented by SEQ ID NO: 2. Also, the expression "polypeptide having the amino acid sequence represented by SEQ ID NO: 2" may also be abbreviated as "the polypeptide of SEQ ID NO: 2," for example. The same applies to the expression "having a/ nucleotide sequence." In this case, the term "having" may be substituted with the expression "comprising" or "consisting of."

[0015] Also, the term "polypeptide" used herein refers to a molecule that is formed via a peptide bond of a plurality of amino acids. Examples of such molecule include not only polypeptide molecules with large numbers of constituent amino acids, but also low-molecular-weight molecules (oligopeptides) with small numbers of amino acids and full-length proteins. The present invention further encompasses full-length CAPRIN-1 proteins each having an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30 (i.e., SEQ ID NOs: 2, 4, 6, ..., 26, 28, and 30).

[0016] The term "subject" used herein refers to vertebrates, including mammals and birds, preferably mammals, and more preferably humans, dogs, cows, and horses.

[0017] The term "sample" used herein refers to a biological sample subjected to examination aimed at detection of pancreatic cancer. Examples of the sample include body fluids, tissues, and cells separated from a subject. Examples of body fluids include, but are not limited to, blood, serum, blood plasma, ascites fluid, and pleural effusion. Tissues or cells of the pancreas that is suspected of being afflicted with cancer are within the scope of the "sample."

[0018] In the method of the present invention, the targets to be measured are to not only canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12, or 14, but also CAPRIN-1 of other mammals (hereinafter, which may also be referred to as a "homolog" (or "ortholog") for canine CAPRIN-1). When it is simply referred to as "CAPRIN-1," CAPRIN-1 from another mammal, including a human, is also a target to be measured, in addition to CAPRIN-1 from a dog. As specifically described in the examples below, the human CAPRIN-1 gene expression level is significantly high in human pancreatic cancer cells, whereas no antibody against human CAPRIN-1 gene is detected in a healthy human body. As such, pancreatic cancer of a mammal other than a dog can be detected by measuring CAPRIN-1 expression in the mammal. An example of CAPRIN-1 of a mammal other than a dog to be measured by the method of the present invention is, but

is not limited to, human CAPRIN-1. Nucleotide sequences encoding human CAPRIN-1 and amino acid sequences therefor are represented by SEQ ID NOs: 1 and 3 and SEQ ID NOs: 2 and 4 in the Sequence Listing. Sequence identity between human CAPRIN-1 and canine CAPRIN-1 is 94% for nucleotide sequence and is 98% for amino acid sequence. The sequence identity of the amino acid sequences of CAPRIN-1 is as high as 98% between genetically distant mammals, such as a dog and a human. Therefore, it is considered that the sequence identity is about 85% or higher between a dog and a mammal other than a human; that is, canine CAPRIN-1 and its homolog. CAPRIN-1, the expression of which is to be measured by the method of the present invention, preferably has 85% or higher, more preferably 90% or higher, and further preferably 95% or higher sequence identity with the amino acid sequence of canine CAPRIN-1 represented by SEQ ID NO: 6, 8, 10, 12, or 14, although the sequence identities are not limited thereto.

[0019] In the first method, the antibody that can be present in a sample can be easily measured by immunoassay using an antigenic substance that undergoes an antigen-antibody reaction with the antibody. Immunoassay itself is a well-known conventional method as specifically described below. As an antigenic substance for immunoassay, for example, the canine CAPRIN-1 protein of SEQ ID NO: 6, 8, 10, 12, or 14 that induces the antibody within the body of a cancer-bearing dog or a fragment containing an epitope of such protein can be used. Further, the antibody has a cross-reactivity. A molecule other than an antigenic substance that actually serves as an immunogen can also bind, via an antigen-antibody reaction, to an antibody induced against an immunogen, as long as the molecule has a structure analogous to an epitope of the immunogen. Between a protein from a certain type of mammal and a homolog thereof from another mammal, in particular, the identity of their amino acid sequences is high, and epitope structures are often analogous to each other. As specifically described in the examples below, the canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12, or 14 undergoes an antigen-antibody reaction with an antibody induced against the canine CAPRIN-1 within the body of a cancer-bearing dog. Also, human CAPRIN-1 undergoes an antigen-antibody reaction with the antibody induced within the body of a cancer-bearing dog. Accordingly, CAPRIN-1 from any mammal can be used as an antigen for immunoassay in accordance with the first method of the present invention.

[0020] When an antigenic substance is a protein or the like having a complicated structure and a high molecular weight, in general, a plurality of sites having different structures are present on the molecule. Therefore, a plurality of types of antibodies capable of recognizing and binding to different sites of such antigenic substances are produced in the body of a subject. Specifically, an antibody that is produced in the subject against an antigenic substance such as a protein is a polyclonal antibody that is a mixture of a plurality of types of antibodies. An antibody now found by the present inventors is also a polyclonal antibody that is specifically present in the serum obtained from a cancer-bearing subject and specifically binds, via an antigen-antibody reaction, to a recombinant CAPRIN-1 protein. The term "polyclonal antibody" used in the present invention refers to an antibody that exists in the serum obtained from a subject containing an antigenic substance and is induced against such antigenic substance.

[0021] In the examples below, polypeptides of SEQ ID NO: 6 and SEQ ID NO: 8 (both, canine CAPRIN-1) and the polypeptide of SEQ ID NO: 2 (human CAPRIN-1) were prepared as antigens for immunoassay of specific antibodies in cancer-bearing living animals. The reactivity between these polypeptides and the antibodies in the serum obtained from a cancer-bearing subject was then confirmed. However, the antibodies mentioned above are polyclonal antibodies, and they naturally bind to polypeptides consisting of homologs of SEQ ID NO: 6, 8, and 2. Even in the case of a fragment of such a polypeptide, it can bind to an antibody contained in the serum obtained from a cancer-bearing subject since some polyclonal antibodies are capable of recognizing the structure of the fragment. That is, both the polypeptide (that is, the full-length CAPRIN-1 protein) of the homolog of SEQ ID NO: 6, 8, or 2 and a fragment thereof can be similarly used for assay of a polyclonal antibody contained specifically in the serum of a cancer-bearing subject, and they are useful for cancer detection. Accordingly, a polypeptide to be used as an antigen for immunoassay in the first method of the present invention is not limited to a polypeptide alone consisting of the full-length region of a CAPRIN-1 protein (e.g., SEQ ID NO: 6, 8, or 2). It can be a polypeptide fragment consisting of at least 7 to 12, and preferably at least 8, 9, or 10 continuous amino acids of the amino acid sequence of a CAPRIN-1 protein that undergoes an antigen-antibody reaction with a polyclonal antibody against the CAPRIN-1 protein (hereinafter, it may be referred to as a "specifically reactive partial polypeptide" for convenience). It is known in the art that a polypeptide comprising about 7 to 12 or more amino acid residues can exert antigenicity. If the number of amino acid residues is too low, however, such polypeptide is highly likely to cross-react with an antibody against a protein other than the CAPRIN-1 protein that exists in the sample. In view of enhancing the accuracy of immunoassay, accordingly, the number of amino acid residues of a polypeptide fragment is preferably 20 or more, 30 or more, and 50 or more, more preferably 100 or more or 150 or more, further preferably 300 or more, and even further preferably 600 or more. The number of amino acid residues may be 1,000 or more, or 1,500 or more.

[0022] Preferable examples of the polypeptides to be used as antigens include the polypeptides of the even-numbered SEQ ID NOs: 2 to 30 or fragments thereof comprising epitopes (e.g., a polypeptide fragment comprising about 7 to 12 or more amino acid residues).

[0023] Nucleotide sequences of polynucleotides encoding proteins consisting of the amino acid sequences of the even-numbered SEQ ID NOs: 2 to 30 (i.e., SEQ ID NOs: 2, 4, 6...28, and 30) are represented by the odd-numbered

SEQ ID NOs: 1 to 29 (i.e., SEQ ID NOs: 1, 3, 5...27, and 29).

[0024] In general, it is well known in the art that protein antigens retain antigenicity almost equivalent to that of the original protein even if a small number of amino acid residues have been substituted, deleted, added, or inserted in the amino acid sequence of the protein. Therefore, a polypeptide having a sequence derived from the amino acid sequence of a CAPRIN-1 protein by substitution, deletion, and/or insertion of a small number of (preferably one or several) amino acid residues, having 80% or higher, 85-90% or higher, preferably 90% or higher, more preferably 95% or higher, further preferably 98% or higher, and still further preferably 99% or higher sequence identity with the original sequence, and specifically binding via an antigen-antibody reaction to an antibody against CAPRIN-1 (hereinafter, the same may be referred to as a "specifically reactive modified polypeptide" for convenience) can be used for cancer detection in a manner similar to the case of the polypeptides described above. Preferably, a specifically reactive modified polypeptide has an amino acid sequence derived from the amino acid sequence of a CAPRIN-1 protein by substitution, deletion, and/or insertion of one or several amino acid residues. The term "several" used herein refers to an integer of 2 to 10, preferably an integer of 2 to 6, and further preferably an integer of 2 to 4.

[0025] The term "sequence identity" used herein with reference to amino acid sequences is determined by aligning two amino acid sequences to be compared, so that as many amino acid residues match as possible, dividing the number of amino acid residues that match by the total number of amino acid residues, and then expressing the results in percentage terms (%). Upon the above alignment, gaps are inserted as appropriate into one or both of the sequences to be compared, according to need. Such sequence alignment can be performed using a well-known program or algorithm, such as BLAST, FASTA, or CLUSTAL W (Karlín and Altschul, Proc. Natl. Acad. Sci. U.S.A., 87: 2264-2268, 1993; Altschul et al., Nucleic Acids Res., 25: 3389-3402, 1997).

[0026] Twenty types of amino acids constituting naturally occurring proteins can be divided into groups of amino acids having properties analogous to each other: neutral amino acids having side chains with low polarity (Gly, Ile, Val, Leu, Ala, Met, and Pro); neutral amino acids having hydrophilic side chains (Asn, Gln, Thr, Ser, Tyr, and Cys); acidic amino acids (Asp and Glu); basic amino acids (Arg, Lys, and His); and aromatic amino acids (Phe, Tyr, Trp, and His). It is known that substitution among these amino acids (that is, conservative substitution) rarely alters the properties of the resulting polypeptide. When amino acid residues of CAPRIN-1 are to be substituted, accordingly, substitution is performed between members of the same group, so that the possibility of maintaining binding with the corresponding antibody becomes higher. In the present invention, however, the above variant may involve non-conservative substitution, as long as immunity-inducing activity equivalent to or almost equivalent to that of an unmodified polypeptide is imparted.

[0027] A polypeptide (hereinafter, which may be referred to as a "specifically reactive addition polypeptide" for convenience) that contains, as a partial sequence, the above polypeptide to be used in the present invention (e.g., prepared by addition of another (poly)peptide to one end or both ends of a polypeptide to be used in the present invention) and specifically binds via an antigen-antibody reaction to an antibody against CAPRIN-1 can also be used for detection of pancreatic cancer in a manner similar to the cases of the above polypeptides.

[0028] The polypeptides used in the present invention can be synthesized in accordance with a chemical synthesis method such as the Fmoc method (the fluorenylmethyloxycarbonyl method) or the tBoc method (the t-butyloxy-carbonyl method) (the Japanese Biochemical Society (ed.), Seikagaku Jikken Koza (Biochemical Experimental Lecture Series) 1, Tanpakushitsu no Kagaku (Protein Chemistry) IV, Kagaku Shushoku to Peptide Gousei (Chemical Modification and Peptide Synthesis), TOKYO KAGAKU DOZIN CO., LTD, Japan, 1981). Also, the polypeptides can be synthesized by a conventional method using various commercially available peptide synthesizers. Alternatively, the polypeptides can be easily prepared by known genetic engineering techniques (e.g., Sambrook et al., Molecular Cloning, 2nd Edition, Current Protocols in Molecular Biology, 1989, Cold Spring Harbor Laboratory Press; Ausubel et al., Short Protocols in Molecular Biology, 3rd Edition, A Compendium of Methods from Current Protocols in Molecular Biology, 1995, John Wiley & Sons). From RNA extracted from a tissue expressing a gene encoding the human CAPRIN-1 of SEQ ID NO: 2 or a homolog thereof, for example, cDNA of the gene is prepared via RT-PCR, the full-length sequence or a desired partial sequence of the cDNA is incorporated into an expression vector, and the vector is then introduced into a host cell. Thus, a polypeptide of interest can be obtained. The nucleotide sequences of cDNAs encoding canine CAPRIN-1 of SEQ ID NOs: 6, 8, 10, 12, and 14 are shown in SEQ ID NOs: 5, 7, 9, 11, and 13, respectively. The nucleotide sequences of human homologs thereof; that is, the cDNAs encoding human CAPRIN-1 of SEQ ID NOs: 2 and 4, are shown in SEQ ID NOs: 1 and 3, respectively. Accordingly, primers used for RT-PCR can be easily designed with reference to these nucleotide sequences. As described below, also, a gene encoding CAPRIN-1 of a non-human mammal can be amplified using primers designed with reference to the nucleotide sequences of the odd-numbered SEQ ID NOs: 1 to 29. Accordingly, cDNA encoding, for example, feline CAPRIN-1 can be easily prepared by techniques similar to the above techniques. RNA extraction, RT-PCR, incorporation of cDNA into a vector, and introduction of a vector into a host cell can be performed by, for example, well-known methods as described below. Also, vectors and host cells used herein are well known, and various vectors and host cells are commercially available.

[0029] The above host cells may be any cells, as long as they can express the above polypeptides. Examples of prokaryotic host cells include *Escherichia coli*. Examples of eukaryotic host cells include cultured mammalian cells, such

as monkey kidney cells (COS1), Chinese hamster ovary cells (CHO), the human embryonic kidney cell line (HEK293), and the mouse embryonic skin cell line (NIH3T3), budding yeast, fission yeast, silkworm cells, and *Xenopus* oocytes.

[0030] When prokaryotic cells are used as host cells, an expression vector having a replication origin in prokaryotic cells, a promoter, a ribosome-binding site, a multi-cloning site, a terminator, a drug-resistance gene, an auxotrophic complementary gene, and the like is used. Examples of expression vectors for *Escherichia coli* include pUC vectors, pBluescriptII, pET expression systems, and pGEX expression systems. DNA encoding the above polypeptide is incorporated into such an expression vector, prokaryotic host cells are transformed with the vector, and the thus obtained transformant is cultured. Thus, the polypeptide encoded by the DNA can be expressed in the prokaryotic host cells. At this time, the polypeptide can also be expressed as a fusion protein with another protein. DNA encoding the above polypeptide can be obtained by preparing cDNA by, for example, RT-PCR, as described above. Alternatively, such DNA can be synthesized by a conventional technique using a commercially available nucleic acid synthesizer, as described below. The nucleotide sequences of cDNAs of the genes encoding CAPRIN-1 of SEQ ID NOs: 2 and 4 are shown in SEQ ID NOs: 1 and 3 in the Sequence Listing, respectively.

[0031] When eukaryotic cells are used as host cells, an expression vector for eukaryotic cells having a promoter, a splicing region, a poly(A) additional site, and the like is used. Examples of such an expression vector include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, an EBV vector, pRS, pcDNA3, and pYES2. As described above, DNA encoding a polypeptide used in the present invention is incorporated into such an expression vector, eukaryotic host cells are transformed with the vector, and the thus obtained transformant is cultured. Thus, the polypeptide encoded by the above DNA can be expressed in eukaryotic host cells. When pIND/V5-His, pFLAG-CMV-2, pEGFP-N1, pEGFP-C1, or the like is used as an expression vector, the above polypeptide can be expressed as a fusion protein with various tags, such as His tags (e.g., (His)₆ to (His)₁₀), a FLAG tag, a myc tag, an HA tag, or GFP.

[0032] An expression vector can be introduced into a host cell in accordance with a well-known technique, such as electroporation, a calcium phosphate method, a liposome method, a DEAE dextran method, microinjection, viral infection, lipofection, or binding with a cell-membrane-permeable peptide.

[0033] A polypeptide of interest can be isolated and purified from host cells using known isolation techniques in combination. Examples of such techniques include treatment using a denaturing agent such as urea or a surfactant, ultrasonication, enzymatic digestion, salting-out, solvent fractionation and precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, and reverse phase chromatography.

[0034] Polypeptides obtained by the above methods include polypeptides in the form of fusion proteins with any other proteins. Examples of such fusion proteins include a fusion protein with glutathione-S-transferase (GST) and a fusion protein with a His tag. Polypeptides in the form of such fusion proteins are also within the scope of the above described specifically reactive addition polypeptides, and such polypeptides can be used for the first detection method of the present invention. Further, polypeptides expressed in transformed cells may occasionally be subjected to various types of modification within cells after translation. Such a post-translationally modified polypeptide can be used in the first detection method of the present invention, as long as it is capable of specifically binding, via an antigen-antibody reaction, to an antibody against a CAPRIN-1 protein. Examples of such post-translational modification include the removal of N-terminal methionine, N-terminal acetylation, glycosylation, limited proteolysis by intracellular protease, myristoylation, isoprenylation, and phosphorylation.

[0035] An antibody in a sample can be easily measured by immunoassay using the above polypeptide as an antigen. Immunoassay itself is well known in the art. Immunoassay is classified into the sandwich method, the competition method, the agglutination method, the Western blot method, and the like based on types of reactions. Also, immunoassay is classified based on labels into radioimmunoassay, fluorescence immunoassay, enzyme immunoassay, and biotin immunoassay, for example. Immunoassay of the above antibody can be performed using any of these methods. Sandwich ELISA or the agglutination method are preferably employed as an immunoassay technique for the above antibody in the method of the present invention, since the procedures of these methods are convenient and require no extensive apparatus and the like, although techniques are not limited thereto. When an enzyme is used as a label for an antibody, such enzyme is not particularly limited, as long as it satisfies conditions such that: the turnover number is high; it remains stable even if it is bound to an antibody; and it specifically causes the color development of the substrate. Enzymes that can be used for general enzyme immunoassay, such as peroxidase, β -galactosidase, alkaline phosphatase, glucose oxidase, acetylcholine esterase, glucose-6-phosphorylation dehydrogenase, and malic acid dehydrogenase, can be used. In addition, enzyme-inhibiting substances, coenzymes, and the like can be used. Binding of these enzymes with antibodies can be performed by known methods involving the use of a cross-linking agent, such as a maleimide compound, the biotin-(strept)avidin system, or the like. As a substrate, a known substance can be used depending on the type of an enzyme to be used. When peroxidase is used as an enzyme, for example, 3,3',5,5'-tetramethylbenzidine can be used. When alkaline phosphatase is used, for example, para-nitrophenol can be used. A radioisotope that is generally used for radioimmunoassay, such as ¹²⁵I or ³H, can be used. A fluorescent dye that is used for general fluorescent antibody techniques, such as fluorescence isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), or a

cyanine fluorescence dye (e.g., Cy3 or Cy5), can be used.

5 [0036] There is no need to explain the above immunoassay techniques herein since these techniques are well known; however, briefly, for example, the sandwich method comprises immobilizing the above polypeptide used as an antigen on a solid phase, allowing the polypeptide to react with a sample such as serum, washing, allowing an appropriate
10 secondary antibody to react with an antibody from the sample, again washing, and then measuring the secondary antibody bound to the solid phase. By immobilizing an antigenic polypeptide on a solid phase, an unbound secondary antibody can be easily removed. Accordingly, it is preferable as an embodiment of the method for detecting cancer of the present invention. As a secondary antibody, an anti-canine IgG antibody, for example, can be used if a sample is from a dog. A secondary antibody is labeled in advance with a labeling substance exemplified above, so that the secondary
15 antibody bound to a solid phase can be measured. The amount of the secondary antibody thus measured corresponds to the amount of the above antibody in the serum sample. When an enzyme is used as a labeling substance, the amount of the antibody can be measured by adding a substrate that is degraded in order to develop color by enzymatic action and then optically measuring the amount of the substrate degraded. When a radioisotope is used as a labeling substance, the amount of radiation from the radioisotope can be measured using a scintillation counter or the like.

20 [0037] In the second method of the present invention, CAPRIN-1 that can be contained in a sample obtained from a subject is measured. As described above, the amount of an antibody that undergoes an antigen-antibody reaction with CAPRIN-1 of a dog, a human, or the like is significantly higher in subjects with pancreatic cancer, compared with healthy subjects. This indicates that the amount of CAPRIN-1 accumulated as an antigen is significantly high in pancreatic cancer cells. In the case of healthy subjects, the CAPRIN-1 expression level is below the detection limit, or CAPRIN-1
25 expression in tissue is weak and it might occur merely within cells. Pancreatic cancer can also be detected by directly measuring CAPRIN-1, as specifically described in the examples below. Therefore, pancreatic cancer can be detected in a subject by measuring CAPRIN-1 itself, as in the case of the first method.

30 [0038] A polypeptide in a sample can be easily measured by well-known immunoassay techniques. Specifically, an antibody that undergoes an antigen-antibody reaction with CAPRIN-1 or an antigen-binding fragment thereof is prepared, and immunoassay is carried out using the same. Thus, the presence of CAPRIN-1 in the sample can be measured. As described above, an antibody has cross-reactivity. With the use of an antibody that undergoes an antigen-antibody
35 reaction with canine CAPRIN-1 of SEQ ID NO: 6 or an antigen-binding fragment thereof, accordingly, not only the canine CAPRIN-1 of SEQ ID NO: 6, but also its homologs in other mammals (e.g., the human CAPRIN-1 of SEQ ID NO: 2 or 4) can be measured. The immunoassay technique itself is a well-known conventional technique, as described above.

40 [0039] This study reveals that CAPRIN-1 is a cell membrane protein that is expressed on the surface of pancreatic cancer cells. A subject with cancer contains many proteases in cancer tissues. Accordingly, the portion of the CAPRIN-1 sequence expressed outside the cancer cells is degraded and separated from the cancer cells, and such portion is larger in amount than the portion of the CAPRIN-1 sequence expressed in the cancer cells. If an antibody capable of binding to the surfaces of pancreatic cancer cells is used as an antibody against CAPRIN-1 in the measurement, or if
45 an antigen-binding fragment thereof is used, accordingly, a larger amount of CAPRIN-1 can be detected, and pancreatic cancer can be diagnosed with higher sensitivity.

50 [0040] In the present invention, accordingly, use of an antibody that binds to a portion expressed on the surface of a pancreatic cancer cell of a CAPRIN-1 protein molecule is preferable. An example of a partial peptide of a CAPRIN-1 protein expressed on the surface of a pancreatic cancer cell is a polypeptide consisting of an amino acid sequence of 7 to 12 or more continuous amino acid residues within the region of amino acid residues (aa) 50 to 98 or amino acid residues (aa) 233 to 305 in any of the amino acid sequences represented by even-numbered SEQ ID NOs: 2 to 30 in the Sequence Listing, excluding SEQ ID NO: 6 and SEQ ID NO: 18. A specific example thereof is, but is not limited to,
55 the amino acid sequence represented by SEQ ID NO: 43 or SEQ ID NO: 61 (in the amino acid sequence represented by SEQ ID NO: 61, a region of the amino acid sequence represented by SEQ ID NO: 62 or SEQ ID NO: 63 is preferable) or an amino acid sequence having 80% or higher, preferably 85% or higher, more preferably 90% or higher, and further preferably 95% or higher sequence identity with the relevant amino acid sequence. In addition, all antibodies binding to these polypeptides fall within the scope of the antibodies used in the present invention. Specific examples include an antibody binding to a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 43 or antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 44 and 45 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 44 and 46 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 44 and 47 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 44 and 48 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 49 and 50 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 51 and 52 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 53 and 54 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 55 and 56 or an antigen-binding fragment thereof, a monoclonal antibody having the amino acid sequences

represented by SEQ ID NOs: 57 and 58 or an antigen-binding fragment thereof, and a monoclonal antibody having the amino acid sequences represented by SEQ ID NOs: 59 and 60 or an antigen-binding fragment thereof.

5 [0041] The term "antigen-binding fragment" used herein refers to an antibody fragment capable of binding to an antigen, such as an Fab fragment, an F(ab)₂ fragment, or an Fv fragment, contained in an antibody molecule. An antibody may be a polyclonal antibody or a monoclonal antibody. For immunoassay, a monoclonal antibody with high reproducibility is preferable. Methods for preparing a polyclonal antibody and a monoclonal antibody using a polypeptide as an immunogen are well known and can be easily performed in a conventional manner. For example, an animal is immunized with CAPRIN-1 or a fragment thereof alone or CAPRIN-1 or a fragment thereof bound to a carrier protein, such as keyhole limpet hemocyanin (KLH), casein, or serum albumin, as an immunogen, together with an adjuvant, and an antibody against CAPRIN-1 can then be induced. Antibody-producing cells, such as splenocytes or lymphocytes, collected from the immunized animal are fused to myeloma cells to prepare hybridomas, and hybridomas producing an antibody that binds to CAPRIN-1 are selected and then grown. Thus, a monoclonal antibody whose corresponding antigen is CAPRIN-1 can be obtained from the culture supernatant. The method described above is a well-known conventional method.

15 [0042] In the third method of the present invention, a nucleic acid encoding CAPRIN-1 (e.g., mRNA or cDNA synthesized from mRNA) that can be contained in a sample obtained from a living organism is measured. As specifically described in the examples below, a nucleic acid encoding the canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12, or 14 or human CAPRIN-1 of SEQ ID NO: 2 or 4 is expressed at a significantly high level in pancreatic cancer cells. Therefore, a cancer existing in the living body can be detected by measuring such nucleic acid in a sample.

20 [0043] mRNA in a sample can be quantitatively measured by, for example, a conventional method, such as real-time detection RT-PCR using the mRNA as a template. Such mRNA can generally be quantitatively measured based on staining intensity or the like in the conventional Northern blot method. The cDNA sequences encoding CAPRIN-1 of the even-numbered SEQ ID NOs: 2 to 30 are represented by the odd-numbered SEQ ID NOs: 1 to 29, respectively. Accordingly, a polynucleotide specifically hybridizing to a partial region in the nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29 (hereinafter, referred to as a "polynucleotide for cancer detection") is prepared based on these sequences, and such polynucleotide is used as a probe or a primer for nucleic acid amplification to determine the amount of the mRNA in a sample. If a polynucleotide is capable of specifically hybridizing to a partial region in the nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29, mRNA encoding CAPRIN-1 in mammals other than dogs and humans can also be measured, as described later. In the present invention, a polynucleotide may be RNA or DNA.

25 [0044] The term "specifically hybridizing to" used herein refers to a situation in which said polynucleotide hybridizes only to a target partial region and does not substantially hybridize to any other regions under stringent hybridization conditions.

30 [0045] The term "under stringent hybridization conditions" used herein refers to conditions employed for annealing in general PCR or detection using a probe. In the case of PCR using Taq polymerase, for example, a reaction is performed at an appropriate annealing temperature ranging from about 54°C to 60°C using a general buffer, such as a buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3 to 9.0), and 1.5 mM MgCl₂. In the case of Northern hybridization, for example, a reaction is performed using a general hybridization solution such as 5x SSPE, 50% formamide, 5x Denhardt's solution, and 0.1-0.5% SDS, or 0.1-5x SSC and 0.1-0.5% SDS at an appropriate hybridization temperature ranging from about 42-65°C. After hybridization, washing is performed with, for example, 0.1-0.2x SSC and 0.1% SDS. Appropriate annealing temperatures or hybridization temperatures are not limited to the above examples, and such temperatures are determined based on the T_m value for a polynucleotide for cancer detection that is used as a primer or a probe and the empirical rules of experimenters. A person skilled in the art can easily determine such temperature range.

35 [0046] The expression "does not substantially hybridize to" used herein refers to a situation in which said polynucleotide does not hybridize to a target partial region at all or a extremely low amount of the polynucleotide hybridizes to a target partial region, that is, in a relatively negligible amount, even when it hybridizes to a target partial region. An example of the polynucleotide specifically hybridizing under such conditions is a polynucleotide having a certain level or higher of a sequence identity with the nucleotide sequence of a target partial region. For example, such polynucleotide has 70% or higher, preferably 80% or higher, more preferably 85% or higher, further preferably 90% or higher, even further preferably 93% or higher, still further preferably 95% or higher, and particularly preferably 98% or higher sequence identity. Most preferably, the polynucleotide has a nucleotide sequence identical to the nucleotide sequence of a target partial region. Sequence identity is defined in the same manner as the sequence identity of the amino acid sequence described above. Even if a terminus of a polynucleotide for cancer detection contains a region that does not hybridize thereto, in the case of a probe, it can be used for detection as long as a hybridizing region occupies about a half or more of the entire probe. In the case of a primer, it can be used for detection as long as a hybridizing region occupies about a half or more of the entire primer and is located on the 3' terminal side, since this allows a normal annealing and extension reaction to take place. When a terminus of a polynucleotide for cancer detection contains a non-hybridizing region, as described above, sequence identity with a target nucleotide sequence is calculated focusing only on the

hybridizing region without taking a non-hybridizing region into consideration.

[0047] In the present invention, the term "partial sequence" (or "partial region") refers to a part of a nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29. Specifically, the partial sequence comprises at least 15 to 19 continuous nucleotides, preferably 18 or more continuous nucleotides, more preferably at least 20 or 25 continuous nucleotides, and further preferably at least 30, 40, or 50 continuous nucleotides. The expression "the nucleotide sequence represented by SEQ ID NO: 5" used herein refers to, in addition to the nucleotide sequence actually shown in SEQ ID NO: 5, a sequence complementary thereto. Accordingly, the expression "a polynucleotide having the nucleotide sequence represented by SEQ ID NO: 5" refers to, for example, a single-stranded polynucleotide having the nucleotide sequence actually represented by SEQ ID NO: 5, a single-stranded polynucleotide having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 5, or a double-stranded polynucleotide consisting of the two single-stranded polynucleotides. When a polynucleotide to be used in the present invention is prepared or a polynucleotide encoding a polypeptide to be used in the present invention is prepared, any of the nucleotide sequences is appropriately selected, and a person skilled in the art can readily perform such selection.

[0048] The number of nucleotides in a polynucleotide for cancer detection is preferably 18 or more in view of ensuring specificity. When the polynucleotide is used as a probe, it preferably comprises 18 or more nucleotides, and it further preferably comprises 20 nucleotides to the full length of the coding region. When the polynucleotide is used as a primer, it preferably comprises 18 to 50 nucleotides. A preferable example of the polynucleotide for cancer detection is a polynucleotide comprising 18 or more continuous nucleotides in a nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29.

[0049] It is apparent to a person skilled in the art who refers to the description of the present invention that: a polynucleotide specifically hybridizing to a partial region in SEQ ID NO: 5, 7, 9, 11, or 13 is used for measuring the amount of a nucleic acid (e.g., mRNA or cDNA synthesized from mRNA) encoding the canine CAPRIN-1 protein of SEQ ID NO: 6, 8, 10, 12, or 14, respectively; and a polynucleotide specifically hybridizing to a partial region in SEQ ID NO: 1 or 3 is used for measuring the amount of a nucleic acid (e.g., mRNA or cDNA synthesized from mRNA) encoding the human CAPRIN-1 protein of SEQ ID NO: 2 or 4, respectively. However, a protein from a given mammal and a homolog thereof from another mammal generally share a high sequence identity even at the nucleotide sequence level. Thus, the sequence identity among the nucleotide sequences of SEQ ID NOs: 1 to 13 is also as high as 94% to 100%. Accordingly, a polynucleotide specifically hybridizing to a partial region of the sequence of SEQ ID NO: 5 can also specifically hybridize to a partial region corresponding to the partial region of any of the odd-numbered SEQ ID NOs: 1 to 29.

[0050] In fact, a pair of primers having the nucleotide sequences represented by SEQ ID NO: 33 and 34 specifically hybridize to both a partial region of any of the odd-numbered SEQ ID NOs: 1 to 29 and a partial region of the sequence of SEQ ID NO: 5, as described in the examples below. Thus, both mRNA encoding the canine CAPRIN-1 of SEQ ID NO: 6 and mRNA encoding a homolog thereof can be measured. With the use of a polynucleotide specifically hybridizing to a partial region of the sequence of SEQ ID NO: 5, accordingly, not only mRNA encoding the canine CAPRIN-1 of SEQ ID NO: 6 but also mRNA encoding the human CAPRIN-1 of SEQ ID NO: 2 or 4 can be measured. Similarly, mRNA encoding CAPRIN-1 of another mammal such as a cat can also be measured. When a polynucleotide for cancer detection is designed, it is more desirable to select partial regions having particularly high sequence identity from among the odd-numbered SEQ ID NOs: 1 to 29 (and identical nucleotide sequences are preferable). If there is a particularly high sequence identity having partial region between canine CAPRIN-1 and human CAPRIN-1, a region showing very high sequence identity with such region is expected to be also present in a homolog gene of another animal species. Through selection of such a partial region, accuracy for measuring mRNA encoding CAPRIN-1 of an animal species other than dogs or humans can be increased.

[0051] A method for measuring a nucleic acid in test object using a polynucleotide specifically hybridizing to a partial region of the nucleic acid as a probe or a primer(s) for nucleic acid amplification method such as PCR is well known. Examples of such method include, in addition to RT-PCR as specifically described in the examples below, Northern blot and *in situ* hybridization. When the amount of mRNA is measured in the present invention, any such well-known measurement method can be employed.

[0052] A nucleic acid amplification method such as PCR is well known in the art, and reagent kits and apparatuses used therefor are commercially available, so that the method can be easily performed. Specifically, denaturation, annealing, and extension steps are each performed using a nucleic acid in test object (e.g., the cDNA of a gene encoding a protein having an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30) as a template and a pair of polynucleotides (primers) for cancer detection in a known buffer in the presence of thermostable DNA polymerase such as Taq polymerase or Pfu polymerase and dNTPs (here, N = A, T, C, and G) by varying the temperature of the reaction solution in each step. In general, the denaturation step is performed at 90°C to 95°C, the annealing step is performed at or near the T_m of the template and the primers (preferably within $\pm 4^\circ\text{C}$), and the extension step is performed at 72°C, which is the optimum temperature for thermostable DNA polymerase such as Taq polymerase or Pfu polymerase, or a temperature near the optimum temperature. The duration of each step is adequately set to between about 30 seconds and 2 minutes. This heating cycle is repeated about 25 to 40 times, for example, so that the template

nucleic acid region sandwiched between a pair of primers is amplified. The nucleic acid amplification method is not limited to PCR, and any other nucleic acid amplification methods well known in the art can be employed. When a nucleic acid amplification method is performed using a pair of polynucleotides for cancer detection as primers and a nucleic acid in test object as a template, as described above, the nucleic acid is amplified. If a sample does not contain the test nucleic acid, however, amplification does not take place. Accordingly, an amplification product may be detected so as to determine the presence or absence of the nucleic acid in the sample. An amplification product can be detected by a method that comprises subjecting a reaction solution after amplification to electrophoresis and then staining the band with ethidium bromide or the like or a method that comprises immobilizing an amplification product after electrophoresis on a solid phase such as a nylon membrane, performing hybridization with a labeling probe that specifically hybridizes to a nucleic acid, washing, and then detecting the label. Also, so-called real-time detection PCR is performed using a quencher fluorescent dye and a reporter fluorescent dye, and the amount of a nucleic acid in a specimen can thus be quantified. Since kits for real-time detection PCR are commercially available, real-time detection PCR can be easily performed. Further, semi-quantitative measurement of a nucleic acid in test object can also be carried out based on electrophoresis band intensity. A nucleic acid in test object may be either mRNA or cDNA reversely transcribed from mRNA. When mRNA is amplified as a nucleic acid, a NASBA method (the 3SR method or TMA method) using the above pair of primers can also be employed. The NASBA method is well known, and kits therefor are also commercially available, so that the method can be easily performed using the above pair of primers.

[0053] As a probe, a labeled probe that is prepared by labeling a polynucleotide for cancer detection with a fluorescent label, a radiolabel, a biotin label, or the like can be used. Methods for labeling a polynucleotide are well known. The presence or absence of a nucleic acid in a sample can be examined by immobilizing a nucleic acid or an amplification product thereof, performing hybridization with a labeled probe, washing, and then measuring the label bound to the solid phase. Alternatively, a polynucleotide for cancer detection is immobilized, a nucleic acid in test object is hybridized thereto, and the test nucleic acid bound to the solid phase can then be detected using the labeled probe or the like. In such a case, a polynucleotide for cancer detection bound to a solid phase is also referred to as a "probe." Methods for measuring a nucleic acid using a polynucleotide probe are also well known in the art. Such a method can be performed by, in a buffer, bringing a polynucleotide probe into contact with a nucleic acid in test object at T_m or near T_m (preferably, $\pm 4^\circ\text{C}$) for hybridization, washing, and then measuring the labeled probe hybridized or the template nucleic acid bound to the solid-phase probe. Examples of such method include well-known methods such as Northern blotting, *in situ* hybridization, and Southern blotting. In the present invention, any well-known method is applicable.

[0054] According to the detection method of the present invention, whether or not a subject animal (or a subject) is afflicted with pancreatic cancer is evaluated based on the presence or amount of CAPRIN-1 expression measured as described above. While pancreatic cancer can be detected only by measuring the presence or amount of CAPRIN-1 expression in a subject animal, it is preferable that the expression levels (the antibody level, polypeptide level, or mRNA level) of CAPRIN-1 in one or more samples of healthy subjects is examined and the determined value of a subject animal is compared with the standard value obtained from healthy subjects, in view of enhancing detection accuracy. To further enhance detection accuracy, CAPRIN-1 expression levels are measured for samples obtained from many patients found to have pancreatic cancer, so as to obtain a standard value for pancreatic cancer patients, and the determined value of a subject animal may then be compared with both the standard value for healthy subjects and the standard value for pancreatic cancer patients. The above standard values can be determined by, for example, quantifying the CAPRIN-1 expression level in each sample and calculating the mean value thereof. The standard value for healthy subjects and the same for pancreatic cancer patients can be determined in advance by measuring CAPRIN-1 expression levels in many healthy subjects and pancreatic cancer patients. When comparison with the standard value is performed in the method of the present invention, accordingly, a standard value determined in advance may be used.

[0055] The detection method of the present invention may comprise diagnosis based on other cancer antigens or cancer markers in combination. This can further enhance the accuracy of pancreatic cancer detection. When an antibody specifically existing in pancreatic cancer patients is measured by the method of the present invention, for example, another polypeptide that is often expressed in a cancer tissue can be used in combination as an antigen in a manner similar to that used for polypeptides described above. Also, the method of the present invention may be performed in combination with diagnosis using a previously known cancer marker.

[0056] Pancreatic cancer to be subjected to the method for detecting pancreatic cancer of the present invention is pancreatic cancer expressing CAPRIN-1. Examples of such cancer include, but are not limited to, pancreatic ductal carcinoma, invasive pancreatic ductal carcinoma, adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), pancreatoblastoma, serous cystadenocarcinoma, solid-pseudopapillary tumor (SPT), gastrinomas (Zollinger-Ellison syndrome), glucagonomas, insulinomas, multiple endocrine neoplasia Type-1 (MEN1) (Wermer syndrome), nonfunctional islet cell tumor, somatostatinomas, and VIPomas. A subject in the method of the present invention is a mammal, preferably a human or a dog.

[0057] Examples of samples to be subjected to the method of the present invention include body fluids, such as blood,

serum, blood plasma, ascites fluid, and pleural effusion, tissues, and cells. In the first method and the second method, in particular, serum, blood plasma, ascites fluid, pleural effusion, tissue, and cell samples can be preferably used. In the third method comprising measuring a nucleic acid such as mRNA, tissue and cell samples are preferable.

[0058] One or more polypeptides to be used as antigens for immunoassay in the first method described above (i.e., the canine CAPRIN-1 of SEQ ID NO: 2 and a homolog thereof, a specifically reactive partial polypeptide, a specifically reactive modified polypeptide, and a specifically reactive addition polypeptide) can be provided as reagents or kits for detection of pancreatic cancer. Such a reagent may consist of the above polypeptide, or it may contain various additives useful for stabilization of the polypeptide, a buffer necessary for assay, secondary antibodies, substrates for enzymes, or the like, separately. Alternatively, such a reagent can be immobilized on a solid phase such as a plate or membrane. Preferable examples of such polypeptides are given above.

[0059] An antibody or an antigen-binding fragment thereof, which undergoes an antigen-antibody reaction with CAPRIN-1, used for immunoassays of CAPRIN-1 by the second method can also be provided in the form of a reagent for pancreatic cancer detection. The reagent for pancreatic cancer detection may consist of the above antibody or an antigen-binding fragment thereof. The reagent may contain various additives useful for stabilization of such antibody or an antigen-binding fragment thereof. Alternatively, a metal, such as manganese or iron, may be bound to the antibody or an antigen-binding fragment thereof. When such metal-bound antibody or an antigen-binding fragment thereof is administered to a living organism, the metal-bound antibody or antigen-binding fragment thereof is accumulated at an increased level at a site at which the antigen protein is present at a higher level. When such metal-bound antibody or antigen-binding fragment thereof is administered to a living organism, the metal-bound antibody or antigen-binding fragment thereof is accumulated at an increased level at a site at which the antigen protein is present at a higher level. Therefore, the metal is measured by MRI or the like, and the presence of cancer cells producing the antigen protein can be thus detected.

[0060] Furthermore, one or more the above polynucleotides for pancreatic cancer detection to be used for measuring a nucleic acid such as mRNA in the third method can also be provided as a reagent or kit for pancreatic cancer detection. In such a case, the reagent for pancreatic cancer detection may consist of the polynucleotide, or it may contain various additives useful for stabilization of the polypeptide, a buffer necessary for assay (e.g., a fluorescent label), and the like, separately. The polynucleotide for pancreatic cancer detection contained in the reagent is preferably a primer(s) or a probe(s). Conditions and preferable examples of the polynucleotide for pancreatic cancer detection are as described above.

Examples

[0061] The present invention will be described in more detail with reference to the following examples, although the technical scope of the present invention is not limited to the examples.

[Example 1] Obtaining pancreatic cancer antigenic protein by SEREX method (1) Construction of cDNA library

[0062] Total RNA was extracted from a testis tissue of a healthy dog by the acid guanidium-phenol-chloroform method, and poly A RNA was purified using an Oligotex-dT30 mRNA purification kit (Takara Shuzo, Co., Ltd.) in accordance with the protocols attached to the kit.

[0063] A canine testis cDNA phage library was synthesized using the thus obtained mRNA (5 μ g). The cDNA phage library was constructed using cDNA Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA GigapackIII Gold Cloning Kit (STRATAGENE) in accordance with the protocols attached to the kits. The size of the thus constructed cDNA phage library was 7.73×10^5 pfu/ml.

(2) Screening of cDNA library using serum

[0064] Immunoscreening was performed using the canine testis cDNA phage library constructed above. Specifically, host *Escherichia coli* (XL1-Blue MRF') was infected with the phage on an NZY agarose plate ($\Phi 90 \times 15$ mm) so as to obtain 2,210 clones. *E. coli* cells were cultured at 42°C for 3 to 4 hours to form plaques. The plate was covered with a nitrocellulose membrane (Hybond C Extra: GE Healthcare Bio-Science) impregnated with IPTG (isopropyl- β -D-thiogalactoside) at 37°C for 4 hours, so that the protein was induced to express and then transferred to the membrane. Thereafter, the membrane was collected and then soaked in TBS (10 mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 0.5% powdered skim milk, followed by shaking at 4°C overnight, so as to suppress nonspecific reactions. The filter was subjected to a reaction with a 500-fold diluted serum of an afflicted dog at room temperature for 2 to 3 hours.

[0065] As the above serum of the afflicted dog, a serum collected from a canine afflicted with pancreatic cancer was used. The serum was stored at -80°C and then subjected to pre-treatment immediately before use. A method for serum pretreatment is as follows. Specifically, host *Escherichia coli* (XL1-Blue MRF') was infected with a λ ZAP Express phage

into which no foreign gene had been inserted, and culture was conducted overnight on a NZY plate medium at 37°C. Subsequently, buffer (0.2 M NaHCO₃, pH 8.3) containing 0.5 M NaCl was added to the plate, the plate was allowed to stand at 4°C for 15 hours, and a supernatant was then collected as an *Escherichia coli*/phage extract. The thus collected *Escherichia coli*/phage extract was then applied to an NHS-column (GE Healthcare Bio-Science), so that an *Escherichia coli*/phage-derived protein was immobilized. The serum of the afflicted dog was applied to the protein-immobilized column for reaction and *Escherichia coli* and an antibody adsorbed to the phage were then removed from the serum. The serum fraction that had passed through the column was diluted 500-fold with TBS containing 0.5% powdered skim milk. The diluted serum fraction was used as an immunoscreening material.

[0066] A membrane onto which the treated serum and the above fusion protein had been blotted was washed 4 times with TBS-T (0.05% Tween 20/TBS), and the membrane was then allowed to react with goat anti-canine IgG (Goat anti-Dog IgG-h+I HRP conjugated, BETHYL Laboratories) diluted 5000-fold with TBS containing 0.5% powdered skim milk as a secondary antibody at room temperature for 1 hour. Detection was performed via an enzymatic color development reaction using the NBT/BCIP reaction solution (Roche). Colonies that matched sites positive for the color development reaction were collected from the NZY agarose plate (Φ90 x 15 mm) and then dissolved in 500 μl of an SM buffer (100 mM NaCl, 10 mM MgClSO₄, 50 mM Tris-HCl, 0.01 % gelatin, pH 7.5). Until colonies positive for color development reaction were unified, secondary screening and tertiary screening were repeated by a method similar to the above, so that 30,940 phage clones reacting with the serum IgG were screened. Thus, 5 positive clones were isolated.

(3) Homology search for isolated antigen gene

[0067] For nucleotide sequence analysis of the 5 positive clones isolated by the above method, a procedure for conversion from phage vectors to plasmid vectors was performed. Specifically, 200 μl of a solution containing host *Escherichia coli* (XL1-Blue MRF') at the absorbance (OD₆₀₀) of 1.0 was prepared. The solution was mixed with 250 μl of a purified phage solution and 1 μl of ExAssist helper phage (STRATAGENE), the mixture was subjected to a reaction at 37°C for 15 minutes, 3 ml of LB medium was added thereto, and culture was then performed at 37°C for 2.5 to 3 hours. Immediately thereafter, the temperature of the solution was kept in a water bath at 70°C for 20 minutes, centrifugation was performed at 4°C and 1000 x g for 15 minutes, and the supernatant was then collected as a phagemid solution. Subsequently, 200 μl of a solution containing phagemid host *Escherichia coli* (SOLR) at the absorbance OD₆₀₀ of 1.0 was prepared. The resulting solution was mixed with 10 μl of a purified phage solution, followed by a reaction at 37°C for 15 minutes. The reaction product (50 ml) was seeded on LB agar medium containing ampicillin (final concentration: 50 μg/ml), and culture was conducted at 37°C overnight. Transformed SOLR single colony was collected and then cultured in LB medium containing ampicillin (final concentration: 50 μg/ml) at 37°C. Thereafter, plasmid DNA containing an insert of interest was purified using the QIAGEN plasmid Miniprep Kit (QIAGEN).

[0068] The purified plasmid was subjected to analysis of the full-length insert sequence by the primer walking method using the T3 primer represented by SEQ ID NO: 31 and the T7 primer represented by SEQ ID NO: 32. As a result of sequence analysis, the gene sequences represented by SEQ ID NOs: 5, 7, 9, 11, and 13 were obtained. A homology search program, BLAST search (<http://www.ncbi.nlm.nih.gov/BLAST/>), was performed using the nucleotide sequences and amino acid sequences (SEQ ID NOs: 6, 8, 10, 12, and 14) of the genes. As a result of this homology search with known genes, all of the 5 obtained genes were found to encode CAPRIN-1. The sequence identity among the 5 genes was 100% for nucleotide sequence and 99% for amino acid sequence in regions translated into proteins. Also, the sequence identity between the canine gene (any of SEQ ID NO: 5, 7, 9, 11, or 13) and a gene encoding a human homolog thereof was 94% for nucleotide sequence and 98% for amino acid sequence in regions translated into proteins. The nucleotide sequences of the human homolog are represented by SEQ ID NOs: 1 and 3 and the amino acid sequences of the same are represented by SEQ ID NOs: 2 and 4. Also, the sequence identity between the obtained canine gene and a gene encoding a cattle homolog was 94% for nucleotide sequence and 97% for amino acid sequence in regions translated into proteins. The nucleotide sequence of the cattle homolog is represented by SEQ ID NO: 15 and the amino acid sequence of the same is represented by SEQ ID NO: 16. The sequence identity between the gene encoding the human homolog and the gene encoding the cattle homolog was 94% for nucleotide sequences and ranged from 93% to 97% for amino acid sequence in regions translated into proteins. Also, the sequence identity between the obtained canine gene and a gene encoding an equine homolog was 93% for nucleotide sequence and 97% for amino acid sequence in regions translated into proteins. The nucleotide sequence of the equine homolog is represented by SEQ ID NO: 17 and the amino acid sequence of the same is represented by SEQ ID NO: 18. The sequence identity between the gene encoding the human homolog and the gene encoding the equine homolog was 93% for nucleotide sequence and 96% for amino acid sequence in regions translated into proteins. Also, the sequence identity between the obtained canine gene and a gene encoding the mouse homolog ranged from 87% to 89% in terms of nucleotide sequence and ranged from 95% to 97% for amino acid sequence in regions translated into proteins. The nucleotide sequences of the mouse homolog are represented by SEQ ID NOs: 19, 21, 23, 25, and 27 and the amino acid sequences of the same are represented by SEQ ID NOs: 20, 22, 24, 26, and 28. The sequence identity between the gene encoding the human

homolog and the gene encoding the mouse homolog ranged from 89% to 91% for nucleotide sequence and ranged from 95% to 96% for amino acid sequence in regions translated into proteins. Also, the sequence identity between the obtained canine gene and a gene encoding a chicken homolog was 82% for nucleotide sequence and 87% for amino acid sequence in regions translated into proteins. The nucleotide sequence of the chicken homolog is represented by SEQ ID NO: 29 and the amino acid sequence of the same is represented by SEQ ID NO: 30. The sequence identity between the gene encoding the human homolog and the gene encoding the chicken homolog ranged from 81 % to 82% for nucleotide sequence and 86% for amino acid sequence in regions translated into proteins.

(4) Gene expression analysis in human pancreatic cancer cell lines

[0069] Expression of the genes obtained by the above method in human normal tissues (i.e., mammary gland, brain, bone marrow, lung, esophagus, pancreas, and testis) and 4 types of pancreatic cancer cell lines (i.e., Capan-2, MIAPaCa-2, PANC-1, and BxPC-3) was examined by RT-PCR (reverse transcription-PCR). A reverse transcription reaction was performed as follows. Specifically, total RNA was extracted from each tissue (50 mg to 100 mg) and each cell line (5-10 x 10⁶ cells) using the TRIZOL reagent (Invitrogen) in accordance with the attached protocols. cDNA was synthesized using the total RNA and the Superscript First-Strand Synthesis System for RT-PCR (Invitrogen) in accordance with the attached protocols. PCR was performed as follows using primers specific to the obtained genes (represented by SEQ ID NOs: 33 and 34). Specifically, PCR was performed by preparing a reaction solution to bring a total amount thereof to 25 μ l with the addition of reagents and an included buffer (i.e., 0.25 μ l of a sample prepared by reverse transcription reaction, the above primers (2 μ M each), dNTPs (0.2 mM each), 0.65 U of ExTaq polymerase (Takara Shuzo, Co., Ltd.)), the resulting solution was subjected to a cycle of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds using a Thermal Cycler (BIO RAD), and this cycle was repeated 30 times. The gene-specific primers mentioned above were used to amplify the region between the nucleotide No. 698 and the nucleotide No. 1124 in the nucleotide sequence represented by SEQ ID NO: 1 (the human CAPRIN-1 gene). For comparison, GAPDH-specific primers (represented by SEQ ID NOs: 35 and 36) were used at the same time. As a result of inspection of human CAPRIN-1 gene expression, expression thereof was observed only in the testis in the case of healthy canine tissues, although expression was observed in the pancreatic cancer cells. The results demonstrate that CAPRIN-1 expression was not observed in normal tissues other than those of the testis, while CAPRIN-1 expression was observed in the pancreatic cancer cells.

(5) CAPRIN-1 expression in normal mouse and canine tissues

[0070] Mice (Balb/c, female) and dogs (beagle dogs, female) were exsanguinated under ether anesthesia and ketamine/isoflurane anesthesia. After laparotomy, organs (stomach, liver, eyeball, thymus gland, muscle, bone marrow, uterus, small intestine, esophagus, heart, kidney, salivary gland, large intestine, mammary gland, brain, lung, skin, adrenal gland, ovary, pancreas, spleen, and bladder) were each transferred to a 10 cm dish containing PBS. Each organ was cut open in PBS and then fixed by perfusion overnight with 0.1 M phosphate buffer (pH 7.4) containing 4% paraformaldehyde (PFA). The perfusate was discarded, the tissue surface of each organ was rinsed with PBS, and a PBS solution containing 10% sucrose was then introduced into a 50 ml centrifugal tube. Each tissue was then introduced into each tube, followed by shaking using a rotor at 4°C for 2 hours. Each solution was substituted with a PBS solution containing 20% sucrose and then allowed to stand at 4°C until tissues precipitated. Each solution was substituted with a PBS solution containing 30% sucrose and then allowed to stand at 4°C until tissues precipitated. Each tissue was removed and a necessary portion was excised with a surgical scalpel. Subsequently, the OCT compound (Tissue Tek) was applied and spread over each tissue surface, and the tissues were then placed on Cryomold. Cryomold was placed on dry ice for rapid freezing. Tissues were sliced into pieces of 10 to 20 μ m long using a cryostat (LEICA), the sliced tissue pieces were then air-dried on glass slides for 30 minutes using a hair dryer, and glass slides onto which sliced tissue pieces had been applied were thus prepared. Subsequently, each glass slide was introduced into a staining bottle filled with PBS-T (saline containing 0.05% Tween 20), a procedure involving exchanging PBS-T with fresh PBS-T was performed every 5 minutes, and this procedure was repeated 3 times. Excess water around each specimen was removed using Kimwipes and each section was then encircled using DAKOPEN (DAKO). As blocking solutions, a MOM mouse Ig blocking reagent (VECTASTAIN) was applied onto mouse tissue and a PBS-T solution containing a 10% fetal calf serum was applied onto canine tissue. The resultants were allowed to stand in a moist chamber at room temperature for 1 hour. Subsequently, a solution prepared with the blocking solution to a 10 μ g/ml anti-CAPRIN-1 monoclonal antibody (monoclonal antibody #8) having the heavy chain variable region of SEQ ID NO: 55 and the light chain variable region of SEQ ID NO: 56, which reacts with the cancer cell surfaces prepared in Example 3, was applied onto each slide glass and then allowed to stand within a moist chamber at 4°C overnight. After 3 instances of 10-minutes-washing with PBS-T, a MOM biotin-labeled anti-IgG antibody (VECTASTAIN) diluted 250-fold with the blocking solution was applied onto each glass slide and then allowed to stand within a moist chamber at room temperature for 1 hour. After 3 instances of 10-minutes-washing with PBS-T, an avidin-biotin ABC reagent (VECTASTAIN) was applied and then allowed to stand

within a moist chamber at room temperature for 5 minutes. After 3times of 10-minutes-washing with PBS-T, a DAB staining solution (10 mg of DAB + 10 μ l of 30% H₂O₂, and 50 ml of 0.05M Tris-HCl, pH 7.6) was applied, and the glass slides were then allowed to stand within a moist chamber at room temperature for 30 minutes. Glass slides were rinsed with distilled water and a hematoxylin reagent (DAKO) was then applied. After being allowed to stand at room temperature for 1 minute, the glass slides were rinsed with distilled water. The glass slides were put in 70%, 80%, 90%, 95%, and 100% ethanol solutions in such order for 1 minute each and then allowed to stand in xylene overnight. The glass slides were removed, coverslipped with Glycergel Mounting Medium (DAKO), and then observed. As a result, CAPRIN-1 expression was observed to a slight degree within cells in all of salivary gland, kidney, colon, and stomach tissues, but no CAPRIN-1 expression was observed on cell surfaces. Also, absolutely no CAPRIN-1 expression was observed in tissues from other organs.

[Example 2] Preparation of canine and human CAPRIN-1 proteins

(1) Preparation of recombinant protein

[0071] A recombinant protein was prepared by the following method based on the gene of SEQ ID NO: 5 obtained in Example 1. PCR was performed by preparing a reaction solution to bring a total amount thereof to 50 μ l with the addition of reagents and an included buffer (i.e., 1 μ l of a vector prepared from the phagemid solution obtained in Example 1 and then subjected to sequence analysis, 2 types of primers containing NdeI and KpnI restriction enzyme cleavage sequences (0.4 μ M each; SEQ ID NOs: 37 and 38), 0.2 mM dNTPs, and 1.25 U PrimeSTAR HS polymerase (Takara Shuzo, Co., Ltd.)), the resulting reaction solution was subjected to a cycle of 98°C for 10 seconds and 68°C for 1.5 minutes using a Thermal Cycler (BIO RAD), and this cycle was repeated 30 times. The above 2 types of primers were used to amplify the region encoding the full-length amino acid sequence of SEQ ID NO: 6 (canine CAPRIN-1). After PCR, the amplified DNA was subjected to 1% agarose gel electrophoresis, and a DNA fragment of about 1.4 kbp was then purified from the gel using a QIAquick Gel Extraction Kit (QIAGEN).

[0072] The purified DNA fragment was ligated to a pCR-Blunt cloning vector (Invitrogen). The vector was transformed into *Escherichia coli*, the plasmid was collected, and the amplified gene fragment was confirmed to match the target sequence via sequencing. The plasmid that matched the target sequence was treated with NdeI and KpnI restriction enzymes, the resultant was purified using a QIAquick Gel Extraction Kit, and the target gene sequence was inserted into a pET30b expression vector (Novagen) for *Escherichia coli* treated with NdeI and KpnI restriction enzymes. With the use of the resulting vector, a His tag-fused recombinant protein can be produced. The plasmid was transformed into *Escherichia coli* BL21 (DE3) for expression, and the target protein was induced to express in *Escherichia coli* with the aid of 1 mM IPTG.

[0073] Separately, the recombinant protein of a canine homolog gene was prepared by the following method based on the gene of SEQ ID NO: 7. PCR was performed by preparing a reaction solution to bring a total amount thereof to 50 μ l with the addition of reagents and an included buffer (i.e., 1 μ l of cDNA, the expression of which was confirmed via RT-PCR, selected from among the various tissues and cellular cDNAs prepared in Example 1, 2 types of primers containing NdeI and KpnI restriction enzyme cleavage sequences (0.4 μ M each; SEQ ID NOs: 39 and 40), 0.2 mM dNTPs, and 1.25 U PrimeSTAR HS polymerase (Takara Shuzo, Co., Ltd.)), the resulting reaction solution was subjected to a cycle of 98°C for 10 seconds and 68°C for 2.5 minutes using a Thermal Cycler (BIO RAD), and this cycle was repeated 30 times. The above 2 types of primers were used to amplify the region encoding the full-length amino acid sequence of SEQ ID NO: 8. After PCR, the amplified DNA was subjected to 1% agarose gel electrophoresis, and a DNA fragment of about 2.2 kbp was then purified from the gel using a QIAquick Gel Extraction Kit (QIAGEN).

[0074] The purified DNA fragment was ligated to a pCR-Blunt cloning vector (Invitrogen). The vector was transformed into *Escherichia coli*, the plasmid was collected, and the amplified gene fragment was confirmed to match the target sequence via sequencing. The plasmid that matched the target sequence was treated with NdeI and KpnI restriction enzymes, the resultant was purified using a QIAquick Gel Extraction Kit, and the target gene sequence was inserted into a pET30b expression vector (Novagen) for *Escherichia coli* treated with NdeI and KpnI restriction enzymes. With the use of the resulting vector, a His tag-fused recombinant protein can be produced. The plasmid was transformed into *Escherichia coli* BL21 (DE3) for expression, and the target protein was induced to express in *Escherichia coli* with the aid of 1 mM IPTG.

[0075] Separately, the recombinant protein of a human homolog gene was prepared by the following method based on the gene of SEQ ID NO: 1. PCR was performed by preparing a reaction solution to bring a total amount thereof to 50 μ l with the addition of reagents and an included buffer (i.e., 1 μ l of cDNA, the expression of which was confirmed via RT-PCR, selected from among the various tissue and cellular cDNAs prepared in Example 1, 2 types of primers containing SacI and XhoI restriction enzyme cleavage sequences (0.4 μ M each; SEQ ID NOs: 41 and 42), 0.2 mM dNTPs, and 1.25 U PrimeSTAR HS polymerase (Takara Shuzo, Co., Ltd.)), the resulting reaction solution was subjected to a cycle of 98°C for 10 seconds and 68°C for 2.5 minutes using a Thermal Cycler (BIO RAD), and this cycle was repeated 30

times. The above 2 types of primers were used to amplify the region encoding the full-length amino acid sequence of SEQ ID NO: 2. After PCR, the amplified DNA was subjected to 1% agarose gel electrophoresis, and a DNA fragment of about 2.1 kbp was then purified from the gel using a QIAquick Gel Extraction Kit (QIAGEN).

5 [0076] The purified DNA fragment was ligated to a pCR-Blunt cloning vector (Invitrogen). The vector was transformed into *Escherichia coli*, the plasmid was collected, and the amplified gene fragment was confirmed to match the target sequence via sequencing. The plasmid that matched the target sequence was treated with *SacI* and *XhoI* restriction enzymes, the resultant was purified using a QIAquick Gel Extraction Kit, and the target gene sequence was inserted into a pET30a expression vector (Novagen) for *Escherichia coli* treated with *SacI* and *XhoI* restriction enzymes. With the use of the resulting vector, a His tag-fused recombinant protein can be produced. The plasmid was transformed into 10 *Escherichia coli* BL21 (DE3) for expression, and the target protein was induced to express in *Escherichia coli* with the aid of 1 mM IPTG.

(2) Purification of recombinant protein

15 [0077] The above-obtained recombinant *Escherichia coli* strain expressing SEQ ID NO: 1, 5, or 7 was cultured at 37°C in LB medium containing 30 µg/ml kanamycin until the absorbance at 600 nm reached around 0.7. Thereafter, isopropyl-β-D-1-thiogalactopyranoside was added to a final concentration of 1 mM, and culture was conducted at 37°C for 4 hours. Subsequently, the culture was centrifuged at 4800 rpm for 10 minutes to collect cells. The cell pellet was suspended in phosphate buffered saline and then centrifuged at 4800 rpm for 10 minutes to wash the cells.

20 [0078] The cells were suspended in phosphate buffered saline and then subjected to ultrasonication on ice. The ultrasonicated *Escherichia coli* solution was centrifuged at 6000 rpm for 20 minutes, the resulting supernatant was designated as a soluble fraction, and the resulting precipitate was designated as an insoluble fraction.

25 [0079] The soluble fraction was added to a nickel chelate column (carrier: Chelating Sepharose™ Fast Flow (GE Healthcare), column capacity: 5 ml, 50 mM hydrochloric acid buffer (pH 8.0) as equilibrating buffer) prepared in accordance with a conventional method. The non-adsorbed fraction was washed with 10 column volumes of 50 mM hydrochloric acid buffer (pH 8.0) and 20 mM phosphate buffer (pH 8.0) containing 20 mM imidazole. Immediately thereafter, 6 beds were eluted with 20 mM phosphate buffer (pH 8.0) containing 100 mM imidazole. After the elution of the protein of interest had been confirmed by Coomassie staining, an elution fraction of 20 mM phosphate buffer (pH 8.0) containing 100 mM imidazole was added to a strong anion exchange column (carrier: Q Sepharose™ Fast Flow (GE Healthcare), column volume: 5 ml, and 20 mM phosphate buffer (pH 8.0) as equilibrating buffer). The non-adsorbed fraction was washed with 10 column volumes of 20 mM phosphate buffer (pH 7.0) and 20 mM phosphate buffer (pH 7.0) containing 200 mM sodium chloride. Immediately thereafter, 5 beds were eluted using 20 mM phosphate buffer (pH 7.0) containing 400 mM sodium chloride. Thus, purified fractions of proteins having the amino acid sequences represented by SEQ ID NO: 2, 6, and 8 were obtained, and these purified fractions were hereafter used as materials for administration tests.

35 [0080] Each of the purified preparations obtained by the above method (200 µl each) was dispensed into 1 ml of a reaction buffer (20 mM Tris-HCl, 50 mM NaCl, 2 mM CaCl₂, pH 7.4), and 2 µl of enterokinase (Novagen) was then added. The preparation was allowed to stand at room temperature overnight for reaction, a His tag was cleaved, and purification was then performed in accordance with the protocols attached to the Enterokinase Cleavage Capture Kit (Novagen). Subsequently, 1.2 ml of the purified preparation obtained by the above method was substituted with physiological phosphate buffer (Nissui Pharmaceutical Co., Ltd.) using ultrafiltration NANOSEP 10K OMEGA (PALL). Sterilized filtration was performed using 0.22 µm HT Tuffryn Acrodisc (PALL), and the resultants were used for the following experiments.

[Example 3] Preparation of antibody against CAPRIN-1

(1) Preparation of polyclonal antibody against CAPRIN-1-derived peptide

50 [0081] In order to obtain an antibody binding to CAPRIN-1, a CAPRIN-1-derived peptide (Arg-Asn-Leu-Glu-Lys-Lys-Lys-Gly-Lys-Leu-Asp-Asp-Tyr-Gln; SEQ ID NO: 43) was synthesized. The peptide as an antigen (1 mg) was mixed with the equivalent volume of an incomplete Freund's adjuvant (IFA) solution, and the mixture was subcutaneously administered to a rabbit 4 times every 2 weeks. Thereafter, blood was collected, and an antiserum containing a polyclonal antibody was obtained. Further, the antiserum was purified using a protein G carrier (GE Healthcare Bio-Sciences), and a polyclonal antibody against the CAPRIN-1-derived peptide was then obtained. Subsequently, the reactivity of the resulting polyclonal antibody to CAPRIN-1 on the cancer cell surface was examined using breast cancer cells. Specifically, 55 10⁶ cells of the human breast cancer cell line MDA-MB-231 V were subjected to centrifugation in a 1.5 ml microcentrifugal tube, a PBS solution supplemented with 0.1% fetal bovine serum (FBS) containing the polyclonal antibody was added thereto, and the resultant was then allowed to stand on ice for 1 hour. After washing with PBS, an FITC-labeled goat anti-mouse IgG antibody (Invitrogen) diluted 500-fold with PBS containing 0.1% FBS was added to the solution, and the

EP 2 741 085 A1

solution was then allowed to stand on ice for 1 hour. After washing with PBS, fluorescence intensity was measured using a FACS Calibur (Becton, Dickinson and Company). Separately, a control was prepared in accordance with a procedure similar to the above, except that PBS containing 0.1% FBS was added instead of the polyclonal antibody. As a result, fluorescence intensity in cells treated with the polyclonal antibody was found to be stronger than that in control cells, and the obtained polyclonal antibody was thus found to bind to the breast cancer cell surface.

(2) Preparation of monoclonal antibody against CAPRIN-1 protein

[0082] The antigenic protein (human CAPRIN-1) (100 μ g) represented by SEQ ID NO: 2 prepared in Example 2 was mixed with the equivalent amount of a MPL+TDM adjuvant (Sigma), and the mixture was used as an antigen solution per mouse. The antigen solution was administered intraperitoneally to a 6-week-old Balb/c mouse (Japan SLC Inc.) and further administered 3 times every week. The spleen was removed 3 days after the final immunization, ground in between two sterilized glass slides, washed with PBS (-) (Nissui), and then centrifuged at 1500 rpm for 10 minutes to remove supernatants. This procedure was repeated 3 times to obtain spleen cells. The thus obtained spleen cells were mixed with the mouse myeloma SP2/0 cells (purchased from ATCC) at a ratio of 10:1. The PEG solution prepared by mixing 200 μ l of RPMI1640 medium containing 10% FBS heated to 37°C and 800 μ l of PEG1500 (Boehringer) was added to the cells. The solution was allowed to stand for 5 minutes for cell fusion. Centrifugation was performed at 1700 rpm for 5 minutes to remove supernatants, the cells were suspended in 150 ml of RPMI1640 medium (HAT selective medium) containing 15% FBS supplemented with 2% equivalent of HAT solution (Gibco), and the suspension was then seeded onto fifteen 96-well plates (Nunc) at 100 μ l/well. Cells were cultured for 7 days at 37°C in the presence of 5% CO₂. Thus, hybridomas resulting from fusion of spleen cells with myeloma cells were obtained.

[0083] Hybridomas were selected using, as an indicator, the binding affinity of the antibody produced by the prepared hybridomas for the CAPRIN-1 protein. The CAPRIN-1 protein solution (1 μ g/ml) prepared in Example 2 was added to a 96-well plate at 100 μ l/well, and the resultant was allowed to stand at 4°C for 18 hours. Each well was washed 3 times with PBS-T, a 0.5% bovine serum albumin (BSA) solution (Sigma) was added at 400 μ l/well, and the plate was then allowed to stand at room temperature for 3 hours. The solution was removed and each well was washed 3 times with 400 μ l of PBS-T. Thereafter, each culture supernatant of the hybridomas obtained above was added at 100 μ l/well, and the resultant was then allowed to stand at room temperature for 2 hours. Each well was washed 3 times with PBS-T, an HRP-labeled anti-mouse IgG (H+L) antibody (Invitrogen) diluted 5000-fold with PBS was added thereto at 100 μ l/well, and the resultant was allowed to stand at room temperature for 1 hour. After each well was washed 3 times with PBS-T, a TMB substrate solution (Thermo) was added at 100 μ l per/well, and the resultant was allowed to stand for 15 to 30 minutes, so as to allow the color to develop. Thereafter, 1N sulfuric acid was added at 100 μ l/well to terminate the reaction. The absorbance was measured at 450 nm and 595 nm using a spectrophotometer. As a result, a plurality of hybridomas producing antibodies exhibiting high absorbance values were selected.

[0084] The thus selected hybridomas were added to a 96-well plate at 0.5 hybridomas per well and then cultured. After 1 week, hybridomas forming single colonies in wells were observed. Cells in these wells were further cultured, and hybridomas were selected using, as an indicator, the binding affinity of the antibody produced by the cloned hybridomas for the CAPRIN-1 protein. The CAPRIN-1 protein solution (1 μ g/ml) prepared in Example 2 was added to a 96-well plate at 100 μ l/well, and the resultant was allowed to stand at 4°C for 18 hours. Each well was washed 3 times with PBS-T, a 0.5% BSA solution was added at 400 μ l/well, and the plate was then allowed to stand at room temperature for 3 hours. The solution was removed and each well was washed 3 times with 400 μ l of PBS-T. Thereafter, each culture supernatant of the hybridomas obtained above was added at 100 μ l/well, and the resultant was then allowed to stand at room temperature for 2 hours. Each well was washed 3 times with PBS-T, an HRP-labeled anti-mouse IgG (H+L) antibody (Invitrogen) diluted 5000-fold with PBS was added thereto at 100 μ l/well, and the resultant was allowed to stand at room temperature for 1 hour. After each well was washed 3 times with PBS-T, a TMB substrate solution (Thermo) was added at 100 μ l per/well and then allowed to stand for 15 to 30 minutes, so as to allow the color to develop. Thereafter, 1N sulfuric acid was added at 100 μ l/well to terminate the reaction, and the absorbance was measured at 450 nm and 595 nm using a spectrophotometer. As a result, a plurality of hybridomas producing monoclonal antibodies exhibiting reactivity to the CAPRIN-1 protein were selected, the culture supernatant of hybridomas was purified using a protein G carrier, and 150 monoclonal antibodies binding to the CAPRIN-1 protein were obtained.

[0085] Subsequently, monoclonal antibodies exhibiting reactivity to the surfaces of cancer cells expressing CAPRIN-1 were selected from among these monoclonal antibodies using breast cancer cells. Specifically, 10⁶ cells of the human breast cancer cell line MDA-MB-231 V were subjected to centrifugation in a 1.5 ml microcentrifugal tube, 100 μ l of the culture supernatant of the hybridomas was added thereto, and the resultant was then allowed to stand on ice for 1 hour. After washing with PBS, an FITC-labeled goat anti-mouse IgG antibody (Invitrogen) diluted 500-fold with PBS containing 0.1% FBS was added to the solution, and the solution was then allowed to stand on ice for 1 hour. After washing with PBS, fluorescence intensity was measured using a FACS Calibur (Becton, Dickinson and Company). Separately, a control was prepared in accordance with a procedure similar to the above, except that a medium was added instead of

the antibody. As a result, 10 monoclonal antibodies exhibiting stronger fluorescence intensity than that of the control; i.e., 10 monoclonal antibodies exhibiting reactivity to the surfaces of breast cancer cells (#1 to #10), were selected. The heavy chain variable regions and the light chain variable regions of these monoclonal antibodies are shown in SEQ ID NOs: 44 to 60. The above monoclonal antibody #1 comprises the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 45, the monoclonal antibody #2 comprises the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 46, the monoclonal antibody #3 comprises the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 47, the monoclonal antibody #4 comprises the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 48, the monoclonal antibody #5 comprises the heavy chain variable region of SEQ ID NO: 49 and the light chain variable region of SEQ ID NO: 50, the monoclonal antibody #6 comprises the heavy chain variable region of SEQ ID NO: 51 and the light chain variable region of SEQ ID NO: 52, the monoclonal antibody #7 comprises the heavy chain variable region of SEQ ID NO: 53 and the light chain variable region of SEQ ID NO: 54, the monoclonal antibody #8 comprises the heavy chain variable region of SEQ ID NO: 55 and the light chain variable region of SEQ ID NO: 56, the monoclonal antibody #9 comprises the heavy chain variable region of SEQ ID NO: 57 and the light chain variable region of SEQ ID NO: 58, and the monoclonal antibody #10 comprises the heavy chain variable region of SEQ ID NO: 59 and the light chain variable region of SEQ ID NO: 60.

(3) Identification of peptides in CAPRIN-1 protein to which antibodies against CAPRIN-1 reacting with breast cancer cell surface bind

[0086] With the use of monoclonal antibodies #1 to #10 against CAPRIN-1 reacting with the surfaces of breast cancer cells obtained above, partial sequences in the CAPRIN-1 protein recognized by these monoclonal antibodies were identified.

[0087] To 100 μ l of a recombinant CAPRIN-1 protein solution adjusted to a concentration of 1 μ g/ μ l with PBS, first of all, DTT (Fluka) was added to result in a final concentration of 10 mM therein, and a reaction was allowed to proceed at 95°C for 5 minutes, so as to reduce disulfide bonds within the CAPRIN-1 protein. Subsequently, iodoacetamide (final concentration: 20 mM; Wako Pure Chemical Industries, Ltd.) was added, and thiol groups were subjected to alkylation at 37°C for 30 minutes under shaded conditions. The monoclonal antibodies #1 to #10 against CAPRIN-1 (50 μ g each) were added to 40 μ g of the reduced-alkylated CAPRIN-1 protein, the volume of the mixture was adjusted to 1 ml with 20 mM phosphate buffer (pH7.0), and the reaction was allowed to proceed at 4°C overnight with stirring and mixing.

[0088] Subsequently, trypsin (Promega) was added to a final concentration of 0.2 μ g. After the reaction was allowed to proceed at 37°C for 1 hour, 2 hours, 4 hours, and then 12 hours, the resultants were mixed with protein A-glass beads (GE), which had been subjected to blocking with PBS containing 1% BSA (Sigma) and washing with PBS in advance, in 1 mM calcium carbonate and NP-40 buffer (20 mM phosphate buffer (pH 7.4), 5 mM EDTA, 150 mM NaCl, and 1% NP-40), and the reaction was allowed to further proceed for 30 minutes.

[0089] The reaction solutions were each washed with 25 mM ammonium carbonate buffer (pH 8.0), antigen-antibody complexes were then eluted using 100 μ l of 0.1 % formic acid, and the eluates were subjected to LC-MS analysis using Q-TOF Premier (Waters-MicroMass) in accordance with the protocols attached to the instrument.

[0090] As a result, the polypeptide of SEQ ID NO: 61 was identified as a partial sequence of CAPRIN-1, which was recognized by all of the monoclonal antibodies #1 to #10 against CAPRIN-1. Further, the peptide of SEQ ID NO: 62 was identified as a partial sequence in the polypeptide of SEQ ID NO: 61 above, which was recognized by the monoclonal antibodies #1 to #4, #5 to #7, and #9. In addition, the monoclonal antibodies #1 to #4 were found to recognize the peptide of SEQ ID NO: 63, which was a partial peptide sequence thereof.

[Example 4] Diagnosis of pancreatic cancer using CAPRIN-1 polypeptide 1) Diagnosis of canine pancreatic cancer

[0091] As a result of pathological diagnosis using the removed tumor tissue samples, blood samples were collected from afflicted dogs confirmed to have malignant pancreatic ductal carcinoma, and sera were separated. With the use of the canine CAPRIN-1 protein (SEQ ID NO: 8) prepared in Example 2 and the anti-canine IgG antibody, the titer of the serum IgG antibody specifically reacting with the canine CAPRIN-1 protein was measured by an ELISA method.

[0092] The prepared canine CAPRIN-1 protein was immobilized by adding a recombinant protein solution diluted to 5 μ g/ml with phosphate buffered saline to a 96-well immobilizer amino plate (Nunc) at 100 μ l/well and then allowing the plate to stand at 4°C overnight. Blocking was performed by adding a 50 mM sodium bicarbonate buffer solution (pH 8.4) (hereafter, referred to as a "blocking solution") containing 0.5% BSA (bovine serum albumin, Sigma Aldrich Japan) at 100 μ l/well, followed by shaking at room temperature for 1 hour. Serum diluted 1000-fold with the blocking solution was added at 100 μ l/well and the mixture was then subjected to a reaction via shaking at room temperature for 3 hours. The reaction product was washed 3 times with phosphate buffered saline containing 0.05% Tween 20 (Wako Pure Chemical Industries, Ltd.; this solution is referred to as "PBS-T" herein), an HRP-modified canine IgG antibody (Goat anti-Dog

IgG-h+I HRP conjugated: BETHYL Laboratories) diluted 3000-fold with the blocking solution was added at 100 μ l/well, and the mixture was subjected to a reaction via shaking at room temperature for 1 hour. After the reaction product was washed 3 times with PBS-T, HRP substrate TMB (1-Step Turbo TMB (tetramethylbenzidine), PIERCE) was added at 100 μ l/well, and an enzyme-substrate reaction was then conducted at room temperature for 30 minutes. Thereafter, a 0.5 M sulfuric acid solution (Sigma Aldrich Japan) was added at 100 μ l/well to terminate the reaction, and the absorbance at 450 nm was measured using a microplate reader. As controls, a specimen onto which no recombinant protein prepared had been immobilized and a specimen to which the serum of a cancer-bearing dog would not be allowed to react were subjected to the treatment and comparison in the same manner as described above.

[0093] As a result, the titer of the antibody against a canine CAPRIN-1 protein of the sera derived from cancer-carrying dogs was found to be higher than that of the controls.

(2) Diagnosis of canine pancreatic cancer using human CAPRIN-1 protein

[0094] With the use of the human CAPRIN-1 protein (SEQ ID NO: 2) prepared in Example 2, the IgG antibody titer of the canine serum reacting with the human CAPRIN-1 protein was measured in the same manner as described above. When serum samples obtained from healthy dogs were subjected to the same measurement, the absorbance at 450 nm was not substantially observed as described above. The serum samples obtained from pancreatic cancer patient dogs of (1) exhibited a higher titer of the antibody against the human CAPRIN-1 protein than that of the control.

(3) Diagnosis of human pancreatic cancer

[0095] With the use of the human CAPRIN-1 protein (SEQ ID NO: 2) prepared in Example 2 and the anti-human IgG antibody, the IgG antibody titer of the serum samples obtained from healthy individuals reacting with the polypeptide was measured. The human CAPRIN-1 protein was immobilized by adding a recombinant protein solution diluted to 100 μ g/ml with phosphate buffered saline to a 96-well immobilizer amino plate (Nunc) at 100 μ l/well and then allowing the plate to stand at 4°C overnight. Blocking was performed in the following manner. That is, 4 g of Block Ace powder (DS PHARMA BIOMEDICAL Co., Ltd.) was dissolved in 100 ml of purified water, the solution was diluted 4-fold with purified water (hereafter, referred to as a "blocking solution"), the blocking solution was added at 100 μ l/well, and the mixture was subjected to shaking at room temperature for 1 hour. Serum diluted 1000-fold with the blocking solution was added at 100 μ l/well and then subjected to a reaction via shaking at room temperature for 3 hours. After washing the resultant 3 times with phosphate buffered saline containing 0.05% Tween 20 (Wako Pure Chemical Industries, Ltd.; this solution is referred to as "PBS-T" herein), an HRP-modified anti-human IgG antibody (HRP-Goat Anti-Human IgG (H+L) Conjugate: Zymed Laboratories) diluted 10000-fold with the blocking solution was added at 100 μ l/well and then subjected to a reaction via shaking at room temperature for 1 hour. After the reaction product was washed 3 times with PBS-T, HRP substrate TMB (1-Step Turbo TMB (tetramethylbenzidine), PIERCE) was added at 100 μ l/well, and an enzyme-substrate reaction was then performed at room temperature for 30 minutes. Thereafter, a 0.5 M sulfuric acid solution (Sigma Aldrich Japan) was added at 100 μ l/well to terminate the reaction, and the absorbance at 450 nm was then measured using a microplate reader. An ovalbumin antigen adjusted to 50 μ g/ml with phosphate buffered saline was immobilized and then used as a positive control. As a result, the absorbance at 450 nm was found to be high in the case of the ovalbumin antigen, although no absorbance (0) was detected in the case of the human CAPRIN-1 protein.

[0096] Further, the serum samples obtained from patients with pancreatic ductal carcinoma were subjected to measurement of the titer of the serum IgG antibody specifically reacting with the human CAPRIN-1 protein (the amino acid sequence of SEQ ID NO: 2) in the same manner as described above. As a result, the absorbance at 450 nm was found to be lower than the lowest detection limit in the case of healthy subjects, although it was found to be high in the case of patients with pancreatic cancer. With the use of the canine CAPRIN-1 protein (SEQ ID NO: 8) prepared in Example 2 and the anti-human IgG antibody, the titer of the human serum IgG antibody specifically reacting with the canine CAPRIN-1 protein was measured in the same manner as described above. As a result, pancreatic cancer patients were found to exhibit higher titers than healthy individuals.

[0097] Thus, it was demonstrated that human pancreatic cancer could be detected by the method of the present invention.

[Example 5] Diagnosis of pancreatic cancer using antibody against CAPRIN-1

(1) Diagnosis of pancreatic cancer by measuring CAPRIN-1 protein

[0098] With the use of the polyclonal antibody against the CAPRIN-1-derived peptide (SEQ ID NO: 43) obtained in Example 3 (1) in combination with each monoclonal antibody against the CAPRIN-1 protein obtained in Example 3 (2), Sandwich ELISA was carried out in order to detect the CAPRIN-1 protein (cancer-bearing individual-derived serum) reacted

positive upon cancer diagnosis using the CAPRIN-1 protein in Example 4 (1)-(3). The polyclonal antibody was used as a primary antibody and each monoclonal antibody was used as a secondary antibody. The amount of the proteins specifically reacting with each of the above antibodies in the sera was measured.

[0099] The primary antibody was immobilized by adding a polyclonal antibody solution diluted to 5 $\mu\text{g/ml}$ with phosphate buffered saline to a 96-well immobilizer amino plate (Nunc) at 100 $\mu\text{l/well}$ and shaking the plate at room temperature for 2 hours. Blocking was performed by adding a 50 mM sodium bicarbonate buffer solution (pH 8.4) (hereafter, referred to as a "blocking solution") containing 0.5% BSA (bovine serum albumin, Sigma Aldrich Japan) at 100 $\mu\text{l/well}$, followed by shaking at room temperature for 1 hour. Thereafter, the serum samples obtained from cancer-bearing individuals diluted with a blocking solution were added at 100 $\mu\text{l/well}$ and then subjected to the reaction via shaking at room temperature for 3 hours. The dilution rate at this time was adjusted with 10-fold dilution series (i.e., 10-1000-fold dilutions). The reaction product was washed 3 times with phosphate buffered saline containing 0.05% Tween 20 (Wako Pure Chemical Industries, Ltd.; this solution is referred to as "PBS-T" herein), each monoclonal antibody as a secondary antibody diluted to a concentration of 1 $\mu\text{g/ml}$ with the blocking solution was added at 100 $\mu\text{l/well}$, and the resultant was then subjected to shaking at room temperature for 1 hour for reaction. The reaction product was washed 3 times with PBS-T, an HRP-labeled anti-mouse IgG (H+L) antibody (Invitrogen) as a tertiary antibody diluted 5000-fold with the blocking solution was added at 100 $\mu\text{l/well}$, and the resultant was then allowed to stand at room temperature for 1 hour. After each well was washed 3 times with PBS-T, a TMB substrate solution (Thermo) was added at 100 μl per/well, and the resultant was allowed to stand for 15 to 30 minutes, so as to allow the color to develop. Thereafter, 1N sulfuric acid was added at 100 $\mu\text{l/well}$ to terminate the reaction. The absorbance was measured at 450 nm using a spectrophotometer.

[0100] When the monoclonal antibodies #1 to #10 reacting with the surfaces of cancer cells were used as secondary antibodies, as a result, high absorbance values were detected in all the dogs with pancreatic ductal carcinoma, although no absorbance was detected in healthy dogs. When monoclonal antibodies that react with the CAPRIN-1 proteins but do not react with the surfaces of cancer cells were used as secondary antibodies, polypeptide values were detected in all specimens. However, all the absorbance values were lower than the detection limit, which were lower than the results for combinations of antibodies reacting with the surfaces of cancer cells.

[0101] Therefore, cancer can also be diagnosed or examined by this technique that comprises detection of the CAPRIN-1 proteins using antibodies against CAPRIN-1.

(2) Diagnosis or examination of cancer by measuring antigenic polypeptide on pancreatic cancer tissue by immunohistochemical staining

[0102] Immunohistochemical staining was performed using an array (BIOMAX) having 101 paraffin-embedded human pancreatic cancer tissue specimens. The array of human pancreatic cancer tissues was treated at 60°C for 3 hours, the resultant was put in a staining bottle filled with xylene, xylene was replaced with fresh xylene every 5 minutes, and this procedure was repeated 3 times. Subsequently, a similar procedure was carried out using ethanol and PBS-T instead of xylene. The array of human pancreatic cancer tissues was put in a staining bottle filled with 10 mM citrate buffer (pH 6.0) containing 0.05% Tween 20, treated at 125°C for 5 minutes, and then allowed to stand at room temperature for 40 minutes or longer. Excess water around each specimen was removed using Kimwipes, each section was encircled with DAKOPEN (DAKO), and an appropriate amount of Peroxidase Block (DAKO) was then added dropwise onto the array. The array was allowed to stand at room temperature for 5 minutes, the array was put in a staining bottle filled with PBS-T, and PBS-T was replaced with fresh PBS-T every 5 minutes. This procedure was performed 3 times. As a blocking solution, a PBS-T solution containing 10% FBS was applied onto the array, and the array was then allowed to stand in a moist chamber at room temperature for 1 hour. Subsequently, the monoclonal antibodies #1 to #10 prepared in Example 3 adjusted to 10 $\mu\text{g/ml}$ with a PBS-T solution containing 5% FBS were applied onto the array, and the array was allowed to stand in a moist chamber at 4°C overnight. After the array was washed with PBS-T for 10 minutes 3 times, an appropriate amount of Peroxidase Labeled Polymer Conjugated (DAKO) was added dropwise onto the array, and the array was allowed to stand in a moist chamber at room temperature for 30 minutes. After the array was washed with PBS-T for 10 minutes 3 times, a DAB color-developing solution (DAKO) was applied onto the array, and the array was then allowed to stand at room temperature for about 10 minutes. After the color-developing solution was discarded, the array was washed with PBS-T for 10 minutes 3 times, rinsed with distilled water, successively put in 70%, 80%, 90%, 95%, and 100% ethanol solutions for 1 minute each, and then allowed to stand in xylene overnight. The glass slides were removed, coverslipped with Glycergel Mounting Medium (DAKO), and then observed. As a result, CAPRIN-1 expression was observed in pancreatic cancer cell membranes and in pancreatic cancer cells in the pancreatic cancer tissue samples with the use of any antibodies. When immunohistochemical staining was carried out with the use of Antibody #8, for example, strong CAPRIN-1 expression was observed in 54 specimens among the total pancreatic cancer tissue specimens (101 specimens) (i.e., 54%).

[0103] Similarly, immunohistochemical staining was carried out using an array (BIOMAX) of paraffin-embedded normal human tissues including normal human pancreatic tissues. Excess water around each specimen was removed using

EP 2 741 085 A1

Kimwipes, each section was encircled with DAKOPEN (DAKO), and an appropriate amount of Peroxidase Block (DAKO) was then added dropwise onto the array. The array was allowed to stand at room temperature for 5 minutes, the array was put in a staining bottle filled with PBS-T, and PBS-T was replaced with fresh PBS-T every 5 minutes. This procedure was performed 3 times. As a blocking solution, a PBS-T solution containing 10% FBS was applied onto the array, and the array was then allowed to stand in a moist chamber at room temperature for 1 hour. Subsequently, the monoclonal antibodies #1 to #10 prepared in Example 3 adjusted to 10 $\mu\text{g/ml}$ in a PBS-T solution containing 5% FBS were applied onto the array, and the array was then allowed to stand in a moist chamber at 4°C overnight. After the array was washed with PBS-T for 10 minutes 3 times, an appropriate amount of Peroxidase Labeled Polymer Conjugated (DAKO) was added dropwise onto the array, and the array was allowed to stand in a moist chamber at room temperature for 30 minutes. After the array was washed with PBS-T for 10 minutes 3 times, a DAB color-developing solution (DAKO) was applied onto the array, and the array was then allowed to stand at room temperature for about 10 minutes. After the color-developing solution was discarded, the array was washed with PBS-T for 10 minutes 3 times, rinsed with distilled water, successively put in 70%, 80%, 90%, 95%, and 100% ethanol solutions for 1 minute each, and then allowed to stand in xylene overnight. The glass slides were removed, coverslipped with Glycergel Mounting Medium (DAKO), and then observed. As a result, none of pancreas-derived normal tissue samples were stained and no CAPRN-1 expression was observed, no matter what antibody was used.

Industrial Applicability

[0104] The present invention is industrially useful for diagnosis or detection of pancreatic cancer.

[0105] All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Free Text of Sequence Listing

[0106] SEQ ID NOs: 31 to 42: primers

EP 2 741 085 A1

SEQUENCE LISTING

<110> Toray Industries, Inc.

5 <120> Method for Detection of Pancreatic Cancer

<130> PH-5297-PCT

<150> JP2011-171364

<151> 2011-08-04

10 <160> 63

<170> PatentIn version 3.1

<210> 1

15 <211> 5562

<212> DNA

<213> Homo sapiens

<220>

20 <221> CDS

<222> (190)..(2319)

<223>

<400> 1

cagagggctg ctggctggct aagtcctcc cgctcccggc tctcgctca ctaggagcgg 60

25 ctctcgggtgc agcgggacag ggcgaagcgg cctgcgccca cggagcgcgc gacactgccc 120

ggaagggacc gccacccttg cccctcagc tgcccactcg tgatttccag cggcctccgc 180

gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg 231

30 Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser

1 5 10

tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg 279

Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala

15 20 25 30

35 gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc 327

Gly Ala Gly Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr

35 40 45

ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac 375

Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp

50 55 60

aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac 423

Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr

65 70 75

45 cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat 471

Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp

80 85 90

50 gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa 519

Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys

95 100 105 110

gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca 567

Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr

115 120 125

55 ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gaa gct gaa 615

EP 2 741 085 A1

	Ile	Lys	Lys	Thr	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	Glu	
				130					135					140			
5	cag	aaa	cgt	tta	aaa	act	gta	ctt	gag	cta	cag	tat	gtt	ttg	gac	aaa	663
	Gln	Lys	Arg	Leu	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	Lys	
			145					150					155				
10	ttg	gga	gat	gat	gaa	gtg	cgg	act	gac	ctg	aaa	caa	ggt	ttg	aat	gga	711
	Leu	Gly	Asp	Asp	Glu	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Asn	Gly	
		160					165					170					
15	gtg	cca	ata	ttg	tcc	gaa	gag	gag	ttg	tca	ttg	ttg	gat	gaa	ttc	tat	759
	Val	Pro	Ile	Leu	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	Tyr	
	175					180				185						190	
20	aag	cta	gta	gac	cct	gaa	cgg	gac	atg	agc	ttg	agg	ttg	aat	gaa	cag	807
	Lys	Leu	Val	Asp	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	Gln	
				195						200				205			
25	tat	gaa	cat	gcc	tcc	att	cac	ctg	tgg	gac	ctg	ctg	gaa	ggg	aag	gaa	855
	Tyr	Glu	His	Ala	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	Glu	
			210					215					220				
30	aaa	cct	gta	tgt	gga	acc	acc	tat	aaa	gtt	cta	aag	gaa	att	gtt	gag	903
	Lys	Pro	Val	Cys	Gly	Thr	Thr	Tyr	Lys	Val	Leu	Lys	Glu	Ile	Val	Glu	
			225					230					235				
35	cgt	gtt	ttt	cag	tca	aac	tac	ttt	gac	agc	acc	cac	aac	cac	cag	aat	951
	Arg	Val	Phe	Gln	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	Asn	
		240					245					250					
40	ggg	ctg	tgt	gag	gaa	gaa	gag	gca	gcc	tca	gca	cct	gca	gtt	gaa	gac	999
	Gly	Leu	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Ala	Val	Glu	Asp	
	255					260				265						270	
45	cag	gta	cct	gaa	gct	gaa	cct	gag	cca	gca	gaa	gag	tac	act	gag	caa	1047
	Gln	Val	Pro	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	
				275						280					285		
50	agt	gaa	gtt	gaa	tca	aca	gag	tat	gta	aat	aga	cag	ttc	atg	gca	gaa	1095
	Ser	Glu	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	
				290				295					300				
55	aca	cag	ttc	acc	agt	ggt	gaa	aag	gag	cag	gta	gat	gag	tgg	aca	gtt	1143
	Thr	Gln	Phe	Thr	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	
			305					310					315				
60	gaa	acg	gtt	gag	gtg	gta	aat	tca	ctc	cag	cag	caa	cct	cag	gct	gca	1191
	Glu	Thr	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	
			320				325					330					
65	tcc	cct	tca	gta	cca	gag	ccc	cac	tct	ttg	act	cca	gtg	gct	cag	gca	1239
	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ala	
				335		340					345				350		
70	gat	ccc	ctt	gtg	aga	aga	cag	cga	gta	caa	gac	ctt	atg	gca	caa	atg	1287
	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	
				355					360						365		
75	cag	ggt	ccc	tat	aat	ttc	ata	cag	gat	tca	atg	ctg	gat	ttt	gaa	aat	1335
	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	
				370				375					380				
80	cag	aca	ctt	gat	cct	gcc	att	gta	tct	gca	cag	cct	atg	aat	cca	aca	1383
	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	

EP 2 741 085 A1

	385	390	395	
5	caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu 400 405 410			1431
	tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr 415 420 425 430			1479
10	cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln 435 440 445			1527
15	ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu 450 455 460			1575
	cca att gat cag att cag gca aca atc tct tta aat aca gac cag act Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr 465 470 475			1623
20	aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln 480 485 490			1671
25	gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala 495 500 505 510			1719
	gct cca ttc caa tcc atg caa acg gtg ttc aat atg aat gcc cca gtt Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val 515 520 525			1767
30	cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag tac cag Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln 530 535 540			1815
35	gcc agt tat aac cag agc ttt tct agt cag cct cac caa gta gaa caa Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln 545 550 555			1863
	aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act tac cat Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His 560 565 570			1911
40	ggt tcc cca gac cag tcc cat caa gtg act ggt aac cac cag cag cct Gly Ser Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro 575 580 585 590			1959
45	cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat tac aat Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn 595 600 605			2007
	agt cgt ggt gtg tct cgt gga ggc tcc cgt ggt gct aga ggc ttg atg Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met 610 615 620			2055
50	aat gga tac cgg ggc cct gcc aat gga ttc aga gga gga tat gat ggt Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly 625 630 635			2103
55	tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser 640 645 650			2151

EP 2 741 085 A1

	cag ttc agt gct ccc cgg gat tac tct ggc tat caa cgg gat gga tat	2199
	Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr	
	655 660 665 670	
5	cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc	2247
	Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala	
	675 680 685	
	cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg caa	2295
10	Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln	
	690 695 700	
	atg aac act cag caa gtg aat taa tctgattcac aggattatgt ttaatcgcca	2349
	Met Asn Thr Gln Gln Val Asn	
	705	
15	aaaacacact ggccagtgta ccataatatg ttaccagaag agttattatc tatttgttct	2409
	ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca ggactacaat	2469
	tgtcagcttt ctattacctg gatatggaag gaaactatct ttactctgca tgttctgtcc	2529
20	taagcgtcat cttgagcctt gcacatgata ctcagattcc tcacccttgc ttaggagtaa	2589
	aacaatatac tttacagggg gataataatc tccatagtta tttgaagtgg cttgaaaaag	2649
	gcaagattga cttttatgac attggataaa atctacaaat cagccctcga gttattcaat	2709
25	gataactgac aaactaaatt atttccctag aaaggaagat gaaaggagtg gagtgtggtt	2769
	tggcagaaca actgcatttc acagcttttc cagttaaatt ggagcactga acgttcagat	2829
	gcataccaaa ttatgcatgg gtcctaatac cacatataag gctggctacc agctttgaca	2889
30	cagcactggt catctggcca acaactgtg gttaaaaaca catgtaaaat gctttttaac	2949
	agctgatact gtataagaca aagccaagat gcaaaattag gctttgattg gcactttttg	3009
	aaaaatatgc acaaatatg ggatgtaatc cggatggccg cttctgtact taatgtgaaa	3069
35	tatttagata cttttttgaa cacttaacag tttctttgag acaatgactt ttgtaaggat	3129
	tggtactatc tatcattcct tatgacatgt acattgtctg tcactaatcc ttggattttg	3189
40	ctgtattgtc acctaaattg gtacaggtac tgatgaaaat ctctagtgga taatcataac	3249
	actctcggtc acatgttttt ccttcagctt gaaagctttt ttttaaaag aaaagatacc	3309
	aatgcctgc tgctaccacc cttttcaatt gctatctttt gaaaggcacc agtatgtggt	3369
45	ttagattgat ttccctgttt cagggaaatc acggacagta gtttcagttc tgatgggata	3429
	agcaaaaaca ataaaacgtt tataaaagtgt gtatcttgaa aactggtgt tcaacagcta	3489
	gcagcttatg tgattcacc catgccacgt tagtgtcaca aattttatgg tttatctcca	3549
50	gcaacatttc tctagtactt gcacttatta tcttttgtct aatttaacct taactgaatt	3609
	ctccgtttct cctggaggca tttatattca gtgataattc cttcccttag atgcataggg	3669
	agagtctcta aatttgatgg aatggacac ttgagtagtg acttagcctt atgtactctg	3729
55	ttggaatttg tgctagcagt ttgagcacta gttctgtgtg cctaggaagt taatgctgct	3789

EP 2 741 085 A1

tattgtctca ttctgacttc atggagaatt aatcccacct ttaagcaaag gctactaagt 3849
 taatggtatt ttctgtgcag aaattaaatt ttattttcag catttagccc aggaattcct 3909
 5 ccagtaggtg ctgagctatt taaaaacaaa actattctca aacattcatc attagacaac 3969
 tggagttttt gctggttttg taacctacca aatggatag gctggtgaac attccacatt 4029
 caaaagtttt gtagggtggt gggaaatggg ggatcttcaa tgtttatfff aaaataaaat 4089
 10 aaaataagtt cttgactfff ctcatgtgtg gttgtggtac atcatattgg aagggttaac 4149
 ctgttactfff ggcaaatgag tttttttttg ctagcacctc cccttgogtg ctttaaatga 4209
 catctgcctg ggatgtacca caaccatatg ttacctgtat cttaggggaa tggataaaat 4269
 15 atttgtggtt tactgggtaa tccctagatg atgtatgctt gcagtcctat ataaaactaa 4329
 atttgctatc tgtgtagaaa ataatttcat gacatttaca atcaggactg aagtaagttc 4389
 ttcacacagt gacctctgaa tcagtttcag agaagggatg ggggagaaaa tgccttctag 4449
 20 gttttgaact tctatgcatt agtgcagatg ttgtgaatgt gtaaagggtg tcatagtttg 4509
 actgtttcta tgtatgtfff ttcaaagaat tgttcctfff tttgaactat aatfffctt 4569
 tttttggtta ttttaccatc acagtttaaa tgtatatctt ttatgtctct actcagacca 4629
 25 ttttttaaa ggggtgcctc attatggggc agagaacttt tcaataagtc tcattaagat 4689
 ctgaatcttg gttctaagca ttctgtataa tatgtgattg cttgtcctag ctgcagaagg 4749
 ctttttgfff ggtcaaatgc atatfffagc agagtttcaa ggaaatgatt gtcacacatg 4809
 30 tcaactgtagc ctcttggtgt agcaagctca catacaaaat actfffgtat atgcataata 4869
 taaatcatct catgtggata tgaacttct tttttaaaac ttaaaaagggt agaattgtat 4929
 tgattacctt gattagggca gttttatffc cagatcctaa taattcctaa aaaatatgga 4989
 35 aaagttfff ttcaatcatt gtacctgat attaaaacaa atatcctffa agtatttcta 5049
 atcagttagc ttctacagtt cttttgtctc cttttatatg cagctcttac gtgggagact 5109
 tttccactta aaggagacat agaatgtgtg cttattctca gaaggttcat taactgaggt 5169
 40 gatgagttaa caactagttg agcagtcagc ttocctaagt ttttaggaca tttgttcatt 5229
 atatfffccg tcatataact agaggaagtg gaatgcagat aagtgccgaa ttcaaccct 5289
 tcatfffatg ttaagctcc tgaatctgca ttccacttg gttgtfffata agcattctaa 5349
 45 atfffagttg attataagtt agatttcaca gaatcagtat tgccttgat cttgtcctff 5409
 ttatggagtt aacggggagg aagaccctc aggaaaacga aagtaaattg ttaaggctca 5469
 50 tcttcatacc tttttccatt ttgaatccta caaaaatact gcaaaaagact agtgaatggt 5529
 taaaattaca ctgattaaa taatatgaaa gtc 5562

55 <210> 2
 <211> 709
 <212> PRT
 <213> Homo sapiens

EP 2 741 085 A1

<400> 2

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 20 25 30

Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala
 35 40 45

Val Gln Thr Glu Ala Met Lys Lys Gln Ile Leu Gly Val Ile Asp Lys Lys
 50 55 60

Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu
 65 70 75 80

Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val
 85 90 95

Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu
 100 105 110

Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys
 115 120 125

Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys
 130 135 140

Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly
 145 150 155 160

Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro
 165 170 175

Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu
 180 185 190

Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu
 195 200 205

His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro
 210 215 220

Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu Arg Val
 225 230 235 240

Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu
 245 250 255

EP 2 741 085 A1

Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln Val
 260 265 270
 5 Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu
 275 280 285
 10 Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln
 290 295 300
 Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr
 305 310 315 320
 15 Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro
 325 330 335
 20 Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro
 340 345 350
 Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly
 355 360 365
 25 Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr
 370 375 380
 30 Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn
 385 390 395 400
 Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg
 405 410 415
 35 Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val
 420 425 430
 40 Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu
 435 440 445
 45 Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile
 450 455 460
 Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala
 465 470 475 480
 50 Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly
 485 490 495
 55 Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro
 500 505 510

EP 2 741 085 A1

Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro
 515 520 525
 5 Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser
 530 535 540
 Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu
 545 550 555 560
 10 Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser
 565 570 575
 15 Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln
 580 585 590
 Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg
 595 600 605
 20 Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly
 610 615 620
 25 Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg
 625 630 635 640
 Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe
 645 650 655
 30 Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln
 660 665 670
 35 Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg
 675 680 685
 40 Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn
 690 695 700
 Thr Gln Gln Val Asn
 705
 45
 <210> 3
 <211> 3553
 <212> DNA
 <213> Homo sapiens
 50
 <220>
 <221> CDS
 <222> (190)..(2274)
 <223>
 55
 <400> 3
 cagagggctg ctggctggct aagtcctcc cgctcccggc tctgcctca ctaggagcgg 60

EP 2 741 085 A1

	ctctcgggtgc agcgggacag ggcgaagcgg cctgcgcca cggagcgcgc gacactgccc	120
	ggaagggacc gccacccttg cccctcagc tgcccactcg tgatttcag cggcctccgc	180
5	gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser 1 5 10	231
10	tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala 15 20 25 30	279
15	gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr 35 40 45	327
20	ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp 50 55 60	375
25	aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr 65 70 75	423
30	cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp 80 85 90	471
35	gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys 95 100 105 110	519
40	gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr 115 120 125	567
45	ata aag aag aca gca cgt ccg gag cag ctt atg aga gaa gaa gct gaa Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu 130 135 140	615
50	cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys 145 150 155	663
55	ttg gga gat gat gaa gtg ccg act gac ctg aaa caa ggt ttg aat gga Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly 160 165 170	711
60	gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr 175 180 185 190	759
65	aag cta gta gac cct gaa ccg gac atg agc ttg agg ttg aat gaa cag Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln 195 200 205	807
70	tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu 210 215 220	855
75	aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu 225 230 235	903

EP 2 741 085 A1

	cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat	951
	Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn	
	240 245 250	
5	ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac	999
	Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp	
	255 260 265 270	
10	cag gta cct gaa gct gaa cct gag cca gca gaa gag tac act gag caa	1047
	Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln	
	275 280 285	
15	agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa	1095
	Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu	
	290 295 300	
20	aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt	1143
	Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val	
	305 310 315	
25	gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca	1191
	Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala	
	320 325 330	
30	tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca	1239
	Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala	
	335 340 345 350	
35	gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg	1287
	Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met	
	355 360 365	
40	cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat	1335
	Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn	
	370 375 380	
45	cag aca ctt gat cct gcc att gta tct gca cag cct atg aat cca aca	1383
	Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr	
	385 390 395	
50	caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa	1431
	Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu	
	400 405 410	
55	tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca	1479
	Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr	
	415 420 425 430	
60	cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa	1527
	Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln	
	435 440 445	
65	ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa	1575
	Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu	
	450 455 460	
70	cca att gat cag att cag gca aca atc tct tta aat aca gac cag act	1623
	Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr	
	465 470 475	
75	aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag	1671
	Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln	
	480 485 490	
80	gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca	1719

EP 2 741 085 A1

	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala	
	495					500					505					510	
5	gct	cca	ttc	caa	tcc	atg	caa	acg	gtg	ttc	aat	atg	aat	gcc	cca	gtt	1767
	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	
				515						520				525			
10	cct	cct	ggt	aat	gaa	cca	gaa	act	tta	aaa	cag	caa	aat	cag	tac	cag	1815
	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys	Gln	Gln	Asn	Gln	Tyr	Gln	
				530					535					540			
15	gcc	agt	tat	aac	cag	agc	ttt	tct	agt	cag	cct	cac	caa	gta	gaa	caa	1863
	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln	Pro	His	Gln	Val	Glu	Gln	
			545					550					555				
20	aca	gag	ctt	cag	caa	gaa	cag	ctt	caa	aca	gtg	ggt	ggc	act	tac	cat	1911
	Thr	Glu	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr	Val	Val	Gly	Thr	Tyr	His	
			560				565					570					
25	ggc	tcc	cca	gac	cag	tcc	cat	caa	gtg	act	ggc	aac	cac	cag	cag	cct	1959
	Gly	Ser	Pro	Asp	Gln	Ser	His	Gln	Val	Thr	Gly	Asn	His	Gln	Gln	Pro	
						580					585					590	
30	cct	cag	cag	aac	act	gga	ttt	cca	cgt	agc	aat	cag	ccc	tat	tac	aat	2007
	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser	Asn	Gln	Pro	Tyr	Tyr	Asn	
					595					600					605		
35	agt	cgt	ggc	gtg	tct	cgt	gga	ggc	tcc	cgt	ggc	gct	aga	ggc	ttg	atg	2055
	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg	Gly	Ala	Arg	Gly	Leu	Met	
				610					615					620			
40	aat	gga	tac	cgg	ggc	cct	gcc	aat	gga	ttc	aga	gga	gga	tat	gat	ggc	2103
	Asn	Gly	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe	Arg	Gly	Gly	Tyr	Asp	Gly	
			625					630					635				
45	tac	cgc	cct	tca	ttc	tct	aac	act	cca	aac	agt	ggc	tat	aca	cag	tct	2151
	Tyr	Arg	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn	Ser	Gly	Tyr	Thr	Gln	Ser	
			640				645					650					
50	cag	ttc	agt	gct	ccc	cgg	gat	tac	tct	ggc	tat	caa	cgg	gat	gga	tat	2199
	Gln	Phe	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly	Tyr	Gln	Arg	Asp	Gly	Tyr	
						660					665					670	
55	cag	cag	aat	ttc	aag	cga	ggc	tct	ggg	cag	agt	gga	cca	cgg	gga	gcc	2247
	Gln	Gln	Asn	Phe	Lys	Arg	Gly	Ser	Gly	Gln	Ser	Gly	Pro	Arg	Gly	Ala	
					675					680					685		
60	cca	cga	ggc	aat	att	ttg	tgg	tgg	tga	tcctagctcc	taagtggagc						2294
	Pro	Arg	Gly	Asn	Ile	Leu	Trp	Trp									
				690													
65	ttctg	ttctg	gcctt	ggaag	agctg	ttaat	agctg	catg	ttagga	atac	attt	atcctt					2354
70	tccag	acttg	ttgct	taggga	ttaaat	gaaa	tgctct	gttt	ctaaa	actta	atctt	ggacc					2414
75	caaatt	tttaa	ttttt	gaatg	attta	atttt	ccctg	tact	atata	aaactg	tottg	aaaac					2474
80	taga	acatat	tctctt	ctca	gaaaa	agtgt	ttttc	caact	gaaa	attatt	tttc	caggtcc					2534
85	taaa	acctgc	taaat	gtttt	tagga	agtac	ttact	gaaac	at	tttt	gtaa	gac	at	tttt	gtg		2594
90	gaat	gagatt	gaac	atttat	ataa	atttat	tattc	ctctt	tcatt	ttttt	gaa	acatg	gcc				2654
95	tatt	atattt	taggg	ccaga	cacc	tttaa	tggcc	ggata	agcc	atagtt	aac	atttaga					2714

EP 2 741 085 A1

gaaccattta gaagtgatag aactaatgga atttgcaatg ccttttggac ctctattagt 2774
gatataaata tcaagttatt tctgactttt aaacaaaact cccaaattcc taacttattg 2834
5 agctatactt aaaaaaaatt acaggtttag agagtttttt gtttttcttt tactgttgga 2894
aaactacttc ccattttggc aggaagttaa cctattttaac aattagagct agcatttcat 2954
gtagtctgaa attctaaatg gttctctgat ttgagggagg ttaaacaatca aacaggtttc 3014
10 ctctattggc cataacatgt ataaaatgtg tgtaaggag gaattacaac gtactttgat 3074
ttgaatacta gtagaaactg gccaggaaaa aggtacattt ttctaaaaat taatggatca 3134
cttggggaatt actgacttga ctagaagtat caaaggatgt ttgcatgtga atgtgggtta 3194
15 tgttctttcc cacctttag catattcgat gaaagttgag ttaactgata gctaaaaatc 3254
tgttttaaca gcatgtaaaa agttatttta tctgttaaaa gtcattatac agttttgaat 3314
gttatgtagt ttctttttaa cagtttaggt aataaggtct gttttcattc tggtgctttt 3374
20 attaattttg atagtatgat gttacttact actgaaatgt aagctagagt gtacactaga 3434
atgtaagctc catgagagca ggtaccttgt ctgtcttctc tgctgtatct attcccaacg 3494
cttgatgatg gtcctggca catagtaggc actcaataaa tatttggtga atgaatgaa 3553

25

<210> 4
<211> 694
<212> PRT
<213> Homo sapiens

30

<400> 4

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15

35

Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30

40

Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala
35 40 45

45

Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys
50 55 60

50

Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu
65 70 75 80

55

Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val
85 90 95

Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu
100 105 110

Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys

EP 2 741 085 A1

		115				120						125				
5	Lys	Thr	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	Glu	Gln	Lys
		130					135					140				
10	Arg	Leu	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	Lys	Leu	Gly
		145				150					155					160
15	Asp	Asp	Glu	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Asn	Gly	Val	Pro
					165					170					175	
20	Ile	Leu	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	Tyr	Lys	Leu
				180					185					190		
25	Val	Asp	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	Gln	Tyr	Glu
			195					200					205			
30	His	Ala	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	Glu	Lys	Pro
		210					215					220				
35	Val	Cys	Gly	Thr	Thr	Tyr	Lys	Val	Leu	Lys	Glu	Ile	Val	Glu	Arg	Val
		225				230					235					240
40	Phe	Gln	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	Asn	Gly	Leu
					245					250					255	
45	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Ala	Val	Glu	Asp	Gln	Val
				260					265					270		
50	Pro	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu
			275					280					285			
55	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln
						295					300					
60	Phe	Thr	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr
		305				310					315					320
65	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro
					325					330					335	
70	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro
				340					345					350		
75	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly
			355					360					365			
80	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr
		370					375					380				

EP 2 741 085 A1

Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn
 385 390 395 400
 5 Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg
 405 410 415
 10 Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val
 420 425 430
 15 Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu
 435 440 445
 Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile
 450 455 460
 20 Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala
 465 470 475 480
 25 Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly
 485 490 495
 Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro
 500 505 510
 30 Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro
 515 520 525
 35 Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser
 530 535 540
 Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu
 545 550 555 560
 40 Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser
 565 570 575
 45 Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln
 580 585 590
 50 Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg
 595 600 605
 Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly
 610 615 620
 55 Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg
 625 630 635 640

EP 2 741 085 A1

Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe
645 650 655

5 Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln
660 665 670

10 Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg
675 680 685

Gly Asn Ile Leu Trp Trp
690

15 <210> 5
<211> 1605
<212> DNA
<213> Canis familiaris

20 <220>
<221> CDS
<222> (46)..(1392)
<223>

25 <400> 5
gtcacaaata acttggagtt tgcaaaagaa ttacagagga gtttc atg gca tta agt 57
Met Ala Leu Ser
1

30 caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 105
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
5 10 15 20

atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 153
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
25 30 35

35 cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 201
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
40 45 50

40 aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 249
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
55 60 65

ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 297
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
70 75 80

45 ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 345
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
85 90 95 100

50 ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 393
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
105 110 115

cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 441
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
120 125 130

55 act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 489

EP 2 741 085 A1

	Thr	His	Asn	His	Gln	Asn	Gly	Leu	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	
			135					140					145				
5	gca	cct	aca	gtt	gaa	gac	cag	gta	gct	gaa	gct	gag	cct	gag	cca	gca	537
	Ala	Pro	Thr	Val	Glu	Asp	Gln	Val	Ala	Glu	Ala	Glu	Pro	Glu	Pro	Ala	
		150					155					160					
10	gaa	gaa	tac	act	gaa	caa	agt	gaa	ggt	gaa	tca	aca	gag	tat	gta	aat	585
	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	
	165					170					175					180	
15	aga	caa	ttt	atg	gca	gaa	aca	cag	ttc	agc	agt	ggt	gaa	aag	gag	cag	633
	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	Phe	Ser	Ser	Gly	Glu	Lys	Glu	Gln	
					185					190					195		
20	gta	gat	gag	tgg	acg	gtc	gaa	aca	gtg	gag	gtg	gtg	aat	tca	ctc	cag	681
	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	
				200					205					210			
25	cag	caa	cct	cag	gct	gcg	tct	cct	tca	gta	cca	gag	ccc	cac	tct	ttg	729
	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	
			215					220					225				
30	act	ccg	gtg	gct	cag	gca	gat	ccc	ctt	gtg	aga	aga	cag	cga	gtc	cag	777
	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	
		230					235					240					
35	gac	ctt	atg	gcg	cag	atg	cag	ggg	ccc	tat	aat	ttc	ata	cag	gat	tca	825
	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	
	245					250					255					260	
40	atg	ctg	gat	ttt	gaa	aac	cag	aca	ctc	gat	cct	gcc	att	gta	tct	gca	873
	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	
					265					270					275		
45	cag	cct	atg	aat	ccg	aca	caa	aac	atg	gac	atg	ccc	cag	ctg	gtt	tgc	921
	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	
				280					285					290			
50	cct	cca	ggt	cat	tct	gaa	tct	aga	ctt	gct	caa	cct	aat	caa	ggt	cct	969
	Pro	Pro	Val	His	Ser	Glu	Ser	Arg	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro	
			295					300					305				
55	gta	caa	cca	gaa	gct	aca	cag	ggt	cct	ttg	ggt	tca	tcc	aca	agt	gag	1017
	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	
		310					315					320					
60	ggg	tat	aca	gca	tct	caa	ccc	ttg	tac	cag	cct	tct	cat	gct	aca	gag	1065
	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	
	325					330					335					340	
65	caa	cga	cca	caa	aag	gaa	cca	att	gac	cag	att	cag	gca	aca	atc	tct	1113
	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	
					345					350					355		
70	tta	aat	aca	gac	cag	act	aca	gcg	tca	tca	tcc	ctt	ccg	gct	gct	tct	1161
	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	
				360					365					370			
75	cag	cct	cag	gta	ttc	cag	gct	ggg	aca	agc	aaa	cca	tta	cat	agc	agt	1209
	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	
			375				380						385				
80	gga	atc	aat	gta	aat	gca	gct	cca	ttc	caa	tcc	atg	caa	acg	gtg	ttc	1257
	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	

EP 2 741 085 A1

Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu
 145 150 155 160
 5 Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr
 165 170 175
 Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly
 10 180 185 190
 Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val
 15 195 200 205
 Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu
 20 210 215 220
 Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg
 25 225 230 235 240
 Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe
 30 245 250 255
 Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala
 35 260 265 270
 Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro
 40 275 280 285
 Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro
 45 290 295 300
 Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser
 50 305 310 315 320
 Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser
 55 325 330 335
 His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln
 340 345 350
 Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu
 355 360 365
 Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro
 370 375 380
 Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met
 385 390 395 400

EP 2 741 085 A1

Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro
 405 410 415

5 Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser
 420 425 430

Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Gly Cys Arg Lys
 435 440 445

10

<210> 7
 <211> 4154
 <212> DNA
 <213> Canis familiaris

15

<220>
 <221> CDS
 <222> (1)..(2154)
 <223>

20

<400> 7
 atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
 Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

25

ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
 20 25 30

30

ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
 Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
 35 40 45

35

cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
 His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
 50 55 60

40

atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
 Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
 65 70 75 80

45

ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
 Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
 85 90 95

50

aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
 Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
 100 105 110

55

aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
 Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
 115 120 125

60

caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
 Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
 130 135 140

65

atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
 Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
 145 150 155 160

70

cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctc 528
 Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu

EP 2 741 085 A1

	165	170	175	
5	aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser 180 185 190			576
	ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser 195 200 205			624
10	ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp 210 215 220			672
15	ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala 225 230 235 240			720
	cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser 245 250 255			768
20	act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Ala Ala Ser 260 265 270			816
25	gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala 275 280 285			864
	gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn 290 295 300			912
30	aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln 305 310 315 320			960
35	gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln 325 330 335			1008
	cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu 340 345 350			1056
40	act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln 355 360 365			1104
45	gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser 370 375 380			1152
	atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala 385 390 395 400			1200
50	cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys 405 410 415			1248
55	cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro 420 425 430			1296

EP 2 741 085 A1

	gta	caa	cca	gaa	gct	aca	cag	gtt	cct	ttg	gtt	tca	tcc	aca	agt	gag	1344
	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	
			435					440					445				
5	ggg	tat	aca	gca	tct	caa	ccc	ttg	tac	cag	cct	tct	cat	gct	aca	gag	1392
	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	
		450					455					460					
10	caa	cga	cca	caa	aag	gaa	cca	att	gac	cag	att	cag	gca	aca	atc	tct	1440
	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	
	465					470					475					480	
15	tta	aat	aca	gac	cag	act	aca	gcg	tca	tca	tcc	ctt	ccg	gct	gct	tct	1488
	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	
					485					490					495		
20	cag	cct	cag	gta	ttc	cag	gct	ggg	aca	agc	aaa	cca	tta	cat	agc	agt	1536
	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	
				500				505						510			
25	gga	atc	aat	gta	aat	gca	gct	cca	ttc	caa	tcc	atg	caa	acg	gtg	ttc	1584
	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	
			515					520					525				
30	aat	atg	aat	gcc	cca	gtt	cct	cct	gtt	aat	gaa	cca	gaa	act	ttg	aaa	1632
	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys	
			530				535					540					
35	caa	caa	aat	cag	tac	cag	gcc	agt	tat	aac	cag	agc	ttt	tct	agt	cag	1680
	Gln	Gln	Asn	Gln	Tyr	Gln	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln	
	545					550					555					560	
40	cct	cac	caa	gta	gaa	caa	aca	gac	ctt	cag	caa	gaa	cag	ctt	caa	aca	1728
	Pro	His	Gln	Val	Glu	Gln	Thr	Asp	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr	
					565					570					575		
45	gtg	gtt	ggc	act	tac	cat	ggt	tcc	cag	gac	cag	ccc	cac	caa	gtg	act	1776
	Val	Val	Gly	Thr	Tyr	His	Gly	Ser	Gln	Asp	Gln	Pro	His	Gln	Val	Thr	
				580					585					590			
50	ggt	aac	cat	cag	cag	cct	ccc	cag	cag	aac	act	gga	ttt	cca	cgt	agc	1824
	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser	
			595				600						605				
55	agt	cag	ccc	tat	tac	aat	agt	cgt	ggt	gtg	tct	cgt	ggt	ggt	tcc	cgt	1872
	Ser	Gln	Pro	Tyr	Tyr	Asn	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg	
			610				615					620					
60	ggt	gct	aga	ggc	tta	atg	aat	gga	tac	agg	ggc	cct	gcc	aat	gga	ttc	1920
	Gly	Ala	Arg	Gly	Leu	Met	Asn	Gly	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe	
	625					630					635					640	
65	aga	gga	gga	tat	gat	ggt	tac	cgc	cct	tca	ttc	tct	aac	act	cca	aac	1968
	Arg	Gly	Gly	Tyr	Asp	Gly	Tyr	Arg	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn	
					645					650					655		
70	agt	ggt	tat	aca	cag	tct	cag	ttc	agt	gct	ccc	cgg	gac	tac	tct	ggc	2016
	Ser	Gly	Tyr	Thr	Gln	Ser	Gln	Phe	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly	
				660				665						670			
75	tat	cag	cgg	gat	gga	tat	cag	cag	aat	ttc	aag	cga	ggc	tct	ggg	cag	2064
	Tyr	Gln	Arg	Asp	Gly	Tyr	Gln	Gln	Asn	Phe	Lys	Arg	Gly	Ser	Gly	Gln	
			675					680					685				

EP 2 741 085 A1

	agt gga cca cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga ccc	2112
	Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro	
	690 695 700	
5	aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa	2154
	Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn	
	705 710 715	
	tctgattcac aggattatgt ttaaacgccca aaaacacact ggccagtgta ccataatatg	2214
10	ttaccagaag agttattatc tatttggttct ccctttcagg aaacttattg taaagggact	2274
	gttttcatcc cataaagaca ggactacaat tgtcagcttt atattacctg gatatggaag	2334
	gaaactattht ttattctgca tgttcttcct aagcgtcatc ttgagccttg cacatgatac	2394
15	tcagattcct cacccttgct taggagtaaa acataatata ctttacaggg tgatatctcc	2454
	atagttattht gaagtggctt ggaaaaagca agattaactt ctgacattgg ataaaaatca	2514
	acaaatcagc cctagagtta ttcaaatggt aattgacaaa aactaaaata tttcccttcg	2574
20	agaaggagtg gaatgtggtt tggcagaaca actgcatttc acagcttttc cggttaaatt	2634
	ggagcactaa acgttttagat gcataccaaa ttatgcatgg gcccttaata taaaaggctg	2694
	gctaccagct ttgacacagc actattcatc ctctggccaa acaactgtgg ttaacaaca	2754
25	catgtaaatt gctttttaac agctgatact ataataagac aaagccaaaa tgcaaaaatt	2814
	gggctttgat tggcactttt tgaaaaatat gcaacaaata tgggatgtaa tctggatggc	2874
	cgcttctgta cttaatgta agtatttaga tacctttttg aacacttaac agtttcttct	2934
30	gacaatgact tttgtaagga ttggtactat ctatcattcc ttataatgta cattgtctgt	2994
	cactaatcct cagatcttgc tgtattgtca cctaaattgg tacaggtact gatgaaaata	3054
	tctaattgat aatcataaca ctcttggca catgtttttc ctgcagcctg aaggttttta	3114
35	aaagaaaaag atatcaaatg cctgctgcta ccaccctttt aaattgctat cttttgaaaa	3174
	gcaccagtat gtgttttaga ttgatttccc tattttaggg aaatgacaga cagtagtttc	3234
	agttctgatg gtataagcaa aacaaataaa acatgtttat aaaagttgta tcttgaacaa	3294
40	ctggtgttca acagctagca gcttatgtgg ttcaccccat gcattgtag tgtttcagat	3354
	tttatggtta tctccagcag ctgtttctgt agtacttgca tttatctttt gtctaaccct	3414
45	aatattctca cggaggcatt tatattcaaa gtggtgatcc cttcacttag acgcataggg	3474
	agagtcacaa gtttgatgaa gaggacagtg tagtaattta tatgctgttg gaatttgtgc	3534
	tagcagtttg agcactagtt ctgtgtgcct atgaacttaa tgctgcttgt catattccac	3594
50	ttgacttca tggagaatta atcccatcta ctcagcaaag gctatactaa tactaagtta	3654
	atggtattht ctgtgcagaa attgaattht gttttattag catttagcta aggaattht	3714
	ccagtaggtg ctgactact aaagaaaaac aaaaacaaga cacaaaacta ttctcaacaa	3774
55	ttcattgtta gacaactgga gtttttgctg gttttgtaac ctactaaaat ggataggctg	3834
	ttgaacattc cacattcaaa agttttttgt aggggtggtgg ggaagggggg gtgtcttcaa	3894

EP 2 741 085 A1

tgtttatntt aaataaaat aagttcttga cttttctcat gtgtggttgt ggtacatcat 3954
 attggaaggg ttatctgntt acttttgcaa atgagtatntt ctcttgctag cacctcccgt 4014
 5 tgtgcgctntt aaatgacatc tgcctgggat gtaccacaac catatgntag ctgtatntta 4074
 tggggaatag ataaaatatt cgtggnttat tgggtaatcc ctagatgtgt atgcttacia 4134
 tcctatatat aaaactaaat 4154
 10
 <210> 8
 <211> 717
 <212> PRT
 <213> Canis familiaris
 15
 <400> 8
 Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15
 20 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
 20 25 30
 Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
 25 35 40 45
 His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
 50 55 60
 30 Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
 65 70 75 80
 Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
 35 85 90 95
 Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
 40 100 105 110
 Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
 115 120 125
 45 Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
 130 135 140
 Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
 50 145 150 155 160
 Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
 165 170 175
 55 Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
 180 185 190

EP 2 741 085 A1

Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
 195 200 205
 5 Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
 210 215 220
 10 Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
 225 230 235 240
 Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
 245 250 255
 15 Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
 260 265 270
 20 Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
 275 280 285
 Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
 290 295 300
 25 Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
 305 310 315 320
 30 Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
 325 330 335
 Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
 340 345 350
 35 Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
 355 360 365
 40 Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
 370 375 380
 45 Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
 385 390 395 400
 Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
 405 410 415
 50 Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
 420 425 430
 55 Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
 435 440 445

EP 2 741 085 A1

Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
 450 455 460

5
 Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
 465 470 475 480

10
 Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
 485 490 495

15
 Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
 500 505 510

20
 Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
 515 520 525

25
 Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
 530 535 540

30
 Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
 545 550 555 560

35
 Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
 565 570 575

40
 Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
 580 585 590

45
 Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
 595 600 605

50
 Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
 610 615 620

55
 Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
 625 630 635 640

60
 Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
 645 650 655

65
 Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
 660 665 670

70
 Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
 675 680 685

75
 Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro
 690 695 700

EP 2 741 085 A1

Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
705 710 715

5 <210> 9
<211> 4939
<212> DNA
<213> *Canis familiaris*

10 <220>
<221> CDS
<222> (1)..(2109)
<223>

15 <400> 9
atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15

20 ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30

25 ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45

30 cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60

35 atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80

40 ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95

45 aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110

50 aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125

55 caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140

60 atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160

65 cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 528
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175

70 aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 576
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190

75 ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 624
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser

EP 2 741 085 A1

	195	200	205	
5	ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp 210 215 220			672
	ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala 225 230 235 240			720
10	cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser 245 250 255			768
15	act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser 260 265 270			816
	gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala 275 280 285			864
20	gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn 290 295 300			912
25	aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln 305 310 315 320			960
	gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln 325 330 335			1008
30	cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu 340 345 350			1056
35	act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln 355 360 365			1104
	gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser 370 375 380			1152
40	atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala 385 390 395 400			1200
45	cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys 405 410 415			1248
	cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro 420 425 430			1296
50	gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu 435 440 445			1344
55	ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu 450 455 460			1392

EP 2 741 085 A1

	caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct	1440
	Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser	
	465 470 475 480	
5	tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct	1488
	Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser	
	485 490 495	
10	cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt	1536
	Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser	
	500 505 510	
15	gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc	1584
	Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe	
	515 520 525	
20	aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa	1632
	Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys	
	530 535 540	
25	caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag	1680
	Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln	
	545 550 555 560	
30	cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca	1728
	Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr	
	565 570 575	
35	gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act	1776
	Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr	
	580 585 590	
40	ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc	1824
	Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser	
	595 600 605	
45	agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt	1872
	Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg	
	610 615 620	
50	ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc	1920
	Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe	
	625 630 635 640	
55	aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac	1968
	Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn	
	645 650 655	
60	agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc	2016
	Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly	
	660 665 670	
65	tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg cag	2064
	Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln	
	675 680 685	
70	agt gga cca cgg gga gcc cca cga ggt aat att ttg tgg tgg tga	2109
	Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn Ile Leu Trp Trp	
	690 695 700	
75	tcctagctcc taagtggagc ttctgttctg gccttggaag agctgttcca tagtctgcat	2169
80	gtaggttaca tgtttaggaat acatttatca ttaccagact tgttgctagg gattaaatga	2229

EP 2 741 085 A1

aatgctctgt ttctaaaact tctcttgaac ccaaatttaa ttttttgaat gactttccct 2289
 gttactatat aaattgtctt gaaaactaga acatttctcc tcctcagaaa aagtgttttt 2349
 5 ccaactgcaa attatttttc aggtcctaaa acctgctaaa tgtttttagg aagtacttac 2409
 tgaacattt ttgtaagaca tttttggaat gagattgaac atttatataa atttattatt 2469
 attcctcttt catttttgaa catgcatatt atatttttagg gtcagaaatc ctttaatggc 2529
 10 caaataagcc atagttacat ttagagaacc atttagaagt gatagaacta actgaaattt 2589
 caatgccttt ggatcattaa tagcgatata aatttcaaat tgtttctgac ttttaataa 2649
 aacatccaaa atcctaacta acttctgaa ctatatttaa aaattacagg ttttaaggagt 2709
 15 ttctggtttt ttttctctta ccatagaaa actgtttcct gtttgccag gaagtcaacc 2769
 tgtgtaataa ttagaagtag catttcatat gatctgaagt tctaaatggg tctctgattt 2829
 aaggaagtt aaattgaata ggtttcctct agttattggc cataacatgt ataaaatgta 2889
 20 tattaaggag gaatacaaag tactttgatt tcaatgctag tagaaactgg ccagcaaaaa 2949
 ggtgcatttt atttttaa ataatggatca cttgggaatt actgacttga agtatcaaag 3009
 gatatttgca tgtgaatgtg ggttatgttc tttctcacct thtagcatat tctatgaaag 3069
 25 ttgagttgac tggtagctaa aaatctgttt taacagcatg taaaagttta ttttatctgt 3129
 tacaagtcat tatacaattt tgaatgttat gtagtttctt tttaacagtt taggtaacaa 3189
 ggtctgtttt tcattctggg gcttttatta attttgatag tatgatgta cttactactg 3249
 30 aaatgtaagc tagagtgtac actagaatgt aagctccatg agagcaggta ccttgtctgt 3309
 cttcactgct gtatctattt ccaacgcctg atgacagtgc ctgacacata gtaggcactc 3369
 aataaatact tgttgaatga atgaatgaat gtagtactgg ggaatactcc attagctcta 3429
 35 ctcttctttt agctagagaa catgagcaaa tttgcgcatg acaacttcca ggacaggtga 3489
 aactgaaga attgacctct taaacctaat aatgtgggta caagctgcc acatgcttct 3549
 tgacttcaga tgaaaatctg cttgaaggca aagcaaataa tatttgaaag aaaaaccaa 3609
 40 tgccattttt gtcttctagg tcgtggaggg cccccaagac ccaacagagg gatgccgcaa 3669
 atgaacactc agcaagtga ttaatctgat tcacaggatt atgtttaaac gccaaaaaca 3729
 cactggccag tgtaccataa tatgttacca gaagagttat tatctatttg ttctcccttt 3789
 45 caggaaactt attgtaaagg gactgttttc atoccataaa gacaggacta caattgtcag 3849
 ctttatatta cctggatatg gaaggaaact atttttattc tgcattgttct tcctaagcgt 3909
 catcttgagc cttgcacatg atactcagat tcctcaccct tgcttaggag taaaacataa 3969
 tacactttac agggtgatat ctccatagtt atttgaagtg gcttgaaaa agcaagatta 4029
 acttctgaca ttggataaaa atcaacaaat cagccctaga gttattcaaa tggtaattga 4089
 50 caaaaactaa aatatttccc ttcgagaagg agtggaatgt ggtttggcag aacaactgca 4149
 tttcacagct tttccggtta aattggagca ctaaactgtt agatgcatac caaattatgc 4209

EP 2 741 085 A1

atggggcctt aatataaaag gctggctacc agctttgaca cagcactatt catcctctgg 4269
 ccaaacaact gtggttaaac aacacatgta aattgctttt taacagctga tactataata 4329
 5 agacaaagcc aaaatgcaaa aattgggctt tgattggcac tttttgaaaa atatgcaaca 4389
 aatatgggat gtaatctgga tggccgcttc tgtacttaat gtgaagtatt tagatacctt 4449
 tttgaacact taacagtttc ttctgacaat gacttttgta aggattggta ctatctatca 4509
 10 ttccttataa tgtacattgt ctgtcactaa tcctcagatc ttgctgtatt gtcacctaaa 4569
 ttggtacagg tactgatgaa aatatctaataa ggataatcat aacactcttg gtcacatggt 4629
 tttcctgcag cctgaagggtt tttaaaagaa aaagatatca aatgcctgct gctaccaccc 4689
 15 ttttaaattg ctatcttttg aaaagcacca gtatgtgttt tagattgatt tccctatttt 4749
 agggaaatga cagacagtag tttcagttct gatggataaa gcaaaacaaa taaaacatgt 4809
 ttataaaagt tgtatcttga aacactgggtg ttcaacagct agcagcttat gtggttcacc 4869
 20 ccatgcattg ttagtgtttc agattttatg gttatctcca gcagctgttt ctgtagtact 4929
 tgcatttatc 4939

 25 <210> 10
 <211> 702
 <212> PRT
 <213> Canis familiaris

 30 <400> 10
 Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

 35 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
 20 25 30

 Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Ala Pro Ala Ser Gln
 35 40 45
 40 His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
 50 55 60

 45 Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
 65 70 75 80

 Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
 85 90 95
 50 Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
 100 105 110

 55 Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
 115 120 125

EP 2 741 085 A1

Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
 130 135 140

5
 Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
 145 150 155 160

10
 Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
 165 170 175

15
 Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
 180 185 190

20
 Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
 195 200 205

25
 Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
 210 215 220

30
 Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
 225 230 235 240

35
 Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
 245 250 255

40
 Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
 260 265 270

45
 Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
 275 280 285

50
 Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
 290 295 300

55
 Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
 305 310 315 320

60
 Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
 325 330 335

65
 Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
 340 345 350

70
 Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
 355 360 365

75
 Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
 370 375 380

EP 2 741 085 A1

Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
 385 390 395 400
 5 Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
 405 410 415
 10 Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
 420 425 430
 Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
 435 440 445
 15 Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
 450 455 460
 20 Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
 465 470 475 480
 Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
 485 490 495
 25 Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
 500 505 510
 30 Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
 515 520 525
 Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
 530 535 540
 35 Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
 545 550 555 560
 40 Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
 565 570 575
 Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
 580 585 590
 Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
 595 600 605
 50 Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
 610 615 620
 55 Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
 625 630 635 640

EP 2 741 085 A1

	Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn	
	645	650 655
5	Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly	
	660	665 670
10	Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln	
	675	680 685
15	Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn Ile Leu Trp Trp	
	690	695 700
20	<210> 11	
	<211> 3306	
	<212> DNA	
	<213> Canis familiaris	
25	<220>	
	<221> CDS	
	<222> (1)..(2040)	
	<223>	
30	<400> 11	
	atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc	48
	Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly	
	1 5 10 15	
35	ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg	96
	Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala	
	20 25 30	
40	ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag	144
	Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln	
	35 40 45	
45	cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag	192
	His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln	
	50 55 60	
50	atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag	240
	Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys	
	65 70 75 80	
55	ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt	288
	Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu	
	85 90 95	
60	aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat	336
	Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn	
	100 105 110	
65	aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt	384
	Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser	
	115 120 125	
70	caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt	432
	Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu	
	130 135 140	
75	atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc	480
	Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu	

EP 2 741 085 A1

	145		150		155		160										
	cag	tat	gtt	ttg	gac	aaa	ttg	gga	gat	gat	gaa	gtg	aga	act	gac	ctg	528
5	Gln	Tyr	Val	Leu	Asp	Lys	Leu	Gly	Asp	Asp	Glu	Val	Arg	Thr	Asp	Leu	
					165					170					175		
	aag	caa	ggt	ttg	aat	gga	gtg	cca	ata	ttg	tct	gaa	gaa	gaa	ttg	tcg	576
	Lys	Gln	Gly	Leu	Asn	Gly	Val	Pro	Ile	Leu	Ser	Glu	Glu	Glu	Leu	Ser	
				180					185					190			
10	ttg	ttg	gat	gaa	ttc	tac	aaa	tta	gca	gac	cct	gaa	cgg	gac	atg	agc	624
	Leu	Leu	Asp	Glu	Phe	Tyr	Lys	Leu	Ala	Asp	Pro	Glu	Arg	Asp	Met	Ser	
			195					200					205				
	ttg	agg	ttg	aat	gag	cag	tat	gaa	cat	gct	tcc	att	cac	ctg	tgg	gac	672
15	Leu	Arg	Leu	Asn	Glu	Gln	Tyr	Glu	His	Ala	Ser	Ile	His	Leu	Trp	Asp	
		210					215					220					
	ttg	ctg	gaa	gga	aag	gaa	aag	tct	gta	tgt	gga	aca	acc	tat	aaa	gca	720
	Leu	Leu	Glu	Gly	Lys	Glu	Lys	Ser	Val	Cys	Gly	Thr	Thr	Tyr	Lys	Ala	
	225					230					235					240	
20	cta	aag	gaa	att	gtt	gag	cgt	gtt	ttc	cag	tca	aat	tac	ttt	gac	agc	768
	Leu	Lys	Glu	Ile	Val	Glu	Arg	Val	Phe	Gln	Ser	Asn	Tyr	Phe	Asp	Ser	
					245					250					255		
	act	cac	aac	cac	cag	aat	ggg	cta	tgt	gag	gaa	gaa	gag	gca	gcc	tca	816
25	Thr	His	Asn	His	Gln	Asn	Gly	Leu	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	
				260					265					270			
	gca	cct	aca	gtt	gaa	gac	cag	gta	gct	gaa	gct	gag	cct	gag	cca	gca	864
	Ala	Pro	Thr	Val	Glu	Asp	Gln	Val	Ala	Glu	Ala	Glu	Pro	Glu	Pro	Ala	
			275					280					285				
30	gaa	gaa	tac	act	gaa	caa	agt	gaa	gtt	gaa	tca	aca	gag	tat	gta	aat	912
	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	
			290				295					300					
	aga	caa	ttt	atg	gca	gaa	aca	cag	ttc	agc	agt	ggt	gaa	aag	gag	cag	960
35	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	Phe	Ser	Ser	Gly	Glu	Lys	Glu	Gln	
	305					310					315					320	
	gta	gat	gag	tgg	acg	gtc	gaa	aca	gtg	gag	gtg	gtg	aat	tca	ctc	cag	1008
	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	
					325					330					335		
40	cag	caa	cct	cag	gct	gcg	tct	cct	tca	gta	cca	gag	ccc	cac	tct	ttg	1056
	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	
				340					345					350			
	act	ccg	gtg	gct	cag	gca	gat	ccc	ctt	gtg	aga	aga	cag	cga	gtc	cag	1104
45	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	
			355					360					365				
	gac	ctt	atg	gcg	cag	atg	cag	ggg	ccc	tat	aat	ttc	ata	cag	gat	tca	1152
	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	
50			370				375					380					
	atg	ctg	gat	ttt	gaa	aac	cag	aca	ctc	gat	cct	gcc	att	gta	tct	gca	1200
	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	
			385			390					395					400	
55	cag	cct	atg	aat	ccg	aca	caa	aac	atg	gac	atg	ccc	cag	ctg	gtt	tgc	1248
	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	
					405					410					415		

EP 2 741 085 A1

	cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct	1296
	Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro	
	420 425 430	
5	gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag	1344
	Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu	
	435 440 445	
10	ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag	1392
	Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu	
	450 455 460	
15	caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct	1440
	Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser	
	465 470 475 480	
20	tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct	1488
	Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser	
	485 490 495	
25	cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt	1536
	Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser	
	500 505 510	
30	gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc	1584
	Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe	
	515 520 525	
35	aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa	1632
	Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys	
	530 535 540	
40	caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag	1680
	Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln	
	545 550 555 560	
45	cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca	1728
	Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr	
	565 570 575	
50	gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act	1776
	Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr	
	580 585 590	
55	ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc	1824
	Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser	
	595 600 605	
60	agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt	1872
	Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg	
	610 615 620	
65	ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc	1920
	Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe	
	625 630 635 640	
70	aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac	1968
	Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn	
	645 650 655	
75	agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc	2016
	Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly	
	660 665 670	

EP 2 741 085 A1

tat cag cgg gga tgc cgc aaa tga acactcagca agtgaattaa tctgattcac 2070
 Tyr Gln Arg Gly Cys Arg Lys
 675

5 aggattatgt ttaaacgcca aaaacacact ggccagtgta ccataatatg ttaccagaag 2130
 agttattatc tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc 2190
 cataaagaca ggactacaat tgtcagcttt atattacctg gatatggaag gaaactattt 2250
 10 ttattctgca tgttcttct aagcgtcatc ttgagccttg cacatgatac tcagattcct 2310
 cacccttgct taggagtaaa acataataca ctttacaggg tgatatctcc atagttattt 2370
 gaagtggcct ggaaaaagca agattaactt ctgacattgg ataaaaatca acaaatcagc 2430
 15 cctagagtta ttcaaatggt aattgacaaa aactaaaata tttcccttcg agaaggagtg 2490
 gaatgtggtt tggcagaaca actgcatttc acagcttttc cggttaaatt ggagcactaa 2550
 acgttttagat gcataccaaa ttatgcatgg gcccttaata taaaaggctg gctaccagct 2610
 20 ttgacacagc actattcatc ctctggccaa acaactgtgg ttaaacaaca catgtaaatt 2670
 gctttttaac agctgatact ataataagac aaagccaaaa tgcaaaaatt gggctttgat 2730
 tggcactttt tgaaaaatat gcaacaaata tgggatgtaa tctggatggc cgcttctgta 2790
 25 cttaatgtga agtatttaga tacctttttg aacacttaac agtttcttct gacaatgact 2850
 tttgtaagga ttggtactat ctatcattcc ttataatgta cattgtctgt cactaatcct 2910
 cagatcttgc tgtattgtca cctaaattgg tacaggtact gatgaaaata tctaattgat 2970
 30 aatcataaca ctcttgggtca catgtttttc ctgcagcctg aaggttttta aaagaaaaag 3030
 atatcaaatg cctgctgcta ccaccctttt aaattgctat cttttgaaaa gcaccagtat 3090
 35 gtgtttttaga ttgatttccc tatttttaggg aaatgacaga cagtagtttc agttctgatg 3150
 gtataagcaa aacaaataaa acatgtttat aaaagttgta tcttgaaca ctggtgttca 3210
 acagctagca gcttatgtgg ttcaccccat gcattgttag tgtttcagat tttatggtta 3270
 40 tctccagcag ctgtttctgt agtacttgca tttatc 3306

<210> 12

<211> 679

<212> PRT

45 <213> Canis familiaris

<400> 12

Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
 20 25 30

55 Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
 35 40 45

EP 2 741 085 A1

His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
 50 55 60

5 Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
 65 70 75 80

10 Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
 85 90 95

15 Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
 100 105 110

20 Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
 115 120 125

25 Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
 130 135 140

30 Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
 145 150 155 160

35 Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
 165 170 175

40 Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
 180 185 190

45 Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
 195 200 205

50 Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
 210 215 220

55 Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
 225 230 235 240

60 Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
 245 250 255

65 Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
 260 265 270

70 Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
 275 280 285

75 Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
 290 295 300

EP 2 741 085 A1

Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
 305 310 315 320
 5 Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
 325 330 335
 10 Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
 340 345 350
 15 Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
 355 360 365
 20 Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
 370 375 380
 25 Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
 385 390 395 400
 30 Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
 405 410 415
 35 Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
 420 425 430
 40 Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
 435 440 445
 45 Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
 450 455 460
 50 Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
 465 470 475 480
 55 Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
 485 490 495
 60 Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
 500 505 510
 65 Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
 515 520 525
 70 Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
 530 535 540
 75 Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
 545 550 555 560
 80 Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr

EP 2 741 085 A1

				565					570					575				
5	Val	Val	Gly	Thr	Tyr	His	Gly	Ser	Gln	Asp	Gln	Pro	His	Gln	Val	Thr		
				580					585					590				
10	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser		
			595					600					605					
15	Ser	Gln	Pro	Tyr	Tyr	Asn	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg		
		610					615					620						
20	Gly	Ala	Arg	Gly	Leu	Met	Asn	Gly	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe		
	625					630					635					640		
25	Arg	Gly	Gly	Tyr	Asp	Gly	Tyr	Arg	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn		
				645						650					655			
30	Ser	Gly	Tyr	Thr	Gln	Ser	Gln	Phe	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly		
			660						665					670				
35	Tyr	Gln	Arg	Gly	Cys	Arg	Lys											
			675															
40	<210>	13																
	<211>	2281																
	<212>	DNA																
	<213>	Canis familiaris																
	<220>																	
	<221>	CDS																
	<222>	(1)..(2154)																
	<223>																	
45	<400>	13																
	atg	ccg	tcg	gcc	acc	agc	ctc	agc	gga	agc	ggc	agc	aag	tcg	tcg	ggc		48
	Met	Pro	Ser	Ala	Thr	Ser	Leu	Ser	Gly	Ser	Gly	Ser	Lys	Ser	Ser	Gly		
	1			5					10					15				
50	ccg	ccg	ccc	ccg	tcg	ggt	tcc	tcc	ggg	agc	gag	gcg	gcg	gcg	gcg	gcg		96
	Pro	Pro	Pro	Pro	Ser	Gly	Ser	Ser	Gly	Ser	Glu	Ala	Ala	Ala	Ala	Ala		
			20					25					30					
55	ggg	gcg	gcg	ggg	gcg	gcg	ggg	gcc	ggg	gcg	gct	gcg	ccc	gcc	tcc	cag		144
	Gly	Ala	Ala	Gly	Ala	Ala	Gly	Ala	Gly	Ala	Ala	Ala	Pro	Ala	Ser	Gln		
			35				40					45						
60	cac	ccc	gcg	acc	ggc	acc	ggc	gct	gtc	cag	acc	gag	gcc	atg	aag	cag		192
	His	Pro	Ala	Thr	Gly	Thr	Gly	Ala	Val	Gln	Thr	Glu	Ala	Met	Lys	Gln		
		50				55						60						
65	atc	ctc	ggg	gtg	atc	gac	aag	aaa	ctc	cgg	aac	ctg	gag	aag	aaa	aag		240
	Ile	Leu	Gly	Val	Ile	Asp	Lys	Lys	Leu	Arg	Asn	Leu	Glu	Lys	Lys	Lys		
	65				70					75					80			
70	ggc	aag	ctt	gat	gat	tac	cag	gaa	cga	atg	aac	aaa	ggg	gaa	agg	ctt		288
	Gly	Lys	Leu	Asp	Asp	Tyr	Gln	Glu	Arg	Met	Asn	Lys	Gly	Glu	Arg	Leu		
				85						90					95			

EP 2 741 085 A1

	aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat	336
	Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn	
	100 105 110	
5	aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt	384
	Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser	
	115 120 125	
10	caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt	432
	Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu	
	130 135 140	
15	atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc	480
	Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu	
	145 150 155 160	
20	cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg	528
	Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu	
	165 170 175	
25	aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg	576
	Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser	
	180 185 190	
30	ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc	624
	Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser	
	195 200 205	
35	ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac	672
	Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp	
	210 215 220	
40	ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca	720
	Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala	
	225 230 235 240	
45	cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc	768
	Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser	
	245 250 255	
50	act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca	816
	Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser	
	260 265 270	
55	gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca	864
	Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala	
	275 280 285	
60	gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat	912
	Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn	
	290 295 300	
65	aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag	960
	Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln	
	305 310 315 320	
70	gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag	1008
	Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln	
	325 330 335	
75	cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg	1056
	Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu	
	340 345 350	

EP 2 741 085 A1

	act	ccg	gtg	gct	cag	gca	gat	ccc	ctt	gtg	aga	aga	cag	cga	gtc	cag	1104
	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	
			355					360					365				
5	gac	ctt	atg	gcg	cag	atg	cag	ggg	ccc	tat	aat	ttc	ata	cag	gat	tca	1152
	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	
		370					375					380					
10	atg	ctg	gat	ttt	gaa	aac	cag	aca	ctc	gat	cct	gcc	att	gta	tct	gca	1200
	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	
		385				390					395					400	
15	cag	cct	atg	aat	ccg	aca	caa	aac	atg	gac	atg	ccc	cag	ctg	gtt	tgc	1248
	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	
				405					410						415		
20	cct	cca	gtt	cat	tct	gaa	tct	aga	ctt	gct	caa	cct	aat	caa	gtt	cct	1296
	Pro	Pro	Val	His	Ser	Glu	Ser	Arg	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro	
				420				425						430			
25	gta	caa	cca	gaa	gct	aca	cag	gtt	cct	ttg	gtt	tca	tcc	aca	agt	gag	1344
	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	
			435				440						445				
30	ggg	tat	aca	gca	tct	caa	ccc	ttg	tac	cag	cct	tct	cat	gct	aca	gag	1392
	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	
		450				455					460						
35	caa	cga	cca	caa	aag	gaa	cca	att	gac	cag	att	cag	gca	aca	atc	tct	1440
	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	
		465			470					475						480	
40	tta	aat	aca	gac	cag	act	aca	gcg	tca	tca	tcc	ctt	ccg	gct	gct	tct	1488
	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	
				485				490							495		
45	cag	cct	cag	gta	ttc	cag	gct	ggg	aca	agc	aaa	cca	tta	cat	agc	agt	1536
	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	
			500				505						510				
50	gga	atc	aat	gta	aat	gca	gct	cca	ttc	caa	tcc	atg	caa	acg	gtg	ttc	1584
	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	
			515				520						525				
55	aat	atg	aat	gcc	cca	gtt	cct	cct	gtt	aat	gaa	cca	gaa	act	ttg	aaa	1632
	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys	
			530			535						540					
60	caa	caa	aat	cag	tac	cag	gcc	agt	tat	aac	cag	agc	ttt	tct	agt	cag	1680
	Gln	Gln	Asn	Gln	Tyr	Gln	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln	
			545			550					555					560	
65	cct	cac	caa	gta	gaa	caa	aca	gac	ctt	cag	caa	gaa	cag	ctt	caa	aca	1728
	Pro	His	Gln	Val	Glu	Gln	Thr	Asp	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr	
				565				570						575			
70	gtg	gtt	ggc	act	tac	cat	ggt	tcc	cag	gac	cag	ccc	cac	caa	gtg	act	1776
	Val	Val	Gly	Thr	Tyr	His	Gly	Ser	Gln	Asp	Gln	Pro	His	Gln	Val	Thr	
			580				585							590			
75	ggt	aac	cat	cag	cag	cct	ccc	cag	cag	aac	act	gga	ttt	cca	cgt	agc	1824
	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser	
			595				600						605				
80	agt	cag	ccc	tat	tac	aat	agt	cgt	ggt	gtg	tct	cgt	ggt	ggt	tcc	cgt	1872

EP 2 741 085 A1

	Ser	Gln	Pro	Tyr	Tyr	Asn	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg	
	610						615					620					
5	ggg	gct	aga	ggc	tta	atg	aat	gga	tac	agg	ggc	cct	gcc	aat	gga	ttc	1920
	Gly	Ala	Arg	Gly	Leu	Met	Asn	Gly	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe	
	625					630					635				640		
10	aga	gga	gga	tat	gat	ggg	tac	cgc	cct	tca	ttc	tct	aac	act	cca	aac	1968
	Arg	Gly	Gly	Tyr	Asp	Gly	Tyr	Arg	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn	
					645					650					655		
15	agt	ggg	tat	aca	cag	tct	cag	ttc	agt	gct	ccc	cgg	gac	tac	tct	ggc	2016
	Ser	Gly	Tyr	Thr	Gln	Ser	Gln	Phe	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly	
				660					665					670			
20	tat	cag	cgg	gat	gga	tat	cag	cag	aat	ttc	aag	cga	ggc	tct	ggg	cag	2064
	Tyr	Gln	Arg	Asp	Gly	Tyr	Gln	Gln	Asn	Phe	Lys	Arg	Gly	Ser	Gly	Gln	
				675				680					685				
25	agt	gga	cca	cgg	gga	gcc	cca	cga	ggg	cgt	gga	ggg	ccc	cca	aga	ccc	2112
	Ser	Gly	Pro	Arg	Gly	Ala	Pro	Arg	Gly	Arg	Gly	Gly	Pro	Pro	Arg	Pro	
		690					695					700					
30	aac	aga	ggg	atg	ccg	caa	atg	aac	act	cag	caa	gtg	aat	taa			2154
	Asn	Arg	Gly	Met	Pro	Gln	Met	Asn	Thr	Gln	Gln	Val	Asn				
	705					710					715						
35	tctgattcac	aggattatgt	ttaaacgcca	aaaacacact	ggccagtgtgta	ccataatatg											2214
40	ttaccagaag	agttattatc	tatttgact	gttttcatcc	cataaagaca	ggactacaat											2274
45	tgtcagc																2281
50	<210>	14															
	<211>	717															
	<212>	PRT															
	<213>	Canis familiaris															
55	<400>	14															
60	Met	Pro	Ser	Ala	Thr	Ser	Leu	Ser	Gly	Ser	Gly	Ser	Lys	Ser	Ser	Gly	
	1				5					10					15		
65	Pro	Pro	Pro	Pro	Ser	Gly	Ser	Ser	Gly	Ser	Glu	Ala	Ala	Ala	Ala	Ala	
				20					25					30			
70	Gly	Ala	Ala	Gly	Ala	Ala	Gly	Ala	Gly	Ala	Ala	Ala	Pro	Ala	Ser	Gln	
		35					40						45				
75	His	Pro	Ala	Thr	Gly	Thr	Gly	Ala	Val	Gln	Thr	Glu	Ala	Met	Lys	Gln	
	50						55					60					
80	Ile	Leu	Gly	Val	Ile	Asp	Lys	Lys	Leu	Arg	Asn	Leu	Glu	Lys	Lys	Lys	
	65					70					75					80	
85	Gly	Lys	Leu	Asp	Asp	Tyr	Gln	Glu	Arg	Met	Asn	Lys	Gly	Glu	Arg	Leu	
					85					90					95		

EP 2 741 085 A1

Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
 100 105 110

5 Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
 115 120 125

Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
 130 135 140

10 Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
 145 150 155 160

15 Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
 165 170 175

Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
 180 185 190

20 Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
 195 200 205

25 Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
 210 215 220

Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
 225 230 235 240

30 Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
 245 250 255

35 Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
 260 265 270

Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
 275 280 285

40 Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
 290 295 300

45 Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
 305 310 315 320

Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
 325 330 335

50 Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
 340 345 350

55 Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln

EP 2 741 085 A1

		355				360						365				
5	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser
		370					375					380				
10	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala
		385				390					395					400
15	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys
				405						410					415	
20	Pro	Pro	Val	His	Ser	Glu	Ser	Arg	Leu	Ala	Gln	Pro	Asn	Gln	Val	Pro
				420					425					430		
25	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu
			435					440					445			
30	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu
		450					455					460				
35	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Ile	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser
		465				470					475					480
40	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser
				485						490					495	
45	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser
				500					505					510		
50	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe
			515					520					525			
55	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	Lys
		530					535					540				
60	Gln	Gln	Asn	Gln	Tyr	Gln	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	Gln
		545				550					555					560
65	Pro	His	Gln	Val	Glu	Gln	Thr	Asp	Leu	Gln	Gln	Glu	Gln	Leu	Gln	Thr
				565						570					575	
70	Val	Val	Gly	Thr	Tyr	His	Gly	Ser	Gln	Asp	Gln	Pro	His	Gln	Val	Thr
			580						585					590		
75	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	Arg	Ser
			595					600					605			
80	Ser	Gln	Pro	Tyr	Tyr	Asn	Ser	Arg	Gly	Val	Ser	Arg	Gly	Gly	Ser	Arg
		610					615					620				

EP 2 741 085 A1

	Gly	Ala	Arg	Gly	Leu	Met	Asn	Gly	Tyr	Arg	Gly	Pro	Ala	Asn	Gly	Phe	
	625					630					635					640	
5	Arg	Gly	Gly	Tyr	Asp	Gly	Tyr	Arg	Pro	Ser	Phe	Ser	Asn	Thr	Pro	Asn	
					645					650					655		
	Ser	Gly	Tyr	Thr	Gln	Ser	Gln	Phe	Ser	Ala	Pro	Arg	Asp	Tyr	Ser	Gly	
10				660					665					670			
	Tyr	Gln	Arg	Asp	Gly	Tyr	Gln	Gln	Asn	Phe	Lys	Arg	Gly	Ser	Gly	Gln	
			675					680					685				
15	Ser	Gly	Pro	Arg	Gly	Ala	Pro	Arg	Gly	Arg	Gly	Gly	Pro	Pro	Arg	Pro	
	690						695					700					
	Asn	Arg	Gly	Met	Pro	Gln	Met	Asn	Thr	Gln	Gln	Val	Asn				
20	705					710					715						
	<210>	15															
	<211>	3386															
25	<212>	DNA															
	<213>	Bos taurus															
	<220>																
	<221>	CDS															
	<222>	(82)..(2208)															
30	<223>																
	<400>	15															
	cgcgctctcgc	cccgtccacc	gattgactcg	ccgctcttgt	ccttcctccc	gctctttctt										60	
	ctctcccctt	acggtttcaa	g	atg	cct	tcg	gcc	acc	agc	cac	agc	gga	agc			111	
35				Met	Pro	Ser	Ala	Thr	Ser	His	Ser	Gly	Ser			10	
				1				5									
	ggc	agc	aag	tcg	tcc	gga	ccg	cca	ccg	ccg	tcg	ggt	tcc	tcc	ggg	aat	159
40	Gly	Ser	Lys	Ser	Ser	Gly	Pro	Pro	Pro	Pro	Ser	Gly	Ser	Ser	Gly	Asn	
					15					20					25		
	gag	gcg	ggg	gcc	ggg	gcc	gcc	gcg	ccg	gct	tcc	caa	cac	ccc	atg	acc	207
	Glu	Ala	Gly	Ala	Gly	Ala	Ala	Ala	Pro	Ala	Ser	Gln	His	Pro	Met	Thr	
				30				35						40			
45	ggc	acc	ggg	gct	gtc	cag	acc	gag	gcc	atg	aag	cag	att	ctc	ggg	gtg	255
	Gly	Thr	Gly	Ala	Val	Gln	Thr	Glu	Ala	Met	Lys	Gln	Ile	Leu	Gly	Val	
			45					50					55				
	atc	gac	aag	aaa	ctt	cgg	aac	ctg	gag	aag	aaa	aag	ggc	aag	ctt	gat	303
50	Ile	Asp	Lys	Lys	Leu	Arg	Asn	Leu	Glu	Lys	Lys	Lys	Gly	Lys	Leu	Asp	
		60					65					70					
	gat	tat	cag	gaa	cga	atg	aac	aaa	ggg	gaa	agg	ctt	aat	caa	gat	cag	351
	Asp	Tyr	Gln	Glu	Arg	Met	Asn	Lys	Gly	Glu	Arg	Leu	Asn	Gln	Asp	Gln	
						80					85					90	
55	ctg	gat	gcc	gtg	tct	aag	tac	cag	gaa	gtc	aca	aat	aac	ttg	gag	ttt	399
	Leu	Asp	Ala	Val	Ser	Lys	Tyr	Gln	Glu	Val	Thr	Asn	Asn	Leu	Glu	Phe	

EP 2 741 085 A1

	95	100	105	
5	gca aaa gaa tta cag agg agt ttc atg gca tta agc caa gat att cag Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln 110 115 120			447
	aaa aca ata aag aag aca gca cgt cgg gag cag ctt atg aga gag gaa Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu 125 130 135			495
10	gct gaa cag aaa cgt tta aaa aca gta ctt gag ctg cag tat gtt ttg Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu 140 145 150			543
15	gac aaa cta gga gat gat gaa gtg aga act gac ctg aag caa ggt ttg Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu 155 160 165 170			591
	aat gga gtg cca ata ttg tct gaa gag gag ttg tcg ttg tta gat gag Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu 175 180 185			639
20	ttc tac aaa tta gca gac cct gaa cga gac atg agc ttg agg ttg aat Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn 190 195 200			687
25	gag cag tat gaa cat gcc tcc att cac ctg tgg gac ttg ctg gaa gga Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly 205 210 215			735
	aag gaa aaa cct gta tgt gga aca act tat aaa gct cta aag gaa att Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile 220 225 230			783
30	gtt gag cgt gtt ttc cag tca aac tac ttt gac agc acc cac aac cac Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His 235 240 245 250			831
35	cag aat ggt ctg tgt gag gaa gag gag gca gcc tca gca cct aca gtt Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val 255 260 265			879
	gaa gac cag gca gct gaa gct gaa cct gag cca gtg gaa gaa tat act Glu Asp Gln Ala Ala Glu Ala Glu Pro Glu Pro Val Glu Glu Tyr Thr 270 275 280			927
40	gaa caa aat gag gtt gaa tca aca gag tat gta aat aga caa ttt atg Glu Gln Asn Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met 285 290 295			975
45	gca gaa aca cag ttc agc agt ggt gaa aag gag cag gta gat gat tgg Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Asp Trp 300 305 310			1023
	aca gtt gaa aca gtt gag gtg gta aat tca ctc cag cag caa cct cag Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln 315 320 325 330			1071
50	gct gca tct cct tca gta cca gaa ccc cac tct ttg acc cca gtg gct Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala 335 340 345			1119
55	caa gcc gat ccc ctc gtg aga aga cag cga gta cag gac ctt atg gca Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala 350 355 360			1167

EP 2 741 085 A1

	caa atg cag ggg ccc tat aat ttc ata cag gat tca atg ttg gat ttt	1215
	Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe	
	365 370 375	
5	gaa aac cag aca ctt gat cct gcc att gta tct gca cag ccg atg aat	1263
	Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn	
	380 385 390	
10	cca gca cag aac atg gac ata ccc cag ctg gtt tgc cct cca gtt cat	1311
	Pro Ala Gln Asn Met Asp Ile Pro Gln Leu Val Cys Pro Pro Val His	
	395 400 405 410	
15	tct gaa tct aga ctt gct caa cct aat caa gtt tct gta cag cca gaa	1359
	Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Ser Val Gln Pro Glu	
	415 420 425	
20	gct aca cag gtt cct ttg gtt tca tcc aca agt gag gga tat aca gca	1407
	Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala	
	430 435 440	
25	tct caa ccc ttg tac caa cct tct cat gct act gac caa cga cca caa	1455
	Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Asp Gln Arg Pro Gln	
	445 450 455	
30	aag gaa ccg att gat cag att cag gcg acg atc tct tta aat aca gac	1503
	Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp	
	460 465 470	
35	cag act aca gca tca tca tcc ctt cct gct gct tct cag cct caa gtg	1551
	Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val	
	475 480 485 490	
40	ttc cag gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta	1599
	Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val	
	495 500 505	
45	aat gca gct cca ttc caa tcc atg caa acg gta ttc aat atg aat gcc	1647
	Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala	
	510 515 520	
50	cca gtt cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag	1695
	Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln	
	525 530 535	
55	tac cag gcc agt tac aac cag agc ttt tcc agt cag cct cac caa gta	1743
	Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val	
	540 545 550	
60	gaa caa aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act	1791
	Glu Gln Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr	
	555 560 565 570	
65	tat cat ggt tct cag gac cag ccc cat caa gtg act ggt aac cac cag	1839
	Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr Gly Asn His Gln	
	575 580 585	
70	cag cct cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat	1887
	Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr	
	590 595 600	
75	tac aac agt cgt ggt gtg tct cgt gga ggt tcc cgt ggt gct aga ggc	1935
	Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly	
	605 610 615	

EP 2 741 085 A1

	ttg atg aat gga tac aga gga cct gct aat gga ttc aga gga gga tat	1983
	Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr	
	620 625 630	
5	gat ggt tac cgc cct tca ttc tct act aac act cca aac agt ggt tat	2031
	Asp Gly Tyr Arg Pro Ser Phe Ser Thr Asn Thr Pro Asn Ser Gly Tyr	
	635 640 645 650	
10	aca caa tct caa ttc agt gct ccc cgg gac tac tct ggc tat cag cgg	2079
	Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg	
	655 660 665	
15	gat gga tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca	2127
	Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro	
	670 675 680	
20	cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg	2175
	Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly	
	685 690 695	
25	atg ccg caa atg aac act cag caa gtg aat taa tctgattcac aggattatgt	2228
	Met Pro Gln Met Asn Thr Gln Gln Val Asn	
	700 705	
30	ttaatcgcca aaaacacact ggccagtgtta ccataatatg ttaccagaag agttattatc	2288
35	tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca	2348
40	ggactacaat tgtcagcttt atattacctg gatatggaag gaaactatct ttactctgca	2408
45	tgttctgtcc taagcgtcat cttgagcctt gcacatgata ctgagattcc tcacccttgc	2468
50	ttaggagtaa aacataatat actttaatgg ggtgatatct ccatagttat ttgaagtggc	2528
55	ttggataaag caagactgac ttctgacatt ggataaaatc tacaatcag ccctagagtc	2588
60	attcagtggt aactgacaaa actaaaatat ttcccttgaa aggaagatgg aaggagtgga	2648
65	gtgtggtttg gcagaacaac tgcattttcac agctttttcca cttaaattgg agcactgaac	2708
70	atntagatgc ataccgaatt atgcatgggc cctaatcaca cagacaaggc tggtgccagc	2768
75	cttaggcttg acacggcagt gttcaccctc tggccagacg actgtggttc aagacacatg	2828
80	taaattgctt ttttaacagct gatactgtat aagacaaagc caaaatgcaa aattaggctt	2888
85	tgattggcac ttttcgaaaa atatgcaaca attaagggat ataactctgga tggccgcttc	2948
90	tgtacttaat gtgaaatatt tagatacctt tcaaacactt aacagtttct ttgacaatga	3008
95	gttttgtaag gattggtagt aaatatcatt ccttatgacg tacattgtct gtcactaatc	3068
100	cttggatctt gctgtattgt cacctaaatt ggtacaggta ctgatgaaaa tctaattggat	3128
105	aatcataaca ctcttggtta catgtttttc ctgcagcctg aaagttttta taagaaaaag	3188
110	acatcaaagc cctgctgctg ccaccctttt aaattgctat cttttgaaaa gcaccagtat	3248
115	gtgttttaga ttgatttccc tatttttaggg aaatgacagt cagtagtttc acttctgatg	3308
120	gtataagcaa acaataaaaa catgtttata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3368
125	aaaaaaaaaa aaaaaaaaaa	3386

EP 2 741 085 A1

<210> 16
 <211> 708
 <212> PRT
 <213> Bos taurus

5
 <400> 16

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

10
 Pro Pro Pro Pro Ser Gly Ser Ser Gly Asn Glu Ala Gly Ala Gly Ala
 20 25 30

15
 Ala Ala Pro Ala Ser Gln His Pro Met Thr Gly Thr Gly Ala Val Gln
 35 40 45

20
 Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
 50 55 60

25
 Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
 65 70 75 80

30
 Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
 85 90 95

35
 Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
 100 105 110

40
 Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
 115 120 125

45
 Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
 130 135 140

50
 Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
 145 150 155 160

55
 Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu
 165 170 175

60
 Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp
 180 185 190

65
 Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
 195 200 205

70
 Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
 210 215 220

75
 Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
 225 230 235 240

EP 2 741 085 A1

Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
 245 250 255
 5
 Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Ala Ala Glu
 260 265 270
 Ala Glu Pro Glu Pro Val Glu Glu Tyr Thr Glu Gln Asn Glu Val Glu
 10 275 280 285
 Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
 290 295 300
 15
 Ser Gly Glu Lys Glu Gln Val Asp Asp Trp Thr Val Glu Thr Val Glu
 305 310 315 320
 Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
 20 325 330 335
 Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val
 25 340 345 350
 Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
 355 360 365
 30
 Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
 370 375 380
 Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Ala Gln Asn Met Asp
 35 385 390 395 400
 Ile Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg Leu Ala
 40 405 410 415
 Gln Pro Asn Gln Val Ser Val Gln Pro Glu Ala Thr Gln Val Pro Leu
 420 425 430
 45
 Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
 435 440 445
 Pro Ser His Ala Thr Asp Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln
 450 455 460
 50
 Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
 465 470 475 480
 55
 Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
 485 490 495

EP 2 741 085 A1

Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
 500 505 510

5

 Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn
 515 520 525

10

 Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn
 530 535 540

15

 Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
 545 550 555 560

20

 Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
 565 570 575

25

 Gln Pro His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln Gln Asn
 580 585 590

30

 Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg Gly Val
 595 600 605

35

 Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
 610 615 620

40

 Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
 625 630 635 640

45

 Phe Ser Thr Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser
 645 650 655

50

 Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn
 660 665 670

55

 Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly
 675 680 685

Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr
 690 695 700

Gln Gln Val Asn
 705

<210> 17
 <211> 3150
 <212> DNA
 <213> Equus caballus

<220>
 <221> CDS
 <222> (1)..(1917)

EP 2 741 085 A1

<223>

<400> 17

5	atg gag ggc aag ctc gat gat tac caa gag cga atg aac aaa gga gaa	48
	Met Glu Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu	
	1 5 10 15	
10	agg ctt aat cag gat cag ctg gat gct gtg tct aag tac cag gaa gtc	96
	Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val	
	20 25 30	
15	aca aat aac ttg gag ttt gcg aaa gaa ttg cag agg agt ttc atg gcg	144
	Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala	
	35 40 45	
20	ttg agt cag gat att cag aaa aca ata aag aag acg gca cgt cgg gag	192
	Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu	
	50 55 60	
25	cag ctt atg aga gaa gaa gct gaa cag aaa cgt tta aaa act gta ctt	240
	Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu	
	65 70 75 80	
30	gag ctg cag tat gtt ttg gac aaa ttg gga gat gaa gaa gtg cga act	288
	Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Glu Glu Val Arg Thr	
	85 90 95	
35	gac ctg aaa caa ggt ttg aat gga gtg cca ata ctc tct gaa gaa gag	336
	Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu	
	100 105 110	
40	ttg tcg ctg ttg gat gag ttc tac aag tta gca gac cct gta cgg gac	384
	Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Val Arg Asp	
	115 120 125	
45	atg agc ttg agg ttg aat gag cag tat gag cat gcc tcc att cac ctg	432
	Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu	
	130 135 140	
50	tgg gac ttg ctg gaa ggg aag gaa aaa tct gtc tgt gga aca acc tat	480
	Trp Asp Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr	
	145 150 155 160	
55	aaa gct ctg agg gaa att gtt gag cgt gtt ttc cag tcc aac tac ttt	528
	Lys Ala Leu Arg Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe	
	165 170 175	
60	gac agc acc cac aac cac cag aat ggg ctc tgt gag gag gaa gag gct	576
	Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Ala	
	180 185 190	
65	acc tca gct cca aca gct gaa gac cag gga gct gaa gct gaa cct gag	624
	Thr Ser Ala Pro Thr Ala Glu Asp Gln Gly Ala Glu Ala Glu Pro Glu	
	195 200 205	
70	cca gca gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat	672
	Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr	
	210 215 220	
75	gta aat aga cag ttt atg gca gaa gcg cag ttc agt ggt gag aag gag	720
	Val Asn Arg Gln Phe Met Ala Glu Ala Gln Phe Ser Gly Glu Lys Glu	
	225 230 235 240	
80	cag gtg gat gag tgg aca gtc gag acg gtc gag gtg gta aat tca ctc	768
	Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu	

EP 2 741 085 A1

	245				250				255								
5	cag	cag	caa	cct	cag	gct	gca	tct	cct	tca	gta	ccg	gag	ccc	cac	tct	816
	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	
				260												270	
	ttg	act	cca	gtg	gct	cag	gca	gat	ccc	ctt	gtg	aga	aga	cag	cga	gta	864
	Leu	Thr	Pro	Val	Ala	Gln	Ala	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	
			275					280								285	
10	cag	gac	ctt	atg	gcg	caa	atg	cag	ggg	ccc	tat	aat	ttc	ata	cag	gat	912
	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	
			290					295								300	
	tca	atg	ctg	gat	ttt	gaa	aac	cag	aca	ctt	gat	cct	gcc	att	gta	tct	960
15	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	
			305				310					315				320	
	gca	cag	cct	atg	aat	cca	gca	cag	aat	atg	gac	atg	ccc	cag	ctg	gtt	1008
	Ala	Gln	Pro	Met	Asn	Pro	Ala	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	
				325								330				335	
20	tgc	cct	cca	gtt	cat	gct	gaa	tct	aga	ctt	gct	caa	cct	aat	caa	gtt	1056
	Cys	Pro	Pro	Val	His	Ala	Glu	Ser	Arg	Leu	Ala	Gln	Pro	Asn	Gln	Val	
				340												350	
	cct	gta	caa	cca	gaa	gct	aca	cag	gtt	cct	ttg	gtt	tca	tcc	aca	agt	1104
25	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	
				355				360								365	
	gag	ggg	tat	aca	gca	tct	cag	ccc	ttg	tac	cag	cct	tct	cat	gct	aca	1152
	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	
			370					375								380	
30	gag	caa	cga	ccg	caa	aag	gaa	ccg	act	gac	cag	atc	cag	gca	aca	atc	1200
	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Thr	Asp	Gln	Ile	Gln	Ala	Thr	Ile	
				385				390								400	
	tct	tta	aat	aca	gac	cag	act	aca	gca	tca	tca	tcc	ctt	cct	gct	gct	1248
35	Ser	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	
				405												415	
	tct	cag	cct	cag	gtg	ttc	cag	gct	ggg	aca	agc	aaa	cct	tta	cac	agc	1296
	Ser	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	
				420												430	
40	agt	ggg	atc	aat	gta	aat	gca	gcg	cca	ttc	cag	tcc	atg	caa	acg	gtg	1344
	Ser	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	
				435				440								445	
	ttc	aac	atg	aat	gcc	ccg	gtt	cct	cct	gtt	aat	gaa	cca	gaa	act	tta	1392
45	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Val	Asn	Glu	Pro	Glu	Thr	Leu	
				450				455								460	
	aaa	cag	caa	aat	cag	tac	cag	gcc	agc	tat	aac	cag	agc	ttt	tcc	agt	1440
	Lys	Gln	Gln	Asn	Gln	Tyr	Gln	Ala	Ser	Tyr	Asn	Gln	Ser	Phe	Ser	Ser	
				465				470								480	
50																	
	ccg	cct	cac	caa	gta	gag	cag	aca	gag	ctt	ccg	caa	gag	cag	ctt	cag	1488
	Pro	Pro	His	Gln	Val	Glu	Gln	Thr	Glu	Leu	Pro	Gln	Glu	Gln	Leu	Gln	
				485												495	
55	acg	gtg	gtt	ggt	act	tac	cat	gct	tcc	caa	gac	cag	ccc	cat	caa	gtg	1536
	Thr	Val	Val	Gly	Thr	Tyr	His	Ala	Ser	Gln	Asp	Gln	Pro	His	Gln	Val	
				500												510	

EP 2 741 085 A1

	acc ggt aac cac cag cag cct ccc cag cag aac act ggg ttt cca cgt	1584
	Thr Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg	
	515 520 525	
5	agc agt cag ccc tat tac aac agt cgt ggt gtg tct cgt gga ggc tcc	1632
	Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser	
	530 535 540	
10	cgt ggt gct aga ggc ttg atg aat gga tac agg ggc cct gcc aat gga	1680
	Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly	
	545 550 555 560	
15	ttc aga gga gga tat gat ggt tac cgc cct tcg ttc tct aac act cca	1728
	Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro	
	565 570 575	
20	aac agc ggt tac aca cag tct cag ttc agt gct ccc cgg gac tac tct	1776
	Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser	
	580 585 590	
25	ggc tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg	1824
	Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly	
	595 600 605	
30	cag agt gga ccc cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga	1872
	Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg	
	610 615 620	
35	ccc aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa	1917
	Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn	
	625 630 635	
40	tctgattcac aggattatct ttaatcgcca aaacacactg gccagtgtac cataatatgt	1977
	taccagaaga gttattatct atttgttctc cctttcagga aacttattgt aaagggactg	2037
	ttttcatccc ataaagacag gactacagtt gtcagcttta tattacctgg atatggaagg	2097
45	aaactatttt tactctgcat gttctgtcct aagcgtcatc ttgagccttg cacatgatac	2157
	tcagattcct ttcccttgct taggagtaaa acataatata ctttatgggg tgataaatatc	2217
	tccatagtta tttgaagtgg cttggaaaaa gcaagattga cttttgacat tggataaaat	2277
50	ctacaaatca gccctagagt ttcattgttca ttcacaaaac taaaatattt cccttgaaag	2337
	gaagatggaa ggactggagt gtggtttggc agaacaactg catttcacag cttttcctat	2397
	taaattggag cactgaatgt taaatgcata ccaaattatg catgggccct taatcacaca	2457
55	tacatggcta ccagctttga cacagcacta ttcattcctct ggccaaacga ctgtggttaa	2517
	aaacacgtgt aaattgcttt ttaacagctg atactgtaaa agacaaagct aaaatgcaaa	2577
	attaggcttt cattggcact tttcgaaaaa tatgcaacaa atttgggatg taatctggat	2637
	ggccacttct gtacttaatg tgaagtattt agataccttt ttgaacactt aacagtttct	2697
	tcgacaatga cttttgtaag gattgtagt atatatcatt ctttatgaca tacattgtct	2757
60	gttgctaatac cttggatctt gctgtattgt cacctaaatt ggtacaggta ctgatgaaaa	2817
	tctctcatgg ataaacctaa cactcttcgt cacatgtttt tcctgcagcc tgaaggtttt	2877

EP 2 741 085 A1

taaaaggaaa agatatcaaa tgcctgctgc taccaccctt ttaaattgct atcttttgaa 2937
 aagcaccagt atgtgttttt agattgattt ccctatttta gggaaatgac agtcagtagt 2997
 5 ttcagttctg atggtataag caaagcaaat aaaacgtggt tataaaaagt gtatcttgaa 3057
 acactggtgt tcaacagcta gcagcttctg tggttcacc cctgccttgt tagtgttacc 3117
 catttatggt tatctccagc agcaatttct cta 3150

10
 <210> 18
 <211> 638
 <212> PRT
 <213> Equus caballus

15 <400> 18

Met Glu Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu
 1 5 10 15

20 Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val
 20 25 30

25 Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala
 35 40 45

Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu
 50 55 60

30 Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu
 65 70 75 80

35 Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Glu Glu Val Arg Thr
 85 90 95

Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu
 100 105 110

40 Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Val Arg Asp
 115 120 125

45 Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu
 130 135 140

50 Trp Asp Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr
 145 150 155 160

Lys Ala Leu Arg Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe
 165 170 175

55 Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala
 180 185 190

EP 2 741 085 A1

Thr Ser Ala Pro Thr Ala Glu Asp Gln Gly Ala Glu Ala Glu Pro Glu
 195 200 205
 5 Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr
 210 215 220
 10 Val Asn Arg Gln Phe Met Ala Glu Ala Gln Phe Ser Gly Glu Lys Glu
 225 230 235 240
 15 Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu
 245 250 255
 20 Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser
 260 265 270
 25 Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val
 275 280 285
 30 Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp
 290 295 300
 35 Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser
 305 310 315 320
 40 Ala Gln Pro Met Asn Pro Ala Gln Asn Met Asp Met Pro Gln Leu Val
 325 330 335
 45 Cys Pro Pro Val His Ala Glu Ser Arg Leu Ala Gln Pro Asn Gln Val
 340 345 350
 50 Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser
 355 360 365
 55 Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr
 370 375 380
 60 Glu Gln Arg Pro Gln Lys Glu Pro Thr Asp Gln Ile Gln Ala Thr Ile
 385 390 395 400
 65 Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala
 405 410 415
 70 Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser
 420 425 430
 75 Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
 435 440 445

EP 2 741 085 A1

Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu
 450 455 460
 5 Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser
 465 470 475 480
 10 Pro Pro His Gln Val Glu Gln Thr Glu Leu Pro Gln Glu Gln Leu Gln
 485 490 495
 15 Thr Val Val Gly Thr Tyr His Ala Ser Gln Asp Gln Pro His Gln Val
 500 505 510
 20 Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
 530 535 540
 25 Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
 545 550 555 560
 30 Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
 565 570 575
 35 Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser
 580 585 590
 40 Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
 595 600 605
 45 Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
 610 615 620
 50 Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
 625 630 635
 <210> 19
 <211> 6181
 <212> DNA
 <213> Mus musculus
 <220>
 <221> CDS
 <222> (179) .. (2302)
 <223>
 <400> 19
 gctggctggc taagtccttc ccgcgccggc tcttgtccca ctaggagcag ctcaagagccg 60
 55 cggggacagg gcgaagcggc ctgcgccac ggagcgcacg tctctgttct caacgcagca 120
 ccacccttgc cccctcggc tgcccactcc agacgtccag cggctccgcg cgcgcacg 178

EP 2 741 085 A1

	atg ccc tcg gcc acc agc cac agc gga agc ggc agc aaa tcg tcg gga	226
	Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly	
	1 5 10 15	
5	ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag gcg gcg gcc ggg gca	274
	Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala	
	20 25 30	
10	gct gcg ccg gct tct cag cat ccg gca acc ggc acc ggc gcc gtc cag	322
	Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln	
	35 40 45	
15	acc gag gcc atg aag cag att ctc ggc gta atc gac aag aaa ctt cgg	370
	Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg	
	50 55 60	
20	aac ctg gag aag aaa aag ggt aaa ctt gat gat tac cag gaa cga atg	418
	Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met	
	65 70 75 80	
25	aat aaa ggg gaa agg ctc aat caa gac cag ctg gat gcc gta tct aag	466
	Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys	
	85 90 95	
30	tac cag gaa gtc aca aat aat ttg gag ttt gca aag gaa tta cag agg	514
	Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg	
	100 105 110	
35	agt ttc atg gca tta agt caa gat att cag aaa aca ata aag aag aca	562
	Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr	
	115 120 125	
40	gca cgt cgg gaa cag ctt atg aga gaa gaa gca gaa cag aag cgc tta	610
	Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu	
	130 135 140	
45	aaa act gta ctt gag tta cag tat gta ttg gat aag ctg gga gat gat	658
	Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp	
	145 150 155 160	
50	gat gtg aga aca gat ctg aaa caa ggt ttg agt gga gtg cca ata ttg	706
	Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu	
	165 170 175	
55	tct gag gag gag ttg tca ttg ctg gat gag ttc tac aag ctc gta gat	754
	Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp	
	180 185 190	
60	cct gag cgt gac atg agt tta agg tta aat gag cag tat gaa cat gcc	802
	Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala	
	195 200 205	
65	tca att cac ttg tgg gat ttg ctg gaa ggg aaa gaa aag cct gtg tgt	850
	Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys	
	210 215 220	
70	gga aca acc tat aaa gct cta aag gaa att gtt gag cgt gtt ttc cag	898
	Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln	
	225 230 235 240	
75	tca aac tac ttt gat agc act cac aat cat caa aat ggg ttg tgt gag	946
	Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu	
	245 250 255	
80	gag gaa gag gcg gct tca gcg ccc aca gtg gag gac cag gta gct gaa	994

EP 2 741 085 A1

	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Thr	Val	Glu	Asp	Gln	Val	Ala	Glu	
				260					265					270			
5	gct	gaa	cct	gag	cca	gcg	gaa	gaa	tac	aca	gag	caa	agt	gag	ggt	gaa	1042
	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	Val	Glu	
			275					280					285				
10	tca	aca	gag	tat	gtc	aat	agg	cag	ttc	atg	gca	gaa	aca	cag	ttc	agc	1090
	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	Phe	Ser	
			290				295					300					
15	agt	ggt	gag	aag	gag	caa	gtg	gat	gag	tgg	aca	ggt	gaa	aca	ggt	gag	1138
	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	Val	Glu	
	305					310					315					320	
20	ggt	gta	aac	tca	ctc	cag	cag	caa	cct	cag	gct	gcg	tcc	cct	tca	gtc	1186
	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val	
					325					330					335		
25	cca	gag	ccc	cac	tct	ttg	act	cca	gtg	gct	cag	tca	gat	cca	ctt	gtg	1234
	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ser	Asp	Pro	Leu	Val	
				340					345					350			
30	aga	agg	cag	cgt	gta	caa	gat	ctt	atg	gca	caa	atg	caa	ggg	ccc	tat	1282
	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	
			355					360					365				
35	aat	ttc	ata	cag	gat	tca	atg	ttg	gat	ttt	gaa	aat	cag	acg	ctt	gat	1330
	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	
			370				375					380					
40	cct	gcc	att	gta	tcc	gca	cag	cct	atg	aac	cct	acc	cag	aac	atg	gat	1378
	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	
	385					390					395					400	
45	atg	cct	cag	ctg	gtt	tgc	cct	cag	gtt	cat	tct	gaa	tct	aga	ctt	gcc	1426
	Met	Pro	Gln	Leu	Val	Cys	Pro	Gln	Val	His	Ser	Glu	Ser	Arg	Leu	Ala	
					405					410					415		
50	caa	tct	aat	caa	gtt	cct	gta	caa	cca	gaa	gcc	aca	cag	ggt	cct	ttg	1474
	Gln	Ser	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	
				420					425					430			
55	gtt	tca	tcc	aca	agt	gag	ggg	tat	aca	gca	tct	cag	ccc	ttg	tac	cag	1522
	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	
			435					440					445				
60	cca	tct	cat	gct	acg	gag	cag	cgg	ccg	cag	aaa	gag	cca	atg	gat	cag	1570
	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Met	Asp	Gln	
			450				455					460					
65	att	cag	gca	aca	ata	tct	ttg	aat	aca	gac	cag	act	aca	gca	tcc	tca	1618
	Ile	Gln	Ala	Thr	Ile	Ser	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	
	465						470				475					480	
70	tcc	ctt	cct	gct	gct	tct	cag	cct	caa	gtg	ttc	cag	gct	ggg	aca	agt	1666
	Ser	Leu	Pro	Ala	Ala	Ser	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	
					485					490					495		
75	aaa	cct	ttg	cac	agc	agt	gga	atc	aat	gta	aat	gca	gct	cca	ttc	cag	1714
	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	
				500					505					510			
80	tcc	atg	caa	acg	gtg	ttc	aat	atg	aat	gct	cca	gtc	cct	cct	gct	aat	1762
	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Ala	Asn	

EP 2 741 085 A1

	515	520	525		
5	gaa cca gaa acg tta Glu Pro Glu Thr Leu	aaa caa cag agt Lys Gln Gln Ser	cag tac cag gcc act Tyr Gln Ala Thr	tat aac Tyr Asn	1810
	530	535	540		
	cag agt ttt tcc agt Gln Ser Phe Ser Ser	cag cct cac caa Gln Pro His Gln	gtg gaa caa Val Glu Gln Thr	aca gag ctt caa Glu Leu Gln	1858
	545	550	555	560	
10	caa gac caa ctg Gln Asp Gln Leu	caa acg gtg gtt Gln Thr Val Val	ggc act tac cat Gly Thr Tyr His	gga tcc cag gac Gly Ser Gln Asp	1906
		565	570	575	
15	cag cct cat caa Gln Pro His Gln	gtg cct ggt aac Val Pro Gly Asn	cac cag caa ccc His Gln Gln Pro	cca cag cag aac Pro Gln Gln Asn	1954
		580	585	590	
	act ggc ttt cca Thr Gly Phe Pro	cgt agc agt cag Arg Ser Ser Gln	cct tat tac aac Pro Tyr Tyr Asn	agt cgt ggg gta Ser Arg Gly Val	2002
	595	600	605		
20	tct cga gga ggg Ser Arg Gly Gly	tct cgt ggt gcc Ser Arg Gly Ala	aga ggc ttg atg Arg Gly Leu Met	aat gga tac agg Asn Gly Tyr Arg	2050
	610	615	620		
25	ggc cct gcc aat Gly Pro Ala Asn	gga ttt aga gga Gly Phe Arg Gly	gga tat gat ggt Gly Tyr Asp Gly	tac cgc cct tca Tyr Arg Pro Ser	2098
	625	630	635	640	
30	ttc tcg aac act Phe Ser Asn Thr	cca aac agt ggt Pro Asn Ser Gly	tat tca cag tct Tyr Ser Gln Ser	cag ttc act gct Gln Phe Thr Ala	2146
		645	650	655	
35	ccc cgg gac tac Pro Arg Asp Tyr	tct ggt tac cag Ser Gly Tyr Gln	cgg gat gga tat Arg Asp Gly Tyr	cag cag aat ttc Gln Gln Asn Phe	2194
		660	665	670	
40	aag cga ggc tct Lys Arg Gly Ser	ggg cag agt gga Gly Gln Ser Gly	cca cgg gga gcc Pro Arg Gly Ala	cca cga ggt cgt Pro Arg Gly Arg	2242
	675	680	685		
45	gga ggg ccc cca Gly Gly Pro Pro	aga ccc aac aga Arg Pro Asn Arg	ggg atg ccg caa Gly Met Pro Gln	atg aac act cag Met Asn Thr Gln	2290
	690	695	700		
50	caa gtg aat taa Gln Val Asn	tgtgatacac aggattatgt	ttaatcgcca aaaacacact		2342
	705				
55	ggccagtgta ccataatatg	ttaccagaag agttattatc	tatttgttct ccctttcagg		2402
	aaacttattg taaagggact	gttttcatcc cataaagaca	ggactgcaat tgtcagcttt		2462
	acattacctg gatatggaag	gaaactatct ttattctgca	tgttctgtcc taagcgtcat		2522
	cttgagcctt gcacacaata	caatactcag attcctcacc	cttgcttagg agtaaaacat		2582
	tatatactta tggggtgata	atatctccat agttagttga	agtggcttgg aaaaaaaaatg		2642
	caagattgaa tttttgacct	tggataaaat ctacaatcag	ccctagaact attcagtggt		2702
	aattgacaaa gttaaagcat	tttctttgaa aggaagatgg	aaggagtgga gtgtggttta		2762
	gcaaaactgc atttcatagc	tttcccatta aattggagca	ccgacagatt aaaagcatac		2822

EP 2 741 085 A1

caaattatgc atgggtcctt actcacacaa gtgaggctgg ctaccagcct tgacatagca 2882
 ctcaactagtc ttctggccaa acgactgtga ttaaaacaca tgtaaattgc tcttttagtag 2942
 5 tggatactgt gtaagacaaa gccaaattgc aaatcaggct ttgattggct cttctggaaa 3002
 atatgcatca aatatggggg ataatctgga tgggctgctg ctgtgctcaa tgtgaactat 3062
 ttagatacct ttggaacact taacagtffc tctgaacaat gacttacatg gggattggctc 3122
 10 ctgtttgtca ttccctacca taattgcatt gtcataccta atccttggat cttgctgtat 3182
 tgttactcaa attggtaata ggtactgatg gaaatcgcta atggatggat aatcataaca 3242
 cttttggctca catgttttct cctgcagcct gaaagttctt aaagaaaaag atatcaaatg 3302
 15 cctgctgcta ccaccctttt aaattgctat ctttagaaaa gcaccggtat gtgttttaga 3362
 ttcatttccc tgttttaggg aatgacagg cagtagtttc agttctgatg gcaaaaacaaa 3422
 taaaaacatg tttctaaaag ttgtatcttg aaacactggg gttcaacagc tagcagctaa 3482
 20 agtaattcaa cccatgcatt gctagtgtca cagcctttgg ttatgtctag tagctgtttc 3542
 tgaagtatth tcatthtact tttgtcaaat ttaaccctgt ttgaattctc tcctttctctc 3602
 aaggagacac ttatgttcaa agtgttgatt ctttgcctta ggtgcataga gagtagacag 3662
 25 tttggagatg gaaaggtag cagtgactta gccatatgth ctgtgttggg atthgtgcta 3722
 gcagtttgag cactagctct gcgtgcctat gaactgaatg ctgcttgtcc cattccattt 3782
 tatgtcatgg agaaataatt ccacttggtg acacaaaggc taagttaatg ttatthtctg 3842
 tacagaaatt aaatthtact tttagcctth tgtaaactth tththththt ttccaagccg 3902
 gtatcagcta ctcaaaaacaa ttctcagata ttcatcatta gacaactgga gthththgctg 3962
 35 gththtgtagc ctactaaaac tgctgaggct gttgaacatt ccacattcaa aagththgta 4022
 ggggtggtgga taatggggaa gcttcaatgt thatththaa ataaataaaa taagthcttg 4082
 actththctca tgtgtgggta tggatcatca tattggaagg gttatctgth tactththgcc 4142
 40 aagactatth tgccagcacc tacacttgth tgctththaaa gacaactacc tgggatgtac 4202
 cacaaccata tgttaattgt atththtattg gatggataaa atgththgthg ththtattggat 4262
 aatccctaga tgggtgtgth cgtgtgthga atataattht atgatagthg gaaagcaaaa 4322
 45 ttgaagaaaa taagththtagt attgaatthg agthctgthg thgattcagth gaatgtctca 4382
 cgtthcgggc thctacccaa agtthtagggc agaaggtgth aaagthgtht gthgththgac 4442
 thgththatth ththaaagthg thththctth caacagcaac atatcattag ctgthcattct 4502
 50 accattgthg thctagthg thththaacgth thcattcaag actgthththaa aagcaacctc 4562
 actggacaga gaactgthaa agthctththcc thaaagatctg agthctthgth actcagthctc 4622
 thctataata tgcaaatgct thcttagagth cagaagacct ththgththgth caagthgthgth 4682
 55 ththaccaga thacagggaa ctgathgthcc thcatgthctc thtagthgthg aagactataa 4742

EP 2 741 085 A1

aatcttttgt acatgcacaa ttcacagtat gtttagatac cacgtgtata atgccccccc 4802
 ctccccagg tagcatgcca ttgatgactt tttgcttagg gccattttat taccagggcc 4862
 5 ttaatatcc taaaaagatg attttttttc atcctttctc ctcttttgat cattgtatct 4922
 tgatattaaa aacatgacct tccaatgatt gtagtaaatt aacttctata gttcttttgt 4982
 ctctatatgt attcatatat atgctattgt atagagactt caaggagaca tggagatgca 5042
 10 tgcttattct caggttcatt cactaagggtg cttggcagac aaccagtttc taagtgcaga 5102
 atgtagttaa gcagcttcat atatgtgcca ggcaatttgt tttgttaaatt tttcatctac 5162
 ttaaggaaat agggatttgt agcttaggct gatcataccc ttcatttcaa ccttaagctc 5222
 15 tcaacctgca tccatccgac ttgagctatt aagtacttta gttttatcga gtataagtta 5282
 acagaaaaag taaattaagc tttgccttta ctattttgaa tttatataca ttctggaaaa 5342
 acttagaaac tgttgatatat ttcattagat taaattatat gaaaatgtga ttgtttatag 5402
 20 caaagcctgt gagttgcata caccctaagg aaaactcctt aagtgtcct tgaagagaga 5462
 agaaaacaatt ctgggtctgg tctttttaag aacaaagcta gactactgta tggtagcact 5522
 gtacattaat agtctgttgt gaagcttgag cagtttcctg catagccttg atccttcacc 5582
 25 gttggcattg aaaatagcag tatccctgat gtacttaaaa cttaaagtca ggttttggtta 5642
 tattttattg taagtcttaa tttcctctaa atactatata tcttttagoga gacaacctga 5702
 aatttattag cacatttggg tatctcttgc ttggcattat ggccagtgtt aactattcag 5762
 30 tggtgaaaaa attaccctc aagacactgg agtgaccca gatgtgtgta gtaagtggca 5822
 tggttcaact gtgtggttaa tgataaatat atgacttagt cggtatgatc tggaaagact 5882
 tgattgaaag ataattcagc tgacataagg atgagtgagg agtggcaaac tggataaaag 5942
 35 agtcaagaga cctgtattcc agtgactcct gttttgttta agcattagca agatctgtct 6002
 ggggaaactg gatagggcag ttttcttcca tgtttagttt ttgtctcaac atttggaaagc 6062
 tattgaaggt tttaaaatgg tgtgtattgt ttttttttgg ggggggggtg gccagaatag 6122
 40 tgggtcatct aataaaaactg ccatttaaaa gatcaaaaaa aaaaaaaaaa aaaaaaaaaa 6181

<210> 20
 <211> 707
 <212> PRT
 <213> Mus musculus

<400> 20

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 20 25 30

Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln

EP 2 741 085 A1

5	Thr	Glu	Ala	Met	Lys	Gln	Ile	Leu	Gly	Val	Ile	Asp	Lys	Lys	Leu	Arg			
	50						55					60							
10	Asn	Leu	Glu	Lys	Lys	Lys	Gly	Lys	Leu	Asp	Asp	Tyr	Gln	Glu	Arg	Met			
	65					70					75					80			
15	Asn	Lys	Gly	Glu	Arg	Leu	Asn	Gln	Asp	Gln	Leu	Asp	Ala	Val	Ser	Lys			
					85					90					95				
20	Tyr	Gln	Glu	Val	Thr	Asn	Asn	Leu	Glu	Phe	Ala	Lys	Glu	Leu	Gln	Arg			
				100					105					110					
25	Ser	Phe	Met	Ala	Leu	Ser	Gln	Asp	Ile	Gln	Lys	Thr	Ile	Lys	Lys	Thr			
			115					120					125						
30	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	Glu	Gln	Lys	Arg	Leu			
	130						135						140						
35	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	Lys	Leu	Gly	Asp	Asp			
	145					150					155					160			
40	Asp	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Ser	Gly	Val	Pro	Ile	Leu			
					165					170					175				
45	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	Tyr	Lys	Leu	Val	Asp			
				180					185					190					
50	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	Gln	Tyr	Glu	His	Ala			
			195					200					205						
55	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	Glu	Lys	Pro	Val	Cys			
	210						215					220							
60	Gly	Thr	Thr	Tyr	Lys	Ala	Leu	Lys	Glu	Ile	Val	Glu	Arg	Val	Phe	Gln			
	225					230					235					240			
65	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	Asn	Gly	Leu	Cys	Glu			
					245					250					255				
70	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Thr	Val	Glu	Asp	Gln	Val	Ala	Glu			
				260					265					270					
75	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	Val	Glu			
			275					280					285						
80	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	Phe	Ser			
	290						295					300							

EP 2 741 085 A1

	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	Val	Glu
	305					310					315					320
5	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val
					325					330					335	
10	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ser	Asp	Pro	Leu	Val
				340					345					350		
15	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr
			355					360					365			
20	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp
		370					375					380				
25	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp
	385					390					395					400
30	Met	Pro	Gln	Leu	Val	Cys	Pro	Gln	Val	His	Ser	Glu	Ser	Arg	Leu	Ala
				405						410					415	
35	Gln	Ser	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu
				420					425					430		
40	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln
			435					440					445			
45	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Met	Asp	Gln
		450					455					460				
50	Ile	Gln	Ala	Thr	Ile	Ser	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser
	465					470					475					480
55	Ser	Leu	Pro	Ala	Ala	Ser	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser
				485						490					495	
60	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln
				500					505					510		
65	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Ala	Asn
			515					520					525			
70	Glu	Pro	Glu	Thr	Leu	Lys	Gln	Gln	Ser	Gln	Tyr	Gln	Ala	Thr	Tyr	Asn
		530					535					540				
75	Gln	Ser	Phe	Ser	Ser	Gln	Pro	His	Gln	Val	Glu	Gln	Thr	Glu	Leu	Gln
	545					550					555					560

EP 2 741 085 A1

Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575

5 Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590

Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605

10 Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620

15 Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640

20 Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655

Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670

25 Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg
675 680 685

30 Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln
690 695 700

Gln Val Asn
705

35 <210> 21
<211> 6141
<212> DNA
<213> Mus musculus

40 <220>
<221> CDS
<222> (139)..(2262)
<223>

45 <400> 21
cccaccgcgc gcgcgcgtag ccgcctgccc gcccgcccgc tgcgcgtttt gtcccgcgtc 60
tctccccgtc cgtctcctga cttgctggtc ttgtccttcc ctcccgcttt tttcctctcc 120
tctcttctcg gtctaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly
1 5 10

50 agc aaa tcg tcg gga ccg ccg ccg ccc tcc ggt tcc tcc ggg agt gag 219
Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Ser Gly Ser Ser Gly Ser Glu
15 20 25

55 gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc 267

EP 2 741 085 A1

	Ala	Ala	Ala	Gly	Ala	Ala	Ala	Pro	Ala	Ser	Gln	His	Pro	Ala	Thr	Gly	
			30					35					40				
5	acc	ggc	gcc	gtc	cag	acc	gag	gcc	atg	aag	cag	att	ctc	ggc	gta	atc	315
	Thr	Gly	Ala	Val	Gln	Thr	Glu	Ala	Met	Lys	Gln	Ile	Leu	Gly	Val	Ile	
		45					50				55						
10	gac	aag	aaa	ctt	cgg	aac	ctg	gag	aag	aaa	aag	ggt	aaa	ctt	gat	gat	363
	Asp	Lys	Lys	Leu	Arg	Asn	Leu	Glu	Lys	Lys	Lys	Gly	Lys	Leu	Asp	Asp	
	60				65					70					75		
15	tac	cag	gaa	cga	atg	aat	aaa	ggg	gaa	agg	ctc	aat	caa	gac	cag	ctg	411
	Tyr	Gln	Glu	Arg	Met	Asn	Lys	Gly	Glu	Arg	Leu	Asn	Gln	Asp	Gln	Leu	
				80						85					90		
20	gat	gcc	gta	tct	aag	tac	cag	gaa	gtc	aca	aat	aat	ttg	gag	ttt	gca	459
	Asp	Ala	Val	Ser	Lys	Tyr	Gln	Glu	Val	Thr	Asn	Asn	Leu	Glu	Phe	Ala	
				95					100					105			
25	aag	gaa	tta	cag	agg	agt	ttc	atg	gca	tta	agt	caa	gat	att	cag	aaa	507
	Lys	Glu	Leu	Gln	Arg	Ser	Phe	Met	Ala	Leu	Ser	Gln	Asp	Ile	Gln	Lys	
			110					115					120				
30	aca	ata	aag	aag	aca	gca	cgt	cgg	gaa	cag	ctt	atg	aga	gaa	gaa	gca	555
	Thr	Ile	Lys	Lys	Thr	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	
		125					130					135					
35	gaa	cag	aag	cgc	tta	aaa	act	gta	ctt	gag	tta	cag	tat	gta	ttg	gat	603
	Glu	Gln	Lys	Arg	Leu	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	
		140				145					150					155	
40	aag	ctg	gga	gat	gat	gat	gtg	aga	aca	gat	ctg	aaa	caa	ggt	ttg	agt	651
	Lys	Leu	Gly	Asp	Asp	Asp	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Ser	
				160						165					170		
45	gga	gtg	cca	ata	ttg	tct	gag	gag	gag	ttg	tca	ttg	ctg	gat	gag	ttc	699
	Gly	Val	Pro	Ile	Leu	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	
				175						180					185		
50	tac	aag	ctc	gta	gat	cct	gag	cgt	gac	atg	agt	tta	agg	tta	aat	gag	747
	Tyr	Lys	Leu	Val	Asp	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	
				190					195					200			
55	cag	tat	gaa	cat	gcc	tca	att	cac	ttg	tgg	gat	ttg	ctg	gaa	ggg	aaa	795
	Gln	Tyr	Glu	His	Ala	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	
		205					210						215				
60	gaa	aag	cct	gtg	tgt	gga	aca	acc	tat	aaa	gct	cta	aag	gaa	att	gtt	843
	Glu	Lys	Pro	Val	Cys	Gly	Thr	Thr	Tyr	Lys	Ala	Leu	Lys	Glu	Ile	Val	
				220			225				230					235	
65	gag	cgt	ggt	ttc	cag	tca	aac	tac	ttt	gat	agc	act	cac	aat	cat	caa	891
	Glu	Arg	Val	Phe	Gln	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	
				240						245					250		
70	aat	ggg	ttg	tgt	gag	gag	gaa	gag	gcg	gct	tca	gcg	ccc	aca	gtg	gag	939
	Asn	Gly	Leu	Cys	Glu	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Thr	Val	Glu	
				255					260					265			
75	gac	cag	gta	gct	gaa	gct	gaa	cct	gag	cca	gcg	gaa	gaa	tac	aca	gag	987
	Asp	Gln	Val	Ala	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	
			270					275						280			
80	caa	agt	gag	ggt	gaa	tca	aca	gag	tat	gtc	aat	agg	cag	ttc	atg	gca	1035
	Gln	Ser	Glu	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	

EP 2 741 085 A1

	285		290			295												
5	gaa Glu 300	aca Thr	cag Gln	ttc Phe	agc Ser	agt Ser	ggt Gly	gag Glu	aag Lys	gag Glu	caa Gln	gtg Val	gat Asp	gag Glu	tgg Trp	aca Thr		1083
						305					310						315	
	gtt Val	gaa Glu	aca Thr	gtt Val	gag Glu	gtt Val	gta Val	aac Asn	tca Ser	ctc Leu	cag Gln	cag Gln	caa Gln	cct Pro	cag Gln	gct Ala		1131
					320					325					330			
10	gcg Ala	tcc Ser	cct Pro	tca Ser	gtc Val	cca Pro	gag Glu	ccc Pro	cac His	tct Ser	ttg Leu	act Thr	cca Pro	gtg Val	gct Ala	cag Gln		1179
					335				340					345				
15	tca Ser	gat Asp	cca Pro	ctt Leu	gtg Val	aga Arg	agg Arg	cag Gln	cgt Arg	gta Val	caa Gln	gat Asp	ctt Leu	atg Met	gca Ala	caa Gln		1227
					350			355					360					
20	atg Met	caa Gln	ggg Gly	ccc Pro	tat Tyr	aat Asn	ttc Phe	ata Ile	cag Gln	gat Asp	tca Ser	atg Met	ttg Leu	gat Asp	ttt Phe	gaa Glu		1275
							370					375						
25	aat Asn	cag Gln	acg Thr	ctt Leu	gat Asp	cct Pro	gcc Ala	att Ile	gta Val	tcc Ser	gca Ala	cag Gln	cct Pro	atg Met	aac Asn	cct Pro		1323
							385				390					395		
30	acc Thr	cag Gln	aac Asn	atg Met	gat Asp	atg Met	cct Pro	cag Gln	ctg Leu	gtt Val	tgc Cys	cct Pro	cag Gln	gtt Val	cat His	tct Ser		1371
					400				405					410				
35	gaa Glu	tct Ser	aga Arg	ctt Leu	gcc Ala	caa Gln	tct Ser	aat Asn	caa Gln	gtt Val	cct Pro	gta Val	caa Gln	cca Pro	gaa Glu	gcc Ala		1419
					415				420					425				
40	aca Thr	cag Gln	gtt Val	cct Pro	ttg Leu	gtt Val	tca Ser	tcc Ser	aca Thr	agt Ser	gag Glu	ggg Gly	tat Tyr	aca Thr	gca Ala	tct Ser		1467
					430			435					440					
45	cag Gln	ccc Pro	ttg Leu	tac Tyr	cag Gln	cca Pro	tct Ser	cat His	gct Ala	acg Thr	gag Glu	cag Gln	cgg Arg	ccg Pro	cag Gln	aaa Lys		1515
					445			450				455						
50	gag Glu	cca Pro	atg Met	gat Asp	cag Gln	att Ile	cag Gln	gca Ala	aca Thr	ata Ile	tct Ser	ttg Leu	aat Asn	aca Thr	gac Asp	cag Gln		1563
					460		465				470					475		
55	act Thr	aca Thr	gca Ala	tcc Ser	tca Ser	tcc Ser	ctt Leu	cct Pro	gct Ala	gct Ala	tct Ser	cag Gln	cct Pro	caa Gln	gtg Val	ttc Phe		1611
					480				485					490				
60	cag Gln	gct Ala	ggg Gly	aca Thr	agt Ser	aaa Lys	cct Pro	ttg Leu	cac His	agc Ser	agt Ser	gga Gly	atc Ile	aat Asn	gta Val	aat Asn		1659
					495				500					505				
65	gca Ala	gct Ala	cca Pro	ttc Phe	cag Gln	tcc Ser	atg Met	caa Gln	acg Thr	gtg Val	ttc Phe	aat Asn	atg Met	aat Asn	gct Ala	cca Pro		1707
					510			515					520					
70	gtc Val	cct Pro	cct Pro	gct Ala	aat Asn	gaa Glu	cca Pro	gaa Glu	acg Thr	tta Leu	aaa Lys	caa Gln	cag Gln	agt Ser	cag Gln	tac Tyr		1755
					525			530				535						
75	cag Gln	gcc Ala	act Thr	tat Tyr	aac Asn	cag Gln	agt Ser	ttt Phe	tcc Ser	agt Ser	cag Gln	cct Pro	cac His	caa Gln	gtg Val	gaa Glu		1803
					540		545				550					555		

EP 2 741 085 A1

	caa aca gag ctt caa caa gac caa ctg caa acg gtg gtt ggc act tac	1851
	Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr	
	560 565 570	
5	cat gga tcc cag gac cag cct cat caa gtg cct ggt aac cac cag caa	1899
	His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His Gln Gln	
	575 580 585	
10	ccc cca cag cag aac act ggc ttt cca cgt agc agt cag cct tat tac	1947
	Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr	
	590 595 600	
15	aac agt cgt ggg gta tct cga gga ggg tct cgt ggt gcc aga ggc ttg	1995
	Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu	
	605 610 615	
20	atg aat gga tac agg ggc cct gcc aat gga ttt aga gga gga tat gat	2043
	Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp	
	620 625 630 635	
25	ggt tac cgc cct tca ttc tcg aac act cca aac agt ggt tat tca cag	2091
	Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln	
	640 645 650	
30	tct cag ttc act gct ccc cgg gac tac tct ggt tac cag cgg gat gga	2139
	Ser Gln Phe Thr Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly	
	655 660 665	
35	tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga	2187
	Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly	
	670 675 680	
40	gcc cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg	2235
	Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro	
	685 690 695	
45	caa atg aac act cag caa gtg aat taa tgtgatacac aggattatgt	2282
	Gln Met Asn Thr Gln Gln Val Asn	
	700 705	
50	ttaatcgcca aaaacacact ggccagtgtgta ccataatatg ttaccagaag agttattatc	2342
	tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca	2402
55	ggactgcaat tgtcagcttt acattacctg gatatggaag gaaactatgt ttattctgca	2462
	tgttctgtcc taagcgtcat cttgagcctt gcacacaata caatactcag attcctcacc	2522
	cttgcttagg agtaaaacat tatatactta tgggggtgata atatctccat agttagttga	2582
60	agtggcttgg aaaaaaatg caagattgaa tttttgacct tggataaaat ctacaatcag	2642
	ccctagaact attcagtggt aattgacaaa gttaaagcat tttctttgaa aggaagatgg	2702
	aaggagtgga gtgtggttta gcaaaactgc atttcatagc tttcccatta aattggagca	2762
65	ccgacagatt aaaagcatac caaattatgc atgggtcctt actcacacaa gtgaggctgg	2822
	ctaccagcct tgacatagca ctactagtc ttctggccaa acgactgtga ttaaaacaca	2882
70	tgtaaatgct tcttttagtag tggatactgt gtaagacaaa gccaaattgc aaatcaggct	2942
	ttgattggct cttctggaaa atatgcatca aatatggggg ataactctgga tgggctgctg	3002

EP 2 741 085 A1

ctgtgctcaa tgtgaactat ttagatacct ttggaacact taacagtttc tctgaacaat 3062
 gacttacatg gggattggtc ctgtttgtca ttccctcacca taattgcatt gtcacacta 3122
 5 atccttggat cttgctgtat tgttactcaa attggttaata ggtactgatg gaaatcgcta 3182
 atggatggat aatcataaca cttttgggtca catgttttct cctgcagcct gaaagtctt 3242
 aaagaaaaag atatcaaatg cctgctgcta ccaccctttt aaattgctat ctttagaaaa 3302
 10 gcaccgggat gtgttttaga ttcatctccc tgttttaggg aaatgacagg cagtagtttc 3362
 agttctgatg gcaaaaacaaa taaaaacatg tttctaaaag ttgtatcttg aaacactggg 3422
 gttcaacagc tagcagctaa agtaattcaa cccatgcatt gctagtgtca cagcctttgg 3482
 15 ttatgtctag tagctgtttc tgaagtattt tcatttatct tttgtcaaat ttaaccctgt 3542
 ttgaattctc tcctttcctc aaggagacac ttatgttcaa agtggtgatt ctttgcctta 3602
 ggtgcataga gagtagacag tttggagatg gaaagggttag cagtgactta gccatatggt 3662
 20 ctgtgttgga atttgtgcta gcagtttgag cactagctct gcgtgcctat gaactgaatg 3722
 ctgcttgtcc cattccattt tatgtcatgg agaaataatt ccaactggta acacaaaggc 3782
 taagttaatg ttatcttctg tacagaaatt aaatcttact tttagccttt tgtaaacttt 3842
 25 tttttttttt ttccaagccg gtatcagcta ctcaaaaaca ttctcagata ttcatcatta 3902
 gacaactgga gtttttgctg gttttgtagc ctactaaaac tgctgaggct gttgaacatt 3962
 ccacattcaa aagttttgta ggggtgggga taatggggaa gttcaatgt ttatcttaa 4022
 30 ataaataaaa taagtcttg acttttctca tgtgtgggta tggtagatca tattggaagg 4082
 gttatctggt tacttttgcc aagactattt tgccagcacc tacacttgtg tgctttaaaa 4142
 gacaactacc tgggatgtac cacaaccata tgttaattgt attttattgg gatggataaa 4202
 35 atgtttgtgg tttattggat aatccctaga tgggtgtgta cgtgtgtaga atataatctt 4262
 atgatagtaa gaaagcaaaa ttgaagaaaa taagttagt attgaattg agttctgaag 4322
 tgaattcagg gaatgtctca cgtttcgggc ttctacccaa agtgtagggc agaagggtga 4382
 40 aaagttggtt gtagtttgac ttgtttattt ttttaagttgc ttattccttt caacagcaac 4442
 atatcattag ctgtcattct accattgcag ttctagttag ttttaacgtc tgcatcgaag 4502
 actgttttaa aagcaacctc actggacaga gaactgctaa agtcttttcc ttaagatctg 4562
 45 agtctttggt actcagtatc ttctataata tgcaaatgct tgtctagagg cagaagacct 4622
 tttgtttggt caagtgtgta ttttaccaga gtacagggaa ctgatgggtcc tacatgtctc 4682
 ttagtgtagt aagactataa aatcttttgt acatgcacaa ttcacagtat gtttagatac 4742
 50 cacgtgtata atgccccccc ctccccagg tagcatgcca ttgatgactt tttgcttagg 4802
 gccatcttat taccagggcc ttaatatctc taaaaagatg attttttttc atcctttctc 4862
 55 ctcttttgat cattgtatct tgatattaaa aacatgacct tccaatgatt gtagtaaatt 4922
 aacttctata gttcttttgt ctctatatgt attcatatat atgctattgt atagagactt 4982

EP 2 741 085 A1

caaggagaca tggagatgca tgcttattct caggttcatt cactaaggtg cttggcagac 5042
 aaccagtttc taagtgcaga atgtagttaa gcagcttcat atatgtgcca ggcaatttgt 5102
 5 tttgttaa at tttcatctac ttaaggaaat agggatttgt agcttaggct gatcataccc 5162
 ttcatttcaa ccttaagctc tcaacctgca tccatccgac ttgagctatt aagtacttta 5222
 gttttatcga gtataagtta acagaaaaag taaattaagc tttgccttta ctattttgaa 5282
 10 tttatataca ttctggaaaa acttagaaac tgttgatatat ttcattagat taaattatat 5342
 gaaaatgtga ttgtttatag caaagcctgt gagttgcata caccctaagg aaaactcctt 5402
 aagtgtcctc tgaagagaga agaaacaatt ctgggtctgg tctttttaag aacaaagcta 5462
 15 gactactgta tggtagcact gtacattaat agtctgttgt gaagcttgag cagtttcctg 5522
 catagccttg atccttcacc gttggcattg aaaatagcag tatccctgat gtacttaaaa 5582
 cttaaagtca ggttttggta tattttatttg taagtcttaa tttcctctaa atactatatac 5642
 20 tcttttagcga gacaacctga aatttattag cacatttggg tatctcttgc ttggcattat 5702
 ggccagtgtt aactattcag tggtgaaaaa attacccctc aagacactgg agtgaccca 5762
 gatgtgtgta gtaagtggca tggttcaact gtgtgggttaa tgataaatat atgacttagt 5822
 25 cggatgatc tggaaagact tgattgaaag ataattcagc tgacataagg atgagtgagg 5882
 agtggcaaac tggataaaag agtcaagaga cctgtattcc agtgactcct gttttgttta 5942
 30 agcattagca agatctgtct ggggaaactg gatagggcag ttttcttcca tgtttagttt 6002
 ttgtctcaac atttggaagc tattgaaggt tttaaaatgg tgtgtattgt ttttttttgg 6062
 ggggggggtg gccagaatag tgggtcatct aataaaactg ccatttaaaa gatcaaaaaa 6122
 35 aaaaaaaaaa aaaaaaaaaa 6141

<210> 22
 <211> 707
 <212> PRT
 <213> Mus musculus

<400> 22

45 Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

50 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 20 25 30

Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
 35 40 45

55 Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
 50 55 60

EP 2 741 085 A1

Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
 65 70 75 80
 5 Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
 85 90 95
 Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
 100 105 110
 10 Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
 115 120 125
 15 Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
 130 135 140
 Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
 145 150 155 160
 20 Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
 165 170 175
 25 Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
 180 185 190
 30 Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
 195 200 205
 Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
 210 215 220
 35 Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
 225 230 235 240
 40 Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
 245 250 255
 Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
 260 265 270
 45 Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
 275 280 285
 50 Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
 290 295 300
 Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
 305 310 315 320
 55 Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val

EP 2 741 085 A1

Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605

5 Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620

10 Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640

15 Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655

20 Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670

Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg
675 680 685

25 Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln
690 695 700

Gln Val Asn
705

30 <210> 23
<211> 6114
<212> DNA
<213> Mus musculus

35 <220>
<221> CDS
<222> (139) .. (2235)
<223>

40 <400> 23
cccaccgcg cgcgcgtag ccgctgcc gccgcccgc tgcgctttt gtcccgcgtc 60
tctccccgtc cgtctcctga cttgctggtc ttgtccttcc ctcccgttt tttcctctcc 120
tctcttctcg gtctaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
45 Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly
1 5 10
agc aaa tcg tcg gga ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag 219
Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu
15 20 25

50 gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc 267
Ala Ala Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly
30 35 40

55 acc gcc gcc gtc cag acc gag gcc atg aag cag att ctc ggc gta atc 315
Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile
45 50 55

EP 2 741 085 A1

	gac aag aaa ctt cgg aac ctg gag aag aaa aag ggt aaa ctt gat gat	363
	Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp	
	60 65 70 75	
5	tac cag gaa cga atg aat aaa ggg gaa agg ctc aat caa gac cag ctg	411
	Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu	
	80 85 90	
	gat gcc gta tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca	459
	Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala	
10	95 100 105	
	aag gaa tta cag agg agt ttc atg gca tta agt caa gat att cag aaa	507
	Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys	
	110 115 120	
15	aca ata aag aag aca gca cgt cgg gaa cag ctt atg aga gaa gaa gca	555
	Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala	
	125 130 135	
	gaa cag aag cgc tta aaa act gta ctt gag tta cag tat gta ttg gat	603
	Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp	
20	140 145 150 155	
	aag ctg gga gat gat gat gtg aga aca gat ctg aaa caa ggt ttg agt	651
	Lys Leu Gly Asp Asp Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser	
	160 165 170	
25	gga gtg cca ata ttg tct gag gag gag ttg tca ttg ctg gat gag ttc	699
	Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe	
	175 180 185	
	tac aag ctc gta gat cct gag cgt gac atg agt tta agg tta aat gag	747
	Tyr Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu	
30	190 195 200	
	cag tat gaa cat gcc tca att cac ttg tgg gat ttg ctg gaa ggg aaa	795
	Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys	
	205 210 215	
35	gaa aag cct gtg tgt gga aca acc tat aaa gct cta aag gaa att gtt	843
	Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val	
	220 225 230 235	
	gag cgt gtt ttc cag tca aac tac ttt gat agc act cac aat cat caa	891
	Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln	
40	240 245 250	
	aat ggg ttg tgt gag gag gaa gag gcg gct tca gcg ccc aca gtg gag	939
	Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu	
	255 260 265	
45	gac cag gta gct gaa gct gaa cct gag cca gcg gaa gaa tac aca gag	987
	Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu	
	270 275 280	
	caa agt gag gtt gaa tca aca gag tat gtc aat agg cag ttc atg gca	1035
	Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala	
50	285 290 295	
	gaa aca cag ttc agc agt ggt gag aag gag caa gtg gat gag tgg aca	1083
	Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr	
	300 305 310 315	
55	gtt gaa aca gtt gag gtt gta aac tca ctc cag cag caa cct cag gct	1131

EP 2 741 085 A1

	Val	Glu	Thr	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	
					320					325					330		
5	gcg	tcc	cct	tca	gtc	cca	gag	ccc	cac	tct	ttg	act	cca	gtg	gct	cag	1179
	Ala	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	
				335				340					345				
10	tca	gat	cca	ctt	gtg	aga	agg	cag	cg	gta	caa	gat	ctt	atg	gca	caa	1227
	Ser	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	
			350					355					360				
15	atg	caa	ggg	ccc	tat	aat	ttc	ata	cag	acg	ctt	gat	cct	gcc	att	gta	1275
	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	
		365				370					375						
20	tcc	gca	cag	cct	atg	aac	cct	acc	cag	aac	atg	gat	atg	cct	cag	ctg	1323
	Ser	Ala	Gln	Pro	Met	Asn	Pro	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	
						385					390					395	
25	gtt	tgc	cct	cag	gtt	cat	tct	gaa	tct	aga	ctt	gcc	caa	tct	aat	caa	1371
	Val	Cys	Pro	Gln	Val	His	Ser	Glu	Ser	Arg	Leu	Ala	Gln	Ser	Asn	Gln	
				400				405							410		
30	gtt	cct	gta	caa	cca	gaa	gcc	aca	cag	g	ctt	ttg	g	tca	tcc	aca	1419
	Val	Pro	Val	Gln	Pro	Glu	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	
				415				420						425			
35	agt	gag	ggg	tat	aca	gca	tct	cag	ccc	ttg	tac	cag	cca	tct	cat	gct	1467
	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	
			430					435					440				
40	acg	gag	cag	cgg	ccg	cag	aaa	gag	cca	atg	gat	cag	att	cag	gca	aca	1515
	Thr	Glu	Gln	Arg	Pro	Gln	Lys	Glu	Pro	Met	Asp	Gln	Ile	Gln	Ala	Thr	
			445				450					455					
45	ata	tct	ttg	aat	aca	gac	cag	act	aca	gca	tcc	tca	tcc	ctt	cct	gct	1563
	Ile	Ser	Leu	Asn	Thr	Asp	Gln	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	
					465						470					475	
50	gct	tct	cag	cct	caa	gtg	ttc	cag	gct	ggg	aca	agt	aaa	cct	ttg	cac	1611
	Ala	Ser	Gln	Pro	Gln	Val	Phe	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	
					480					485					490		
55	agc	agt	gga	atc	aat	gta	aat	gca	gct	cca	ttc	cag	tcc	atg	caa	acg	1659
	Ser	Ser	Gly	Ile	Asn	Val	Asn	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	
				495				500						505			
60	gtg	ttc	aat	atg	aat	gct	cca	gtc	cct	cct	gct	aat	gaa	cca	gaa	acg	1707
	Val	Phe	Asn	Met	Asn	Ala	Pro	Val	Pro	Pro	Ala	Asn	Glu	Pro	Glu	Thr	
			510					515					520				
65	tta	aaa	caa	cag	agt	cag	tac	cag	gcc	act	tat	aac	cag	agt	ttt	tcc	1755
	Leu	Lys	Gln	Gln	Ser	Gln	Tyr	Gln	Ala	Thr	Tyr	Asn	Gln	Ser	Phe	Ser	
			525				530					535					
70	agt	cag	cct	cac	caa	gtg	gaa	caa	aca	gag	ctt	caa	caa	gac	caa	ctg	1803
	Ser	Gln	Pro	His	Gln	Val	Glu	Gln	Thr	Glu	Leu	Gln	Gln	Asp	Gln	Leu	
						545					550					555	
75	caa	acg	gtg	gtt	ggc	act	tac	cat	gga	tcc	cag	gac	cag	cct	cat	caa	1851
	Gln	Thr	Val	Val	Gly	Thr	Tyr	His	Gly	Ser	Gln	Asp	Gln	Pro	His	Gln	
					560					565					570		
80	gtg	cct	gg	aac	cac	cag	caa	ccc	cca	cag	cag	aac	act	ggc	ttt	cca	1899
	Val	Pro	Gly	Asn	His	Gln	Gln	Pro	Pro	Gln	Gln	Asn	Thr	Gly	Phe	Pro	

EP 2 741 085 A1

	575	580	585	
	cgt agc agt cag cct tat tac aac agt cgt ggg gta tct cga gga ggg			1947
5	Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly	590	595	600
	tct cgt ggt gcc aga ggc ttg atg aat gga tac agg ggc cct gcc aat			1995
	Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn	605	610	615
10	gga ttt aga gga gga tat gat ggt tac cgc cct tca ttc tcg aac act			2043
	Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr	620	625	630
	cca aac agt ggt tat tca cag tct cag ttc act gct ccc cgg gac tac			2091
15	Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala Pro Arg Asp Tyr	640	645	650
	tct ggt tac cag cgg gat gga tat cag cag aat ttc aag cga ggc tct			2139
	Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser	655	660	665
20	ggg cag agt gga cca cgg gga gcc cca cga ggt cgt gga ggg ccc cca			2187
	Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro	670	675	680
	aga ccc aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa			2235
25	Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn	685	690	695
	tgtgatacac aggattatgt ttaatcgcca aaaacacact ggccagtgta ccataatatg			2295
	ttaccagaag agttattatc tatttgttct ccctttcagg aaacttattg taaagggact			2355
30	gttttcatcc cataaagaca ggactgcaat tgtcagcttt acattacctg gatatggaag			2415
	gaaactatatt ttattctgca tgttctgtcc taagcgtcat cttgagcctt gcacacaata			2475
	caatactcag attcctcacc cttgcttagg agtaaaacat tatatactta tggggtgata			2535
35	atatctccat agttagtga agtggcttgg aaaaaaatg caagattgaa tttttgacct			2595
	tggataaaat ctacaatcag ccctagaact attcagtggt aattgacaaa gttaaagcat			2655
	tttctttgaa aggaagatgg aaggagtgga gtgtggttta gcaaaactgc atttcatagc			2715
40	tttcccatta aattggagca ccgacagatt aaaagcatac caaattatgc atgggtcctt			2775
	actcacacaa gtgaggctgg ctaccagcct tgacatagca ctactagtc ttctggccaa			2835
	acgactgtga ttaaaacaca tgtaaattgc tctttagtag tggatactgt gtaagacaaa			2895
45	gccaaattgc aaatcaggct ttgattggct cttctggaaa atatgcatca aatatggggg			2955
	ataatctgga tgggctgctg ctgtgctcaa tgtgaactat ttagatacct ttggaacact			3015
	taacagtttc tctgaacaat gacttacatg gggattggtc ctgtttgtca ttcctcacca			3075
50	taattgcatt gtcatcacta atccttggat cttgctgtat tgttactcaa attgtaata			3135
	ggtactgatg gaaatcgcta atggatggat aatcataaca cttttgggtca catgttttct			3195
	cctgcagcct gaaagttctt aaagaaaaag atatcaaatg cctgctgcta ccaccctttt			3255
55	aaattgctat ctttagaaaa gcaccggtat gtgttttaga ttcatttccc tgttttaggg			3315

EP 2 741 085 A1

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

aatgacagg cagtagtttc agttctgatg gcaaaacaaa taaaacatg tttctaaaag 3375
 ttgtatcttg aaacactggg gttcaacagc tagcagctaa agtaattcaa cccatgcatt 3435
 gctagtgtca cagcctttgg ttatgtctag tagctgtttc tgaagtattt tcatttatct 3495
 tttgtcaaat ttaaccctgt ttgaattctc tcctttcctc aaggagacac ttatgttcaa 3555
 agtgttgatt ctttgcctta ggtgcataga gagtagacag tttggagatg gaaaggttag 3615
 cagtgactta gccatatggt ctgtgttgga atttgtgcta gcagtttgag cactagctct 3675
 gcgtgcctat gaactgaatg ctgcttgcc cattccattt tatgtcatgg agaaataatt 3735
 ccacttggtg acacaaaggc taagttaatg ttatcttctg tacagaaatt aaatcttact 3795
 tttagccttt tgtaaacttt tttttttttt ttccaagccg gtatcagcta ctcaaaacaa 3855
 ttctcagata ttcattcatta gacaactgga gtttttgctg gttttgtagc ctactaaaac 3915
 tgctgaggct gttgaacatt ccacattcaa aagttttgta ggggtgtgga taatggggaa 3975
 gcttcaatgt ttatctttaa ataaataaaa taagttcttg acttttctca tgtgtgggta 4035
 tggtagatca tattggaagg gttatctggt tacttttgcc aagactattt tgccagcacc 4095
 tacacttggt tgcttttaaa gacaactacc tgggatgtac cacaaccata tgtaattgt 4155
 attttattgg gatggataaa atgtttggtg tttattggat aatccctaga tgggtgtgta 4215
 cgtgtgtaga atataatttt atgatagtaa gaaagcaaaa ttgaagaaaa taagtttagt 4275
 attgaatttg agttctgaag tgaattcagg gaatgtctca cgtttcgggc ttctacccaa 4335
 agtgtagggc agaaggtgta aaagttgttt gtagtttgac ttgtttattt tttaaagttgc 4395
 ttattccttt caacagcaac atatcattag ctgtcattct accattgcag ttctagttag 4455
 ttttaacgtc tgcattcaag actgttttaa aagcaacctc actggacaga gaactgctaa 4515
 agtcttttcc ttaagatctg agtctttggt actcagtatc ttctataata tgcaaatgct 4575
 tgtctagagg cagaagacct tttgtttggt caagtgtgta ttttaccaga gtacagggaa 4635
 ctgatggtcc tacatgtctc ttagtgtagt aagactataa aatcttttgt acatgcacaa 4695
 ttcacagtat gtttagatac cacgtgtata atgccccccc ctccccagc tagcatgcca 4755
 ttgatgactt tttgcttagg gccatthtat taccagggcc ttaatattcc taaaaagatg 4815
 attttttttc atcctttctc ctcttttgat cattgtatct tgatattaaa aacatgacct 4875
 tccaatgatt gtagtaaatt aacttctata gttcttttgt ctctatatgt attcatatat 4935
 atgctattgt atagagactt caaggagaca tggagatgca tgcttattct caggttcatt 4995
 cactaagggtg cttggcagac aaccagtttc taagtgcaga atgtagttaa gcagcttcat 5055
 atatgtgcca ggcaatttgt tttgttaa atttcatctac ttaaggaaat agggatttgt 5115
 agcttaggct gatcatacc ttcatthcaa ccttaagctc tcaacctgca tccatccgac 5175
 ttgagctatt aagtacttta gttttatcga gtataagtta acagaaaaag taaattaagc 5235

EP 2 741 085 A1

tttgccttta ctatthttgaa tttatataca ttctggaaaa acttagaaac tgttgtatat 5295
 ttcattagat taaattatat gaaaatgtga ttgtttatag caaagcctgt gagttgcata 5355
 5 caccctaagg aaaactcctt aagtgtctct tgaagagaga agaaacaatt ctgggtctgg 5415
 tcttttttaag aacaaagcta gactactgta tgtagcact gtacattaat agtctgttgt 5475
 gaagcttgag cagtttcctg catagccttg atccttcacc gttggcattg aaaatagcag 5535
 10 tatccctgat gtacttaaaa cttaaagtca ggttttggtta tatttatttg taagtcttaa 5595
 tttcctctaa atactatata tcttttagcga gacaacctga aatttattag cacatttggg 5655
 tatctcttgc ttggcattat ggccagtgtt aactattcag tggtgaaaaa attaccctc 5715
 15 aagacactgg agtgacccca gatgtgtgta gtaagtggca tggttcaact gtgtgggtaa 5775
 tgataaatat atgacttagt cggtagatc tggaaagact tgattgaaag ataattcagc 5835
 tgacataagg atgagtgagg agtggcaaac tggataaaaag agtcaagaga cctgtattcc 5895
 20 agtgactcct gttttgttta agcattagca agatctgtct ggggaaactg gatagggcag 5955
 ttttcttcca tgtttagttt ttgtctcaac atttgggaagc tattgaaggt tttaaaatgg 6015
 tgtgtattgt ttttttttgg ggggggggtg gccagaatag tgggtcatct aataaaactg 6075
 25 ccatttaaaa gatcaaaaaa aaaaaaaaaa aaaaaaaaaa 6114

<210> 24
 <211> 698
 <212> PRT
 <213> Mus musculus

<400> 24

35 Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15
 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 40 20 25 30
 Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
 45 35 40 45
 Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
 50 50 55 60
 Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
 55 65 70 75 80
 Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
 85 90 95
 Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
 100 105 110

EP 2 741 085 A1

Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
 115 120 125
 5 Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
 130 135 140
 10 Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
 145 150 155 160
 15 Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
 165 170 175
 20 Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
 180 185 190
 25 Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
 195 200 205
 30 Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
 210 215 220
 35 Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
 225 230 235 240
 40 Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
 245 250 255
 45 Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
 260 265 270
 50 Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
 275 280 285
 55 Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
 290 295 300
 60 Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
 305 310 315 320
 65 Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
 325 330 335
 70 Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
 340 345 350
 75 Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
 355 360 365

EP 2 741 085 A1

Asn Phe Ile Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met
 370 375 380

5

Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Gln Val
 385 390 395 400

10

His Ser Glu Ser Arg Leu Ala Gln Ser Asn Gln Val Pro Val Gln Pro
 405 410 415

Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr
 420 425 430

15

Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro
 435 440 445

20

Gln Lys Glu Pro Met Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr
 450 455 460

Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln
 465 470 475 480

25

Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn
 485 490 495

30

Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn
 500 505 510

Ala Pro Val Pro Pro Ala Asn Glu Pro Glu Thr Leu Lys Gln Gln Ser
 515 520 525

35

Gln Tyr Gln Ala Thr Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln
 530 535 540

40

Val Glu Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly
 545 550 555 560

Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His
 565 570 575

45

Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro
 580 585 590

50

Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg
 595 600 605

Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly
 610 615 620

55

Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr

EP 2 741 085 A1

	Ser	Phe	Met	Ala	Leu	Ser	Gln	Asp	Ile	Gln	Lys	Thr	Ile	Lys	Lys	Thr	
			115					120					125				
5	gca	cgt	cgg	gaa	cag	ctt	atg	aga	gaa	gaa	gca	gaa	cag	aag	cgc	tta	610
	Ala	Arg	Arg	Glu	Gln	Leu	Met	Arg	Glu	Glu	Ala	Glu	Gln	Lys	Arg	Leu	
		130					135					140					
10	aaa	act	gta	ctt	gag	tta	cag	tat	gta	ttg	gat	aag	ctg	gga	gat	gat	658
	Lys	Thr	Val	Leu	Glu	Leu	Gln	Tyr	Val	Leu	Asp	Lys	Leu	Gly	Asp	Asp	
	145				150						155					160	
15	gat	gtg	aga	aca	gat	ctg	aaa	caa	ggt	ttg	agt	gga	gtg	cca	ata	ttg	706
	Asp	Val	Arg	Thr	Asp	Leu	Lys	Gln	Gly	Leu	Ser	Gly	Val	Pro	Ile	Leu	
				165						170					175		
20	tct	gag	gag	gag	ttg	tca	ttg	ctg	gat	gag	ttc	tac	aag	ctc	gta	gat	754
	Ser	Glu	Glu	Glu	Leu	Ser	Leu	Leu	Asp	Glu	Phe	Tyr	Lys	Leu	Val	Asp	
				180					185					190			
25	cct	gag	cgt	gac	atg	agt	tta	agg	tta	aat	gag	cag	tat	gaa	cat	gcc	802
	Pro	Glu	Arg	Asp	Met	Ser	Leu	Arg	Leu	Asn	Glu	Gln	Tyr	Glu	His	Ala	
			195					200					205				
30	tca	att	cac	ttg	tgg	gat	ttg	ctg	gaa	ggg	aaa	gaa	aag	cct	gtg	tgt	850
	Ser	Ile	His	Leu	Trp	Asp	Leu	Leu	Glu	Gly	Lys	Glu	Lys	Pro	Val	Cys	
		210					215					220					
35	gga	aca	acc	tat	aaa	gct	cta	aag	gaa	att	gtt	gag	cgt	gtt	ttc	cag	898
	Gly	Thr	Thr	Tyr	Lys	Ala	Leu	Lys	Glu	Ile	Val	Glu	Arg	Val	Phe	Gln	
	225					230					235					240	
40	tca	aac	tac	ttt	gat	agc	act	cac	aat	cat	caa	aat	ggg	ttg	tgt	gag	946
	Ser	Asn	Tyr	Phe	Asp	Ser	Thr	His	Asn	His	Gln	Asn	Gly	Leu	Cys	Glu	
				245					250						255		
45	gag	gaa	gag	gcg	gct	tca	gcg	ccc	aca	gtg	gag	gac	cag	gta	gct	gaa	994
	Glu	Glu	Glu	Ala	Ala	Ser	Ala	Pro	Thr	Val	Glu	Asp	Gln	Val	Ala	Glu	
				260					265					270			
50	gct	gaa	cct	gag	cca	gcg	gaa	gaa	tac	aca	gag	caa	agt	gag	gtt	gaa	1042
	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	Gln	Ser	Glu	Val	Glu	
			275					280					285				
55	tca	aca	gag	tat	gtc	aat	agg	cag	ttc	atg	gca	gaa	aca	cag	ttc	agc	1090
	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	Glu	Thr	Gln	Phe	Ser	
		290					295					300					
60	agt	ggt	gag	aag	gag	caa	gtg	gat	gag	tgg	aca	gtt	gaa	aca	gtt	gag	1138
	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	Val	Glu	Thr	Val	Glu	
	305					310					315					320	
65	gtt	gta	aac	tca	ctc	cag	cag	caa	cct	cag	gct	gcg	tcc	cct	tca	gtc	1186
	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	Ala	Ser	Pro	Ser	Val	
				325						330					335		
70	cca	gag	ccc	cac	tct	ttg	act	cca	gtg	gct	cag	tca	gat	cca	ctt	gtg	1234
	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	Ser	Asp	Pro	Leu	Val	
				340					345					350			
75	aga	agg	cag	cgt	gta	caa	gat	ctt	atg	gca	caa	atg	caa	ggg	ccc	tat	1282
	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly	Pro	Tyr	
			355					360					365				
80	aat	ttc	ata	cag	gat	tca	atg	ttg	gat	ttt	gaa	aat	cag	acg	ctt	gat	1330
	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	Asn	Gln	Thr	Leu	Asp	

EP 2 741 085 A1

	ttc tcg aac act cca aac agt ggt tat tca cag tct cag ttc act gct	2146
	Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala	
	645 650 655	
5	ccc cgg gac tac tct ggt tac cag cgg gat gga tat cag cag aat ttc	2194
	Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe	
	660 665 670	
10	aag cga ggc tct ggg cag agt gga cca cgg gga gcc cca cga ggt aat	2242
	Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn	
	675 680 685	
15	ata ttg tgg tgg tga tcctagctcc tatgtggagc ttctgttctg gccttggaag	2297
	Ile Leu Trp Trp	
	690	
20	aactgttcat agtccgcatg taggttacat gtttaggaata catttatctt ttccagactt	2357
	gttgctaaag attaaatgaa atgctctggt tctaaaattt catcttgaat ccaaatttta	2417
	atthttgaat gactttccct gctgttgtct tcaaaatcag aacattttct ctgcctcaga	2477
25	aaagcgtttt tccaactgga aatttatthtt tcaaggtctta aaacctgcta aatgtthttt	2537
	ggaagtacct actgaaactt tttgtaagac atthtttgaa cgagcttgaa catttatata	2597
	aatttatthac cctctthtgat tthttgaaaca tgcatattat atthtaggctg agaagccctt	2657
30	caaatggcca gataagccac agthtttagct agagaacctt ttagaattga cataactaat	2717
	ctaaacttga acactthttag gaccaatggt agtgthtctaa ataccaacat atthtctgatg	2777
	thttaaacaga tctcccaaat tcttaggacc ttgatgtcat thaaatttag aatgacaagc	2837
	thtaagaggct thagthttcat thgtthtttca agtaatgaaa aataattthct tacatgggca	2897
35	gatagthaat thgttgaaca attacaggta gcattthcatg thaatctgatg thtctaaatgg	2957
	thtctthtatt gaaggaggth aaagaattag gthttcttaca gthttthggct ggccatgaca	3017
	thgtataaaat gtatattaag gaggaattat aaagtactth aattthgatg ctagtggcaa	3077
40	thgatcatta agaaagtact thaaagcaaa aggtthaatgg gthcatctggg aaaaatactg	3137
	aagtatcaaa ggtatthtga thgtgaatgtg ggthtatgtht thtctatcca cthttagca	3197
	tattctatga aagthtgagth aatgatagc thaaatatct gthttcaacag catgthaaaa	3257
45	gthattthta ctgthacaag thattataca atthttgatg thtctgagth thtthttaac	3317
	agthttaggth caaaggthctg thttcattct gthgctthttt thtaattthg atagthtgat	3377
	gthcactthct attgaaatgt aagctagcgt gthacctthaga atgtgagctc catgagagca	3437
50	ggtaccttht thgtctthcac thgtgtatct attthcaacg cthcatgaca gthgctggca	3497
	catagthaggc actcaataaa thctthgtthga atgaaatgaaa aaaaaaaaa a	3548
55	<210> 26	
	<211> 692	
	<212> PRT	
	<213> Mus musculus	

EP 2 741 085 A1

<400> 26

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15

Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 20 25 30

Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
 35 40 45

Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
 50 55 60

Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
 65 70 75 80

Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
 85 90 95

Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
 100 105 110

Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
 115 120 125

Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
 130 135 140

Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
 145 150 155 160

Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
 165 170 175

Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
 180 185 190

Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
 195 200 205

Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
 210 215 220

Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
 225 230 235 240

Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
 245 250 255

EP 2 741 085 A1

Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
 260 265 270
 5 Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
 275 280 285
 10 Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
 290 295 300
 Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
 305 310 315 320
 15 Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
 325 330 335
 20 Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
 340 345 350
 Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
 355 360 365
 25 Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
 370 375 380
 30 Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
 385 390 395 400
 Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
 405 410 415
 35 Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
 420 425 430
 40 Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
 435 440 445
 45 Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
 450 455 460
 Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
 465 470 475 480
 50 Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
 485 490 495
 55 Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
 500 505 510

EP 2 741 085 A1

Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
 515 520 525
 5
 Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
 530 535 540
 10
 Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
 545 550 555 560
 Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
 565 570 575
 15
 Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
 580 585 590
 20
 Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
 595 600 605
 Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
 610 615 620
 25
 Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
 625 630 635 640
 30
 Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
 645 650 655
 Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
 660 665 670
 35
 Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn
 675 680 685
 40
 Ile Leu Trp Trp
 690
 45
 <210> 27
 <211> 3508
 <212> DNA
 <213> Mus musculus
 50
 <220>
 <221> CDS
 <222> (139)..(2217)
 <223>
 55
 <400> 27
 cccaccgcgc gcgcgcgtag ccgcctgcc gcccgcccgc tgcgcgtttt gtcccgcgtc 60
 tctcccgcgc cgtctcctga cttgctggtc ttgtccttcc ctcccgcttt tttcctctcc 120
 tctcttctcg gtctaaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
 Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly

EP 2 741 085 A1

	1	5	10	
5	agc aaa tcg tcg gga ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Ser Gly Ser Ser Gly Ser Glu 15 20 25	219		
10	gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc Ala Ala Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly 30 35 40	267		
15	acc ggc gcc gtc cag acc gag gcc atg aag cag att ctc ggc gta atc Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile 45 50 55	315		
20	gac aag aaa ctt cgg aac ctg gag aag aaa aag ggt aaa ctt gat gat Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp 60 65 70 75	363		
25	tac cag gaa cga atg aat aaa ggg gaa agg ctc aat caa gac cag ctg Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu 80 85 90	411		
30	gat gcc gta tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala 95 100 105	459		
35	aag gaa tta cag agg agt ttc atg gca tta agt caa gat att cag aaa Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys 110 115 120	507		
40	aca ata aag aag aca gca cgt ccg gaa cag ctt atg aga gaa gaa gca Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala 125 130 135	555		
45	gaa cag aag cgc tta aaa act gta ctt gag tta cag tat gta ttg gat Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp 140 145 150 155	603		
50	aag ctg gga gat gat gat gtg aga aca gat ctg aaa caa ggt ttg agt Lys Leu Gly Asp Asp Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser 160 165 170	651		
55	gga gtg cca ata ttg tct gag gag gag ttg tca ttg ctg gat gag ttc Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe 175 180 185	699		
60	tac aag ctc gta gat cct gag cgt gac atg agt tta agg tta aat gag Tyr Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu 190 195 200	747		
65	cag tat gaa cat gcc tca att cac ttg tgg gat ttg ctg gaa ggg aaa Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys 205 210 215	795		
70	gaa aag cct gtg tgt gga aca acc tat aaa gct cta aag gaa att gtt Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val 220 225 230 235	843		
75	gag cgt gtt ttc cag tca aac tac ttt gat agc act cac aat cat caa Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln 240 245 250	891		
80	aat ggg ttg tgt gag gag gaa gag gcg gct tca gcg ccc aca gtg gag Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu 255 260 265	939		

EP 2 741 085 A1

	gac	cag	gta	gct	gaa	gct	gaa	cct	gag	cca	gcg	gaa	gaa	tac	aca	gag	987
	Asp	Gln	Val	Ala	Glu	Ala	Glu	Pro	Glu	Pro	Ala	Glu	Glu	Tyr	Thr	Glu	
			270					275					280				
5	caa	agt	gag	ggt	gaa	tca	aca	gag	tat	gtc	aat	agg	cag	ttc	atg	gca	1035
	Gln	Ser	Glu	Val	Glu	Ser	Thr	Glu	Tyr	Val	Asn	Arg	Gln	Phe	Met	Ala	
		285					290					295					
10	gaa	aca	cag	ttc	agc	agt	ggt	gag	aag	gag	caa	gtg	gat	gag	tgg	aca	1083
	Glu	Thr	Gln	Phe	Ser	Ser	Gly	Glu	Lys	Glu	Gln	Val	Asp	Glu	Trp	Thr	
	300					305					310					315	
15	ggt	gaa	aca	ggt	gag	ggt	gta	aac	tca	ctc	cag	cag	caa	cct	cag	gct	1131
	Val	Glu	Thr	Val	Glu	Val	Val	Asn	Ser	Leu	Gln	Gln	Gln	Pro	Gln	Ala	
					320					325					330		
20	gag	tcc	cct	tca	gtc	cca	gag	ccc	cac	tct	ttg	act	cca	gtg	gct	cag	1179
	Ala	Ser	Pro	Ser	Val	Pro	Glu	Pro	His	Ser	Leu	Thr	Pro	Val	Ala	Gln	
				335					340					345			
25	tca	gat	cca	ctt	gtg	aga	agg	cag	cg	gta	caa	gat	ctt	atg	gca	caa	1227
	Ser	Asp	Pro	Leu	Val	Arg	Arg	Gln	Arg	Val	Gln	Asp	Leu	Met	Ala	Gln	
			350					355					360				
30	atg	caa	ggg	ccc	tat	aat	ttc	ata	cag	gat	tca	atg	ttg	gat	ttt	gaa	1275
	Met	Gln	Gly	Pro	Tyr	Asn	Phe	Ile	Gln	Asp	Ser	Met	Leu	Asp	Phe	Glu	
		365					370					375					
35	aat	cag	acg	ctt	gat	cct	gcc	att	gta	tcc	gca	cag	cct	atg	aac	cct	1323
	Asn	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser	Ala	Gln	Pro	Met	Asn	Pro	
	380					385					390					395	
40	acc	cag	aac	atg	gat	atg	cct	cag	ctg	ggt	tgc	cct	cag	ggt	cat	tct	1371
	Thr	Gln	Asn	Met	Asp	Met	Pro	Gln	Leu	Val	Cys	Pro	Gln	Val	His	Ser	
				400					405					410			
45	gaa	tct	aga	ctt	gcc	caa	tct	aat	caa	ggt	cct	gta	caa	cca	gaa	gcc	1419
	Glu	Ser	Arg	Leu	Ala	Gln	Ser	Asn	Gln	Val	Pro	Val	Gln	Pro	Glu	Ala	
				415					420				425				
50	aca	cag	ggt	cct	ttg	ggt	tca	tcc	aca	agt	gag	ggg	tat	aca	gca	tct	1467
	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr	Ser	Glu	Gly	Tyr	Thr	Ala	Ser	
			430					435					440				
55	cag	ccc	ttg	tac	cag	cca	tct	cat	gct	acg	gag	cag	cg	ccg	cag	aaa	1515
	Gln	Pro	Leu	Tyr	Gln	Pro	Ser	His	Ala	Thr	Glu	Gln	Arg	Pro	Gln	Lys	
		445					450					455					
60	gag	cca	atg	gat	cag	att	cag	gca	aca	ata	tct	ttg	aat	aca	gac	cag	1563
	Glu	Pro	Met	Asp	Gln	Ile	Gln	Ala	Thr	Ile	Ser	Leu	Asn	Thr	Asp	Gln	
	460					465					470					475	
65	act	aca	gca	tcc	tca	tcc	ctt	cct	gct	gct	tct	cag	cct	caa	gtg	ttc	1611
	Thr	Thr	Ala	Ser	Ser	Ser	Leu	Pro	Ala	Ala	Ser	Gln	Pro	Gln	Val	Phe	
					480					485					490		
70	cag	gct	ggg	aca	agt	aaa	cct	ttg	cac	agc	agt	gga	atc	aat	gta	aat	1659
	Gln	Ala	Gly	Thr	Ser	Lys	Pro	Leu	His	Ser	Ser	Gly	Ile	Asn	Val	Asn	
				495					500					505			
75	gca	gct	cca	ttc	cag	tcc	atg	caa	acg	gtg	ttc	aat	atg	aat	gct	cca	1707
	Ala	Ala	Pro	Phe	Gln	Ser	Met	Gln	Thr	Val	Phe	Asn	Met	Asn	Ala	Pro	
			510					515					520				

EP 2 741 085 A1

	gtc cct cct gct aat gaa cca gaa acg tta aaa caa cag agt cag tac	1755
	Val Pro Pro Ala Asn Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr	
	525 530 535	
5	cag gcc act tat aac cag agt ttt tcc agt cag cct cac caa gtg gaa	1803
	Gln Ala Thr Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu	
	540 545 550 555	
10	caa aca gag ctt caa caa gac caa ctg caa acg gtg gtt ggc act tac	1851
	Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr	
	560 565 570	
15	cat gga tcc cag gac cag cct cat caa gtg cct ggt aac cac cag caa	1899
	His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His Gln Gln	
	575 580 585	
20	ccc cca cag cag aac act ggc ttt cca cgt agc agt cag cct tat tac	1947
	Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr	
	590 595 600	
25	aac agt cgt ggg gta tct cga gga ggg tct cgt ggt gcc aga ggc ttg	1995
	Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu	
	605 610 615	
30	atg aat gga tac agg ggc cct gcc aat gga ttt aga gga gga tat gat	2043
	Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp	
	620 625 630 635	
35	ggt tac cgc cct tca ttc tcg aac act cca aac agt ggt tat tca cag	2091
	Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln	
	640 645 650	
40	tct cag ttc act gct ccc cgg gac tac tct ggt tac cag cgg gat gga	2139
	Ser Gln Phe Thr Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly	
	655 660 665	
45	tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga	2187
	Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly	
	670 675 680	
50	gcc cca cga ggt aat ata ttg tgg tgg tga tcctagctcc tatgtggagc	2237
	Ala Pro Arg Gly Asn Ile Leu Trp Trp	
	685 690	
55	ttctgtttctg gccttggag aactgttcat agtccgcatg taggttacat gttaggaata	2297
	catttatctt ttccagactt gttgctaaag attaaatgaa atgctctggt tctaaaattt	2357
	catcttgaat ccaaatttta atttttgaat gactttccct gctgttgtct tcaaaatcag	2417
	aacatthttct ctgcctcaga aaagcgtttt tccaactgga aatttatttt tcaggtctta	2477
	aaacctgcta aatgtthttta ggaagtacct actgaaactt tttgtaagac atthtttgaa	2537
	cgagcttgaa catttatata aatttattac cctctttgat ttttgaaaca tgcatattat	2597
	atttaggctg agaagccctt caaatggcca gataagccac agtttttagct agagaacat	2657
	ttagaattga cataactaat ctaaacttga aacttttttag gaccaatggt agtgttctaa	2717
	ataccaacat atthttctgatg tttaaacaga tctoccaaact tcttaggacc ttgatgtcat	2777
	taaaatttag aatgacaagc ttaagaggct ttagtttcat ttgtttttca agtaatgaaa	2837
	aataattttct tacatgggca gatagttaat ttgttgaaca attacaggta gcatttcatg	2897

EP 2 741 085 A1

5 taatctgatg ttctaaatgg ttctcttatt gaaggagggtt aaagaattag gtttcttaca 2957
 gtttttggct ggccatgaca tgtataaaat gtatattaag gaggaattat aaagtacttt 3017
 aatttgaatg ctagtggcaa ttgatcatta agaaagtact ttaaagcaaa aggttaatgg 3077
 gtcacatctggg aaaaatactg aagtatcaaa ggtatttgca tgtgaatgtg ggttatgttc 3137
 ttctatccca ccttgtagca tattctatga aagttgagtt aatgatagc taaaatatct 3197
 10 gtttcaacag catgtaaaaa gttattttaa ctgttacaag tcattataca attttgaatg 3257
 ttctgtagtt tctttttaac agtttaggta caaagggtctg ttttcattct ggtgcttttt 3317
 attaattttg atagtatgat gtcacttcct attgaaatgt aagctagcgt gtaccttaga 3377
 15 atgtgagctc catgagagca ggtaccttgt ttgtcttcac tgctgtatct attccaacg 3437
 cctcatgaca gtgcctggca catagtaggc actcaataaa tacttgttga atgaatgaaa 3497
 aaaaaaaaaa a 3508

20
 <210> 28
 <211> 692
 <212> PRT
 <213> Mus musculus

25 <400> 28

Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
 1 5 10 15
 30 Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
 20 25 30
 35 Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
 35 40 45
 Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
 50 55 60
 40 Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
 65 70 75 80
 45 Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
 85 90 95
 Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
 100 105 110
 50 Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
 115 120 125
 55 Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
 130 135 140

EP 2 741 085 A1

Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
 145 150 155 160
 5 Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
 165 170 175
 Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
 10 180 185 190
 Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
 15 195 200 205
 Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
 20 210 215 220
 Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
 25 225 230 235 240
 Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
 30 245 250 255
 Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
 35 260 265 270
 Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
 40 275 280 285
 Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
 45 290 295 300
 Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
 50 305 310 315 320
 Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
 325 330 335
 Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
 45 340 345 350
 Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
 50 355 360 365
 Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
 370 375 380
 55 Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
 385 390 395 400

EP 2 741 085 A1

Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
 405 410 415

5 Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
 420 425 430

10 Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
 435 440 445

Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
 450 455 460

15 Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
 465 470 475 480

20 Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
 485 490 495

Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
 500 505 510

25 Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
 515 520 525

30 Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
 530 535 540

35 Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
 545 550 555 560

Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
 565 570 575

40 Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
 580 585 590

45 Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
 595 600 605

Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
 610 615 620

50 Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
 625 630 635 640

55 Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
 645 650 655

EP 2 741 085 A1

Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670

5 Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn
675 680 685

Ile Leu Trp Trp
690

10

<210> 29
<211> 2109
<212> DNA
<213> Gallus gallus

15

<220>
<221> CDS
<222> (1)..(2109)
<223>

20

<400> 29
atg ccc tcg gct acc aac ggc acc atg gcg agc agc agc ggg aag gcg 48
Met Pro Ser Ala Thr Asn Gly Thr Met Ala Ser Ser Ser Gly Lys Ala
1 5 10 15

25

ggc ccg ggc ggc aac gag cag gcc ccg gcg gcg gca gcg gcg gcc ccg 96
Gly Pro Gly Gly Asn Glu Gln Ala Pro Ala Ala Ala Ala Ala Pro
20 25 30

30

cag gcg tcg ggc ggc agc atc acc tcg gtt cag acc gag gcc atg aag 144
Gln Ala Ser Gly Gly Ser Ile Thr Ser Val Gln Thr Glu Ala Met Lys
35 40 45

35

cag atc ttg gga gtg atc gac aaa aag ctc cgc aac ctc gag aag aaa 192
Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys
50 55 60

40

aag agc aaa ctt gac gat tac cag gaa cga atg aac aag ggg gaa cgt 240
Lys Ser Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg
65 70 75 80

45

cta aat caa gat caa ctg gat gca gtg tca aaa tac cag gaa gtg aca 288
Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr
85 90 95

50

aat aac ctg gaa ttc gct aaa gaa ctg cag agg agc ttt atg gca ctg 336
Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu
100 105 110

55

agc caa gat atc cag aaa aca ata aaa aag acg gct cgc agg gag cag 384
Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln
115 120 125

ctg atg aga gaa gag gct gag cag aag cgt tta aag act gtg cta gag 432
Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu
130 135 140

ctg cag ttc att ttg gac aag ttg ggt gac gat gaa gtg cgc agt gac 480
Leu Gln Phe Ile Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Ser Asp
145 150 155 160

55

ttg aaa caa gga tca aat gga gta ccg gta ctg aca gag gag gaa ctg 528
Leu Lys Gln Gly Ser Asn Gly Val Pro Val Leu Thr Glu Glu Glu Leu

EP 2 741 085 A1

	165	170	175		
5	aca atg ctg gat Thr Met Leu Asp 180	gaa ttt tac aag Glu Phe Tyr Lys 185	cta gtt tac cct Leu Val Tyr Pro 190	gaa agg gac atg Glu Arg Asp Met 190	576
	aac atg agg ttg Asn Met Arg Leu 195	aat gag cag tat Asn Glu Gln Tyr 200	gag caa gca tct Glu Gln Ala Ser 205	ggt cac ctg tgg Val His Leu Trp 205	624
10	gac tta ctg gaa Asp Leu Leu Glu 210	ggg aag gaa aaa Gly Lys Glu Lys 215	ccc gtt tgt gga Pro Val Cys Gly 220	aca acc tat aaa Thr Thr Tyr Lys 220	672
15	gcc ctg aag gag Ala Leu Lys Glu 225	ggt gtt gaa cgt Val Val Glu Arg 230	att ctt caa act Ile Leu Gln Thr 235	agt tac ttt gat Ser Tyr Phe Asp 240	720
	agc acc cat aac Ser Thr His Asn 245	cat cag aac ggg His Gln Asn Gly 245	tta tgt gag gaa Leu Cys Glu Glu 250	gag gca gca gca Glu Glu Glu Glu 255	768
20	ccc aca cct gca Pro Thr Pro Ala 260	gta gaa gag act Val Glu Asp Thr 265	gta gca gaa gct Val Ala Glu Ala 270	gag cct gat cca Glu Pro Asp Pro 270	816
25	gca gaa gaa ttt Ala Glu Glu Phe 275	act gaa cct act Thr Glu Pro Thr 280	gaa gtt gaa tcg Glu Val Glu Ser 285	act gag tat gta Thr Glu Tyr Val 285	864
30	aac aga caa ttc Asn Arg Gln Phe 290	atg gca gag act Met Ala Glu Thr 295	cag ttc agc agt Gln Phe Ser Ser 300	agt gag aag gaa Ser Ser Ser Glu Lys Glu 300	912
	cag gta gat gag Gln Val Asp Glu 305	tgg aca gtt gaa Trp Thr Val Glu 310	acg gtt gag gtt Thr Val Glu Val 315	gta aat tca ctg Val Val Val Asn Ser Leu 320	960
35	cag caa caa aca Gln Gln Gln Thr 325	caa gct aca tct Gln Ala Thr Ser 330	cct cca gtt cct Pro Pro Val Pro 335	gaa cct cat aca Glu Pro His Thr 335	1008
40	ctc act act gtg Leu Thr Thr Val 340	gct caa gca gat Gln Ala Asp 345	cct ctt gtt aga Pro Leu Val Arg 350	aga aga cag aga Arg Arg Gln Arg 350	1056
	cag gac ctt atg Gln Asp Leu Met 355	gcc cag atg cag Ala Gln Met Gln 360	ggt cca tat aac Gly Pro Tyr Asn 365	ttc atg cag gac Phe Met Gln Asp 365	1104
45	tct atg ctg gag Ser Met Leu Glu 370	ttt gag aac cag Phe Glu Asn Gln 375	aca ctt gat cct Thr Leu Asp Pro 380	gcc att gta tct Ala Ile Val Ser 380	1152
50	gca cag ccc atg Ala Gln Pro Met 385	aat cca gca cag Asn Pro Ala Gln 390	aat ttg gac atg Asn Leu Asp Met 395	ccg caa atg gtc Pro Gln Met Val 400	1200
	tgc cct cca gtt Cys Pro Pro Val 405	cat act gag tca His Thr Glu Ser 410	aga ctt gcc cag Arg Leu Ala Gln 415	cct aat caa gtt Pro Asn Gln Val 415	1248
55	cct gtg caa cca Pro Val Gln Pro 420	gaa gct acg cag Glu Ala Thr Gln 425	gtt ccc ttg gtt Val Pro Leu Val 430	tca tct aca agt Ser Ser Thr Ser 430	1296

EP 2 741 085 A1

	gag gga tat aca gcc tcc cag ccc atg tat cag cct tct cat acc aca	1344
	Glu Gly Tyr Thr Ala Ser Gln Pro Met Tyr Gln Pro Ser His Thr Thr	
	435 440 445	
5	gag caa cgg cca cag aag gaa tcc att gac cag att cag gct tca atg	1392
	Glu Gln Arg Pro Gln Lys Glu Ser Ile Asp Gln Ile Gln Ala Ser Met	
	450 455 460	
10	tca ctg aat gca gac cag acc ccg tca tca tca tca ctt ccc act gca	1440
	Ser Leu Asn Ala Asp Gln Thr Pro Ser Ser Ser Ser Leu Pro Thr Ala	
	465 470 475 480	
15	tcc cag ccg caa gtt ttc caa gct gga tct agc aaa cct ttg cat agc	1488
	Ser Gln Pro Gln Val Phe Gln Ala Gly Ser Ser Lys Pro Leu His Ser	
	485 490 495	
20	agc gga atc aat gtt aat gca gct cca ttc caa tcc atg caa aca gta	1536
	Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val	
	500 505 510	
25	ttc aac atg aat gca cct gtt cct cct gtt aat gag cca gaa gcc ctt	1584
	Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Ala Leu	
	515 520 525	
30	aag caa caa aat cag tac cag gcc agt tac aac cag agt ttc tcc aat	1632
	Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Asn	
	530 535 540	
35	cag cca cac caa gta gaa caa tca gat ctt cag caa gaa cag ctc cag	1680
	Gln Pro His Gln Val Glu Gln Ser Asp Leu Gln Gln Glu Gln Leu Gln	
	545 550 555 560	
40	aca gtg gtt ggt act tac cat ggt tct ccg gac cag acc cat caa gtg	1728
	Thr Val Val Gly Thr Tyr His Gly Ser Pro Asp Gln Thr His Gln Val	
	565 570 575	
45	gca gga aac cac cag caa cct ccc cag cag aat act gga ttt cca cgc	1776
	Ala Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg	
	580 585 590	
50	aac agt cag cct tat tac aac agt cgg gga gtg tct cgt ggt gga tca	1824
	Asn Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser	
	595 600 605	
55	cgt ggg act cgt gga ttg atg aat ggt tac agg gga cct gca aat gga	1872
	Arg Gly Thr Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly	
	610 615 620	
60	ttt aga gga gga tat gat ggc tac cgt cct tca ttt tcc aac act ccg	1920
	Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro	
	625 630 635 640	
65	aac agt ggt tac acg cag ccc caa ttt aat gct cct cga gat tat tca	1968
	Asn Ser Gly Tyr Thr Gln Pro Gln Phe Asn Ala Pro Arg Asp Tyr Ser	
	645 650 655	
70	aac tac cag cgg gat gga tat cag cag aac ttc aaa cgt ggt tct gga	2016
	Asn Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly	
	660 665 670	
75	caa agt ggg cct cgg gga gct cct cga ggt cgt gga ggg ccc cca aga	2064
	Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg	
	675 680 685	

EP 2 741 085 A1

cca aac aga ggg atg cct caa atg aac gct cag caa gtg aat taa 2109
 Pro Asn Arg Gly Met Pro Gln Met Asn Ala Gln Gln Val Asn
 690 695 700

5 <210> 30
 <211> 702
 <212> PRT
 <213> Gallus gallus

10 <400> 30

Met Pro Ser Ala Thr Asn Gly Thr Met Ala Ser Ser Ser Gly Lys Ala
 1 5 10 15

15 Gly Pro Gly Gly Asn Glu Gln Ala Pro Ala Ala Ala Ala Ala Ala Pro
 20 25 30

20 Gln Ala Ser Gly Gly Ser Ile Thr Ser Val Gln Thr Glu Ala Met Lys
 35 40 45

Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys
 50 55 60

25 Lys Ser Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg
 65 70 75 80

30 Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr
 85 90 95

Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu
 100 105 110

35 Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln
 115 120 125

40 Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu
 130 135 140

Leu Gln Phe Ile Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Ser Asp
 145 150 155 160

45 Leu Lys Gln Gly Ser Asn Gly Val Pro Val Leu Thr Glu Glu Glu Leu
 165 170 175

50 Thr Met Leu Asp Glu Phe Tyr Lys Leu Val Tyr Pro Glu Arg Asp Met
 180 185 190

Asn Met Arg Leu Asn Glu Gln Tyr Glu Gln Ala Ser Val His Leu Trp
 195 200 205

55 Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys

EP 2 741 085 A1

	210		215		220														
5	Ala 225	Leu	Lys	Glu	Val	Val 230	Glu	Arg	Ile	Leu	Gln 235	Thr	Ser	Tyr	Phe	Asp 240			
		Ser	Thr	His	Asn 245	His	Gln	Asn	Gly	Leu	Cys 250	Glu	Glu	Glu	Glu	Ala 255	Ala		
10		Pro	Thr	Pro	Ala 260	Val	Glu	Asp	Thr	Val 265	Ala	Glu	Ala	Glu	Pro	Asp 270	Pro		
15	Ala	Glu	Glu	Phe 275	Thr	Glu	Pro	Thr	Glu	Val	Glu	Ser	Thr 285	Glu	Tyr	Val			
	Asn 290	Arg	Gln	Phe	Met	Ala	Glu 295	Thr	Gln	Phe	Ser	Ser	Ser	Glu	Lys	Glu			
20	Gln 305	Val	Asp	Glu	Trp	Thr 310	Val	Glu	Thr	Val	Glu 315	Val	Val	Asn	Ser	Leu 320			
25	Gln	Gln	Gln	Thr	Gln 325	Ala	Thr	Ser	Pro	Pro 330	Val	Pro	Glu	Pro	His 335	Thr			
	Leu	Thr	Thr	Val 340	Ala	Gln	Ala	Asp	Pro 345	Leu	Val	Arg	Arg	Gln 350	Arg	Val			
30	Gln	Asp	Leu	Met	Ala	Gln	Met	Gln	Gly 360	Pro	Tyr	Asn	Phe 365	Met	Gln	Asp			
35	Ser 370	Met	Leu	Glu	Phe	Glu	Asn 375	Gln	Thr	Leu	Asp	Pro	Ala	Ile	Val	Ser			
40	Ala 385	Gln	Pro	Met	Asn	Pro 390	Ala	Gln	Asn	Leu	Asp 395	Met	Pro	Gln	Met	Val 400			
	Cys	Pro	Pro	Val	His 405	Thr	Glu	Ser	Arg	Leu 410	Ala	Gln	Pro	Asn	Gln 415	Val			
45	Pro	Val	Gln	Pro	Glu 420	Ala	Thr	Gln	Val	Pro	Leu	Val	Ser	Ser	Thr 430	Ser			
50	Glu	Gly	Tyr	Thr	Ala	Ser	Gln	Pro	Met 440	Tyr	Gln	Pro	Ser 445	His	Thr	Thr			
	Glu 450	Gln	Arg	Pro	Gln	Lys	Glu 455	Ser	Ile	Asp	Gln	Ile 460	Gln	Ala	Ser	Met			
55	Ser 465	Leu	Asn	Ala	Asp	Gln 470	Thr	Pro	Ser	Ser	Ser	Ser	Leu	Pro	Thr	Ala 480			

EP 2 741 085 A1

Ser Gln Pro Gln Val Phe Gln Ala Gly Ser Ser Lys Pro Leu His Ser
 485 490 495
 5 Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
 500 505 510
 10 Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Ala Leu
 515 520 525
 15 Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Asn
 530 535 540
 20 Gln Pro His Gln Val Glu Gln Ser Asp Leu Gln Gln Glu Gln Leu Gln
 545 550 555 560
 Thr Val Val Gly Thr Tyr His Gly Ser Pro Asp Gln Thr His Gln Val
 565 570 575
 25 Ala Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg
 580 585 590
 30 Asn Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
 595 600 605
 Arg Gly Thr Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
 610 615 620
 35 Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
 625 630 635 640
 40 Asn Ser Gly Tyr Thr Gln Pro Gln Phe Asn Ala Pro Arg Asp Tyr Ser
 645 650 655
 Asn Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
 660 665 670
 45 Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
 675 680 685
 50 Pro Asn Arg Gly Met Pro Gln Met Asn Ala Gln Gln Val Asn
 690 695 700
 <210> 31
 <211> 20
 <212> DNA
 <213> Artificial
 55 <220>
 <223> T3 primer

	<400> 31		
	aattaaccct cactaaagg		20
5	<210> 32		
	<211> 19		
	<212> DNA		
	<213> Artificial		
	<220>		
10	<223> T7 primer		
	<400> 32		
	taatagcact cactatagg		19
15	<210> 33		
	<211> 18		
	<212> DNA		
	<213> Artificial		
20	<220>		
	<223> primer		
	<400> 33		
	aaggtttgaa tggagtgc		18
25	<210> 34		
	<211> 18		
	<212> DNA		
	<213> Artificial		
30	<220>		
	<223> primer		
	<400> 34		
35	tgctcctttt caccactg		18
	<210> 35		
	<211> 18		
	<212> DNA		
40	<213> Artificial		
	<220>		
	<223> GAPDH primer		
45	<400> 35		
	gggctgcttt taactctg		18
	<210> 36		
	<211> 18		
50	<212> DNA		
	<213> Artificial		
	<220>		
	<223> GAPDH primer		
55	<400> 36		
	ccaggaaatg agcttgac		18

<210> 37
 <211> 27
 <212> DNA
 <213> Artificial
 5
 <220>
 <223> primer
 <400> 37
 catatggcat taagtcaaga tattcag 27
 10
 <210> 38
 <211> 23
 <212> DNA
 <213> Artificial
 15
 <220>
 <223> primer
 <400> 38
 ggtacctttg cggcatccct ctg 23
 20
 <210> 39
 <211> 21
 <212> DNA
 <213> Artificial
 25
 <220>
 <223> primer
 <400> 39
 catatgccgt cggccaccag c 21
 30
 <210> 40
 <211> 22
 <212> DNA
 <213> Artificial
 35
 <220>
 <223> primer
 <400> 40
 ggtaccattc acttgctgag tg 22
 40
 <210> 41
 <211> 23
 <212> DNA
 <213> Artificial
 45
 <220>
 <223> primer
 <400> 41
 gagctcatgc cctcggccac cag 23
 50
 <210> 42
 <211> 23
 <212> DNA
 <213> Artificial
 55

EP 2 741 085 A1

<220>
<223> primer

5 <400> 42
ctcgagttaa ttcacttgct gag

23

10 <210> 43
<211> 14
<212> PRT
<213> Homo sapiens

15 <400> 43
Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln
1 5 10

20 <210> 44
<211> 148
<212> PRT
<213> Mus musculus

25 <400> 44
Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly
1 5 10 15

30 Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys
20 25 30

35 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

40 Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu
50 55 60

45 Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn
65 70 75 80

50 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
85 90 95

55 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val
100 105 110

60 Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
115 120 125

65 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro
130 135 140

70 Pro Ser Val Tyr
145

EP 2 741 085 A1

<210> 45
 <211> 132
 <212> PRT
 <213> Mus musculus

5

<400> 45

Ala Val Leu Arg Cys Ser Arg Gly Leu Leu Val Ile Trp Ile Ser Asp
 1 5 10 15

10

Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Thr Ala Gly Glu
 20 25 30

15

Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Trp Ser Val
 35 40 45

20

Asn Gln Lys Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Gln Arg Gln Pro
 50 55 60

Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Arg Glu Ser Trp Val Pro
 65 70 75 80

25

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
 85 90 95

30

Ser Asn Val His Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln His Asn
 100 105 110

His Gly Ser Phe Leu Pro Ser Arg Ser Glu Gln Val Pro Ser Trp Arg
 115 120 125

35

Ser Asn Asn Arg
 130

40

<210> 46
 <211> 117
 <212> PRT
 <213> Mus musculus

<400> 46

45

Arg Thr Thr Ser His Met Asp Ser Asp Ile Gln Leu Thr Gln Ser Pro
 1 5 10 15

50

Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg
 20 25 30

Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln
 35 40 45

55

Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp
 50 55 60

EP 2 741 085 A1

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser
 65 70 75 80

5 Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys
 85 90 95

10 Gln His Phe Trp Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu
 100 105 110

15 Ile Lys Gln Ser Asp
 115

<210> 47
 <211> 94
 <212> PRT
 <213> Mus musculus

20 <400> 47

Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser
 1 5 10 15

25 Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu
 20 25 30

30 Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe
 35 40 45

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val
 50 55 60

35 Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp
 65 70 75 80

40 Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Gln
 85 90

<210> 48
 <211> 105
 <212> PRT
 <213> Mus musculus

45 <400> 48

Gly Leu Phe Cys Ser Val Glu Arg Cys His Tyr Gln Leu Gln Ser Ser
 1 5 10 15

50 Gln Asn Leu Leu Ser Ile Val Asn Arg Tyr His Tyr Met Ser Gly Asn
 20 25 30

55 Pro Pro Lys Leu Leu Val Tyr Pro Ala Leu Leu Ile Tyr Glu Ala Ser
 35 40 45

EP 2 741 085 A1

Ile Thr Lys Ser Cys Val Pro Asp Arg Phe Thr Arg Ser Gly Ser Gly
50 55 60

5 Thr Asn Phe Thr Leu Thr Ile Asn Phe Val His Ala Asp Asp Leu Ile
65 70 75 80

10 Phe Tyr Tyr Cys Gln His Asn Arg Gly Ser Phe Leu Pro Ser Ser Ser
85 90 95

Val Gln Val Pro Arg Arg Arg Ser Asn
100 105

15 <210> 49
<211> 100
<212> PRT
<213> Mus musculus

20 <400> 49

Asp Ile Leu Gln Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn
1 5 10 15

25 Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile Gly Leu Ile
20 25 30

30 Asn Pro Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys
35 40 45

Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu
50 55 60

35 Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp
65 70 75 80

40 Gly Val Trp Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
85 90 95

Val Ser Ser Lys
100

45 <210> 50
<211> 90
<212> PRT
<213> Mus musculus

50 <400> 50

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala
1 5 10 15

55 Val Ala Trp Tyr Gln Gln Lys Pro Arg Gln Ser Pro Lys Ala Leu Ile

EP 2 741 085 A1

20 25 30
 5 Tyr Leu Ala Ser Asn Arg Asp Thr Gly Leu Pro Asp Arg Phe Pro Gly
 35 40 45
 Arg Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Thr Asn Val Gln Ser
 50 55 60
 10 Glu Asp Leu Glu Asp Tyr Phe Cys Leu Gln His Cys Asn Tyr Pro Asn
 65 70 75 80
 15 Glu Phe Arg Gly Cys Thr Lys Val Pro Ile
 85 90
 <210> 51
 <211> 116
 <212> PRT
 <213> Mus musculus
 <400> 51
 20
 25 Leu Gln Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys
 1 5 10 15
 Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Gln
 20 25 30
 30 Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile
 35 40 45
 35 Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys Gly Lys
 50 55 60
 40 Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu
 65 70 75 80
 45 Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly
 85 90 95
 50 Glu Tyr Gly Asn Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr
 100 105 110
 Val Ser Ser Asn
 115
 <210> 52
 <211> 100
 <212> PRT
 <213> Mus musculus
 <400> 52
 55

EP 2 741 085 A1

Thr Ser Asp Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala
 1 5 10 15
 Ser Gln Asp Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly
 5 20 25 30
 Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly
 10 35 40 45
 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu
 50 55 60
 Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu
 15 65 70 75 80
 Gln Tyr Asp Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu
 20 85 90 95
 Ile Lys Gln Lys
 100
 <210> 53
 <211> 108
 <212> PRT
 <213> Mus musculus
 <400> 53
 Ala Trp Leu Ser Gln Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys
 1 5 10 15
 Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu
 35 20 25 30
 Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro
 40 35 40 45
 Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr
 50 50 55 60
 Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
 45 65 70 75 80
 Tyr Cys Ala Arg Pro Ile His Tyr Tyr Tyr Gly Ser Ser Leu Ala Tyr
 50 85 90 95
 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys
 100 105
 <210> 54
 <211> 104

EP 2 741 085 A1

<212> PRT
 <213> Mus musculus

<400> 54

5
 Glu Phe His Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg
 1 5 10 15
 Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr
 10 20 25 30
 Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser
 35 40 45
 15
 Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg
 50 55 60
 Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala
 65 70 75 80
 Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Gly Arg Ser Glu Val
 85 90 95
 25
 Val Pro Ser Trp Arg Ser Asn Lys
 100

<210> 55
 <211> 109
 <212> PRT
 <213> Mus musculus

<400> 55

30
 35
 Pro Arg Ala Ser Leu Gly Val Ser Glu Thr Leu Leu Cys Thr Ser Gly
 1 5 10 15
 Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro Gly
 40 20 25 30
 Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr
 35 40 45
 45
 Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
 50 55 60
 Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala
 65 70 75 80
 Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Asn Trp Ala Phe Asp
 85 90 95
 55
 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys

EP 2 741 085 A1

100

105

5

<210> 56
 <211> 94
 <212> PRT
 <213> Mus musculus

<400> 56

10

Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser
 1 5 10 15

15

Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu
 20 25 30

20

Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe
 35 40 45

25

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val
 50 55 60

30

Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp
 65 70 75 80

Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gln
 85 90

35

<210> 57
 <211> 111
 <212> PRT
 <213> Mus musculus

<400> 57

40

Pro Ala Cys Leu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser
 1 5 10 15

Gly Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro
 20 25 30

45

Gly Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly
 35 40 45

50

Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser
 50 55 60

Arg Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg
 65 70 75 80

55

Ala Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Pro Leu Leu Tyr
 85 90 95

EP 2 741 085 A1

Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 100 105 110

5
 <210> 58
 <211> 102
 <212> PRT
 <213> Mus musculus

10
 <400> 58

Arg Leu Pro Phe Tyr Ser Leu Glu Gln Arg Ala Thr Ile Ser Tyr Arg
 1 5 10 15

15
 Ala Ser Lys Asn Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn
 20 25 30

20
 Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Val Ser
 35 40 45

25
 Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly
 50 55 60

30
 Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala
 65 70 75 80

35
 Thr Tyr Tyr Cys Gln His Ile Arg Glu Leu Thr Arg Ser Glu Leu Val
 85 90 95

Pro Ser Trp Lys Ser Asn
 100

40
 <210> 59
 <211> 101
 <212> PRT
 <213> Mus musculus

45
 <400> 59

Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His
 1 5 10 15

50
 Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile
 20 25 30

55
 Asp Pro Ser Asn Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys
 35 40 45

Ala Thr Leu Asn Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu
 50 55 60

60
 Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly
 65 70 75 80

EP 2 741 085 A1

Leu Arg His Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val
85 90 95

5 Thr Val Ser Ser Lys
100

<210> 60
<211> 99
10 <212> PRT
<213> Mus musculus

<400> 60

15 Thr Ile Leu Trp Arg Glu Gly Pro Phe Ser Tyr Arg Ala Ser Lys Ser
1 5 10 15

20 Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro
20 25 30

25 Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser
35 40 45

30 Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
50 55 60

35 Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
65 70 75 80

40 Gln His Ile Arg Glu Leu Thr Arg Ser Glu Glu Val Pro Ser Trp Arg
85 90 95

45 Ser Asn Lys

<210> 61
40 <211> 58
<212> PRT
<213> Homo sapiens

<400> 61

45 Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly
1 5 10 15

50 Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln
20 25 30

55 Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser
35 40 45

Glu Val Glu Ser Thr Glu Tyr Val Asn Arg
50 55

<210> 62
 <211> 15
 <212> PRT
 <213> Homo sapiens

5

<400> 62

Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg
 1 5 10 15

10

<210> 63
 <211> 11
 <212> PRT
 <213> Homo sapiens

15

<400> 63

Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg
 1 5 10

20

Claims

1. A method for detecting pancreatic cancer, comprising measuring the presence or an amount of a polypeptide having a reactivity of specifically binding to an antibody against a CAPRIN-1 protein via an antigen-antibody reaction, or the presence or an amount of a nucleic acid encoding the polypeptide, in a sample separated from a subject.
2. The method according to claim 1, wherein the polypeptide to be measured is a CAPRIN-1 protein consisting of an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30, or a polypeptide consisting of an amino acid sequence having 85-90% or higher sequence identity with the CAPRIN-1 protein.
3. The method according to claim 1 or 2, wherein the subject is a human or a dog.
4. The method according to claim 3, wherein the subject is a dog and the polypeptide to be measured comprises an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30.
5. The method according to claim 4, wherein the subject is a dog and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 6, 8, 10, 12, or 14.
6. The method according to claim 3, wherein the subject is a human and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 2 or 4.
7. The method according to any one of claims 1 to 6, wherein the presence or an amount of the polypeptide is determined by immunologically measuring an antibody induced against the polypeptide to be measured in the body of a subject, which antibody may be contained in the sample.
8. The method according to any one of claims 1 to 6, wherein the presence or an amount of a nucleic acid encoding the polypeptide is determined by measuring a nucleic acid encoding the polypeptide contained in the sample.
9. The method according to claim 8, wherein the presence or an amount of the nucleic acid in the sample is measured using a polynucleotide specifically hybridizing to a partial sequence comprising at least 15 to 19 nucleotides or at least 20 to 30 nucleotides in the nucleotide sequence of the nucleic acid or a sequence complementary thereto.
10. The method according to claim 9, wherein the subject is a dog and the polynucleotide specifically hybridizes to a partial sequence comprising at least 15 to 19 nucleotides or at least 20 to 30 nucleotides in the nucleotide sequence represented by SEQ ID NO: 5, 7, 9, 11, or 13 or a sequence complementary thereto.
11. The method according to claim 9, wherein the subject is a human and the polynucleotide specifically hybridizes to

EP 2 741 085 A1

a partial sequence comprising at least 15 to 19 nucleotides or at least 20 to 30 nucleotides in the nucleotide sequence represented by SEQ ID NO: 1 or 3 or a sequence complementary thereto.

- 5
12. The method according to any one of claims 1 to 6, wherein the presence or an amount of the polypeptide is determined by measuring the polypeptide contained in the sample.
13. The method according to claim 12, wherein the measurement is an immunological assay.
- 10
14. The method according to any one of claims 1 to 14, wherein the sample is blood, serum, blood plasma, ascites fluid, pleural effusion, tissues, or cells.
- 15
15. A reagent or kit for detecting pancreatic cancer, comprising one or more polypeptides having a reactivity of binding via an antigen-antibody reaction to an antibody induced against a CAPRIN-1 protein in the body of a subject.
- 16
16. A reagent or kit for detecting pancreatic cancer, comprising one or more antibodies that undergo an antigen-antibody reaction with a polypeptide having a reactivity of binding, via an antigen-antibody reaction, to an antibody against a CAPRIN-1 protein and produced in the body of a subject or to an antigen-binding fragment of the antibody.
- 20
17. The reagent or kit according to claim 15 or 16, wherein the CAPRIN-1 protein consists of an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30.
- 25
18. The reagent or kit according to claim 16 or 17, wherein the antibody or the antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the polypeptide is an antibody or an antigen-binding fragment thereof that binds to the surface of a pancreatic cancer cell.
- 30
19. The reagent or kit according to any one of claims 16 to 18, wherein the antibody or the antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the polypeptide comprises an antibody or a fragment thereof having an immunological reactivity with a polypeptide consisting of an amino acid sequence comprising at least 7 to 12 continuous amino acid residues within the region of amino acid residue Nos. 50 to 98 or amino acid residue Nos. 233 to 344 of the amino acid sequence represented by any of even-numbered SEQ IDS NO: 2 to 30 except for SEQ ID NOs: 6 and 18.
- 35
20. The reagent or kit according to any one of claims 16 to 19, wherein the antibody or an antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the polypeptide is one or more antibodies or antigen-binding fragments thereof selected from the group consisting of: an antibody binding to a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 43 or an antigen-binding fragment of the antibody; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 45 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 46 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 47 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 44 and 48 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 49 and 50 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 51 and 52 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 53 and 54 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 55 and 56 or an antigen-binding fragment thereof; a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 57 and 58 or an antigen-binding fragment thereof; and a monoclonal antibody comprising the amino acid sequences represented by SEQ ID NOs: 59 and 60 or an antigen-binding fragment thereof.
- 40
- 45
- 50
- 55
21. A reagent or kit for detecting pancreatic cancer, comprising one or more polynucleotides that specifically hybridize to a partial sequence comprising at least 15 to 19 nucleotides or at least 20 to 30 nucleotides in the nucleotide sequence represented by any of the odd-numbered SEQ ID NOs: 1 to 29 and encoding a CAPRIN-1 protein or in a sequence complementary to the nucleotide sequence.
22. A method for detecting pancreatic cancer, comprising measuring the presence or an amount of a CAPRIN-1 protein, an antibody against CAPRIN-1 protein, or a nucleic acid encoding the CAPRIN-1 protein, in a sample from a subject using at least one reagent or kit according to any one of claims 15 to 21.

23. The method for detecting pancreatic cancer according to any one of claims 1 to 14, comprising measuring the presence or an amount of a CAPRIN-1 protein, an antibody against CAPRIN-1 protein, or a nucleic acid encoding the CAPRIN-1 protein, in a sample from a subject using at least one reagent or kit according to any one of claims 15 to 21.

5

10

15

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2012/069824

A. CLASSIFICATION OF SUBJECT MATTER <i>G01N33/574(2006.01) i, C12Q1/68(2006.01) i, G01N33/53(2006.01) i, C07K14/47(2006.01) n, C07K16/18(2006.01) n, C12N15/02(2006.01) n, C12P21/08(2006.01) n</i> According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) <i>G01N33/574, C12Q1/68, G01N33/53, C07K14/47, C07K16/18, C12N15/02, C12P21/08</i> Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2012 Kokai Jitsuyo Shinan Koho 1971-2012 Toroku Jitsuyo Shinan Koho 1994-2012 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE (STN) , JSTPlus/JMEDPlus/JST7580 (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/A	WO 2010/016527 A1 (Toray Industries, Inc.), 11 February 2010 (11.02.2010), claims 1 to 22 & EP 2325648 A1	15-21/4, 5, 10
A	US 2008/0107668 A1 (Immunotope), 08 May 2008 (08.05.2008), & EP 2061503 A	4, 5, 10, 15-21
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 October, 2012 (22.10.12)		Date of mailing of the international search report 06 November, 2012 (06.11.12)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2012/069824

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-3, 6-9, 11-14, 22, 23
because they relate to subject matter not required to be searched by this Authority, namely:
(See extra sheet)
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2012/069824

Continuation of Box No.II-1 of continuation of first sheet (2)

Claims 1-3, 6-9, 11-14, 22 and 23 include "a method for detecting pancreatic cancer" which is a method for diagnosing the human body. Thus, the inventions of these claims relate to a subject matter which this international searching authority is not required, under the provisions of PCT Article 17(2)(a)(i) and PCT Rule 39.1, to search.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2010016526 A [0006]
- WO 2010016527 A [0006]

Non-patent literature cited in the description

- **KARLIN ; ALTSCHUL.** *Proc. Natl. Acad. Sci. U.S.A.*, 1993, vol. 87, 2264-2268 [0025]
- **ALTSCHUL et al.** *Nucleic Acids Res.*, 1997, vol. 25, 3389-3402 [0025]
- Seikagaku Jikken Koza. Tanpakushitsu no Kagaku. TOKYO KAGAKU DOZIN CO., LTD, 1981, vol. 1 [0028]
- Molecular Cloning. **SAMBROOK et al.** *Current Protocols in Molecular Biology*. Cold Spring Harbor Laboratory Press, 1989 [0028]
- Short Protocols in Molecular Biology. **AUSUBEL et al.** *A Compendium of Methods from Current Protocols in Molecular Biology*. John Wiley & Sons, 1995 [0028]

专利名称(译)	检测胰腺癌的方法		
公开(公告)号	EP2741085A1	公开(公告)日	2014-06-11
申请号	EP2012819473	申请日	2012-08-03
[标]申请(专利权)人(译)	东丽株式会社		
申请(专利权)人(译)	TORAY INDUSTRIES, INC.		
当前申请(专利权)人(译)	TORAY INDUSTRIES, INC.		
[标]发明人	IDO TAKAYOSHI OKANO FUMIYOSHI		
发明人	IDO, TAKAYOSHI OKANO, FUMIYOSHI		
IPC分类号	G01N33/574 C12Q1/68 G01N33/53 C07K14/47 C07K16/18 C12N15/02 C12P21/08		
CPC分类号	C07K16/18 C07K14/47 C07K14/4738 C07K16/30 C07K16/303 C07K2317/34 C07K2317/56 C12Q1/6886 C12Q2600/158 G01N33/57438 G01N2333/705		
优先权	2011171364 2011-08-04 JP		
其他公开文献	EP2741085A4 EP2741085B1		
外部链接	Espacenet		

摘要(译)

本发明涉及使用新型肿瘤标志物检测胰腺癌的方法。具体地，本发明提供了一种用于检测胰腺癌的方法，包括测量通过抗原-抗体反应与从受试者分离的样品中的抗CAPRIN-1蛋白的抗体具有结合反应性的多肽的存在或量，并且用于检测胰腺癌的试剂或试剂盒，其包含CAPRIN-1蛋白或其片段，针对其的抗体或编码其的多核苷酸。

SEQUENCE LISTING	
<110>	Toray Industries, Inc.
<120>	Method for Detection of Pancreatic Cancer
<130>	PH-5297-PCT
<150>	JP2011-171364
<151>	2011-08-04
<160>	63
<170>	PatentIn version 3.1
<210>	1
<211>	DS62
<212>	DNA
<213>	Homo sapiens
<220>	CDS
<221>	(190)..(2319)
<223>	
<400>	1
ctctcgggtgc atg ccc tgg gcc acc agc cac agc ggg agc gcc agc agc agc tgg	60
ctctcgggtgc agcgggacag gggcagcggc cctgcggccc cggagcggc gacactgccc	120
ggaagggacc gccacccttg cccctcagc tgcacctgc tgattccag cggcctcggc	180
gagcgcag atg ccc tgg gcc acc agc cac agc ggg agc gcc agc agc agc tgg	231
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser	
1 5 10	
tcc gga ccg cca ccg ccg tgg ggt tcc tcc ggg agt gag ggg gcc ggg	279
Ser Gly Pro Pro Pro Ser Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala	
15 20 25 30	
gga gcc ggg gcc gcc gcc gcc ggt tct cag cac ccc gcc acc gcc acc	327
Gly Ala Gly Ala Ala Ala Pro Ala Ser Glu His Pro Ala Thr Gly Thr	
35 40 45	
ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtc atc gac	375
Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp	
50 55 60	
aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac	423
Lys Lys Leu Arg Asn Ser Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr	
65 70 75	
cag gaa cga atg aac aaa ggg gaa agg ctt aat cca gat cag ctg gat	471
Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp	
80 85 90	
gcc gct tcc aag tac cag gaa gtc aca aat aat tgg ggg tct gcc aaa	519
Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys	
95 100 110	
gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca	567
Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr	
115 120 125	
ata aag aag aca gcc cgt cgg gag cag ctt atg aga gaa gaa gct gaa	615